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ABSTRACT OF THE DISSERTATION
Caveolins and JNKs Influence Brain Endothelial Permeability
after Juvenile TBI
By
David Olufemi Ajao
Doctor of Philosophy, Graduate Program in Physiology
Loma Linda University, December 2013
Dr. Jérôme Badaut, Chairperson
Disruption of blood-brain barrier (BBB) is a key secondary event that exacerbates
brain damage following traumatic brain injury (TBI). BBB disruption is particularly
damaging to the developing brain – which is highly vulnerable to various stress stimuli,
resulting in increased brain swelling, disrupted cerebral blood flow (CBF) autoregulation,
long-term disabilities and death following TBI in young demographic. Unsurprisingly,
BBB disruption and the resultant cerebral edema have emerged as therapeutic targets in
juvenile TBI. It is therefore important to understand the molecular players and
mechanisms involved in TBI-induced BBB disruption in the juvenile brain. To this end,
the endothelial caveolins and c-Jun N-terminal kinases (JNKs) were identified as
proteins of interest in the regulation of brain endothelial permeability after injury. These
were investigated under a three-fold aim. The first was to characterize the acute and
long-term histological and functional changes occurring following injury to the developing
brain. Second was the attempt to profile the changes in expression patterns of caveolins
after juvenile TBI in conjunction with BBB disruption. And lastly, the effects of molecular
agents that target JNK (DJNKI-1) and caveolin (cavtratin) pathways respectively were
examined on BBB integrity, and on imaging, histological and functional outcomes.
To achieve these aims, an experimental model of TBI in juvenile rats was
developed and characterized. Evidence emerged that long-term white matter dysfunction
occurs in this model, in parallel with delayed neurodevelopment and persistence of

xx

behavioral deficits, which mimics data from clinical and longitudinal TBI observations.
There was both acute and long-term increase in the expression level of caveolin-1 in the
endothelium and reactive astrocytes following juvenile TBI. Furthermore, acute
administration of cavtratin, a peptide mimetic of caveolin-1 scaffolding domain, markedly
reduced edema formation and lesion volume without improving sensorimotor outcome in
the acute time points. However, competitive inhibition of the JNK pathway with acute
administration of DJNKI-1 markedly ameliorates BBB permeability, reduced edema
formation, and improves neuroimaging and neurological outcomes at both acute and
chronic time points. These findings could potentially be exploited for future therapeutic
applications in juvenile brain trauma.
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CHAPTER ONE
INTRODUCTION:
ENDOTHELIAL TIGHT JUNCTIONS, CAVEOLINS, AND C-JUN NTERMINAL KINASES IN CONTEXT OF JUVENILE TRAUMATIC
BRAIN INJURY

Traumatic Brain Injury (TBI): Prevalence and Long-Term
Outcome
Traumatic brain injury (TBI) is ‘caused by a bump, blow or jolt to the head or a
penetrating head injury that disrupts the normal function of the brain’ (Faul, 2010).
Increasingly higher incidence rate of TBI and accompanying mortality and disability is
seen in the United States (Coronado et al., 2011) and in other countries around the
world (Tagliaferri et al., 2006, Kiening and Unterberg, 2007, Moppett, 2007), making it a
global menace and potential pandemic. According to Center for Disease Control (CDC)
reports, an annual average of 53,014 deaths was associated with TBI in the US alone
between 1997 and 2007 (about 18 deaths per 100,000 population) (Coronado et al.,
2011). The leading causes of TBI-related deaths during this period are: firearm-related
incidents, motor vehicle accidents, and falls (Coronado et al., 2011).
TBI is an increasingly troubling public health concern among childhood/pediatric
populations (Schneier et al., 2006, Kochanek et al., 2010), with childhood and pediatric
being defined as the developmental period between birth and adolescence (Faul, 2010).
In trauma centers in the United States, head injury represents 75 – 97% of all pediatric
trauma deaths (Yeates et al., 2002, Schneier et al., 2006). In comparison to other age
groups, the pediatric populations have higher proportion of annual TBI-related
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emergencies (close to half a million) (Faul, 2010, Dawodu, 2011), and experience longer
hospital stays, increased mortality, and protracted neurological and cognitive deficits
(Schwartz et al., 2003, Keenan and Bratton, 2006, Coronado et al., 2011), all associated
with enormous economic burden (Schneier et al., 2006). These statistics underscore the
higher risk of TBI facing the pediatric populations.
Another important point to note is that TBI incidence rate is higher for males than
females at every age (Faul, 2010). For example, there is a disproportionate male-tofemale TBI incidence ratio of 4:1 in US pediatric populations. Previous investigators
have highlighted factors thought to be responsible for this male-to-female disparity,
including higher activity levels and increased participation in risky sports by males
(Centers for Disease and Prevention, 1997). It has been estimated that nearly 300,000
sports-related TBIs occur in the United States per annum (Sosin et al., 1996, Centers for
Disease and Prevention, 1997).
Long-term problems associated with moderate to severe TBI include
sensorimotor (postural instability, dyspraxia, pain in the face and extremities, etc.) (Davis
and Dean, 2010), neuropsychiatric (e.g. anxiety disorder, depression, etc.) (Brown et al.,
1981, Yeates et al., 2002, Schwartz et al., 2003, Nicholl and LaFrance, 2009), and
cognitive deficits (e.g. poor attention and executive function deficit; thought and impulse
disorder) (Chadwick et al., 1981, Max et al., 2000). These dysfunctions have been
shown to last for decades post-TBI (Thomsen, 1984, 1992, Morton and Wehman, 1995,
Sbordone et al., 1995, Hoofien et al., 2001). These TBI-associated long-term problems
originate from various pathophysiological processes and mechanisms set in motion postTBI. This is the focus of next sub-section below.
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Traumatic Brain Injury: Mechanisms of Primary and Secondary
Injuries
TBI processes are generally classified into either primary or secondary injury
mechanism. Primary injury consists of the initial insult(s) to the cranium and brain tissue,
and may manifest as either focal (e.g. skull fractures, intracranial hematomas,
lacerations, contusions, penetrating wounds) or diffuse injuries (e.g. diffuse axonal
injury, acceleration and deceleration injury) (Gennarelli, 1993, Dawodu, 2011). Strict
adherence to preventatives measures such as wearing of helmet (during cycling, sports
events or dangerous industrial work) and using seatbelts or child-restraint (in
automobiles) may reduce the damage caused by primary injury (Dawodu, 2011).
Secondary injury, however, consists of a complex array of cellular processes and
pathophysiological events which are delayed consequences of the initial insult, and may
continue for a long time (Park et al., 2008, Dawodu, 2011). Secondary injuries may
include: impaired cerebral blood flow and hemodynamics, ischemia, hypoxia,
excitotoxicity, impaired metabolism, increased free radical formation, disruption of bloodbrain barrier, and edema. Unlike primary injury, the gradual onsets of the secondary
injury mechanisms make them theoretically amenable to treatment (Park et al., 2008).
Research efforts are therefore geared towards utilizing this window of opportunity
through development of therapies (e.g. pharmacological agents aimed at reducing
blood-brain barrier damage and curtailing brain edema) that could potentially minimize
secondary injury damage and facilitate functional recovery (Donkin and Vink, 2010,
Shlosberg et al., 2010).

How the Juvenile Brain Differs from Adult Brain with and without
TBI
For the rest of this dissertation, the term ‘juvenile TBI’ is used to indicate TBI
occurring in the pediatric/childhood period. Mounting evidence is showing that juvenile
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brain is uniquely different from adult brain both in terms of natural physical and
physiological status and also in terms of response to TBI (Giza and Prins, 2006, Giza et
al., 2007, Ibrahim et al., 2012, Maxwell, 2012). First, there are differences in the physical
attributes of juvenile heads, skulls, and brains versus those of adults. The pediatric skull
is thinner, flexible, and more pliable than adult skull (Giza, 2006). There is, for instance,
an open fontanelle in infants which is thought to make them more susceptible to
subdural hematoma following TBI (Khilnani, 2004, Giza, 2006). This flexibility affects the
forces being transmitted to the brain tissue following trauma and the handling of
increased intracranial pressure (ICP) (Giza, 2006). Other pediatric anatomical features
such as disproportionately large head-to-body ratio, weaker neck muscles, and large
subarachnoid space in which the brain can move more freely compared to adults further
predispose the pediatric population to TBI (Zuckerman and Conway, 1997, Giza, 2006),
and especially increases the rate of occurrence of diffuse axonal injury (DAI) (Gleckman
et al., 1999).
Developmental processes in the pediatric brain are unique and different from
those of adult brain (Giza et al., 2007, Maxwell, 2012). Maturation of brain cells and
structures, and changes of synaptic density and integrated brain functions all continue
well into adulthood (Giza et al., 2007, Groeschel et al., 2010). For instance, myelination
of axons in some brain regions continues progressively post-partum and lasts into the
third decade of life (Ballesteros et al., 1993, Luna et al., 2004, Blakemore and
Choudhury, 2006, Maxwell, 2012). The unmyelinated fibers in immature brains are
preferentially vulnerable to structural and functional damage after TBI (Reeves et al.,
2012), resulting in cognitive and behavioral alterations (Jonsson et al., 2013). TBIassociated injury to unmyelinated axons is thought to affect emerging skills more
vigorously than established skills possibly due to disruption of developing neural
networks mediating the skills (Lehnung et al., 2001, Jonsson et al., 2013).
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Young age is considered a risk factor for complications resulting from secondary
injuries such as disruption of neural and sensory-motor pathways (Kriel et al., 1989,
Anderson et al., 2005, Anderson et al., 2012, Crowe et al., 2012). In the developing
brain, brain water content is higher than in adult brain (Counsell and Rutherford, 2002),
resulting in reduced brain compliance and making the brain more susceptible to diffuse
swelling (Aldrich et al., 1992, Giza, 2006, Lenroot and Giedd, 2006). The developing
brain is in associated with higher cerebral blood flow (CBF) which may be related to
lower cerebrovascular resistance, and post-traumatic hyperemia and diffuse cerebral
swelling which are more common in children (Suzuki, 1990, Zwienenberg and Muizelaar,
1999, Giza, 2006, Udomphorn et al., 2008).
Approximately 50% of children who suffer severe TBI will develop diffuse
cerebral swelling (DCS) which has been defined as ‘‘compressed or obliterated
mesencephalic cisterns, cerebrospinal fluid (CSF) spaces, and/or small to normal size
ventricles in the absence of other intracranial pathology” (Aldrich et al., 1992, Adelson,
2009). Although DCS is noted as the most common cause of brain death in both
pediatric and adult TBI (Becker et al., 1977, Marshall et al., 1979), it is however about
3.5 times more common in children than adults (Zimmerman et al., 1978, Aldrich et al.,
1992, Adelson, 2009). Moreover, childhood victims of TBI who present with DCS have
been estimated to have three-fold higher mortality than those without it (Aldrich et al.,
1992, Bauer et al., 1999). About 50% of all children who present DCS following jTBI
suffer mortality within 6 days (Aldrich et al., 1992), while those that surviving bear longlasting neurological deficits (Yeates et al., 2002, Schwartz et al., 2003). Neuropathologic
changes associated with DCS include: obliterated CSF spaces, vascular congestion,
edema (both cytotoxic and vasogenic), varying degrees of herniation, and cell death
(Adelson, 2009). Furthermore, DCS in jTBI has been linked to the endangerment of BBB
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by oxidative stress due to diminished antioxidant capacity in the juvenile brain compared
to adult brain (Bauer et al., 1999, Fan et al., 2003).
Experimental evidence has been provided in support of age-dependent
differences in cerebral and systemic hemodynamic responses following brain injury
(Armstead, 1999). Younger age is found to be associated with increased impairment of
cerebral autoregulation (triggering hypo- or hyperperfusion) and poorer outcomes
following moderate to severe TBI (Vavilala et al., 2004, Freeman et al., 2008). Neonates
and infants have a limited range of brain autoregulation compared to adults (Armstead,
2005), which predisposes them to cerebrovascular dysfunction following jTBI.
The unique vulnerabilities of juvenile brains to TBI highlighted above have
triggered a rethink among scientists on the extent to which ‘brain plasticity’ (defined as
brain’s ability to repair itself) during development could make up for the damage done,
and foster structural brain repair and functional recovery following jTBI (Anderson et al.,
2005, Anderson et al., 2012). An emerging opinion is that brain plasticity is insufficient to
make up for the vulnerabilities of the juvenile brain by canceling out the deleterious
structural and functional effects of jTBI (Anderson et al., 2005, Giza, 2006). The damage
done to the developing brain by jTBI often results in decades-long or life-long
complications and deficits of sensory-motor, cognitive, and neuropsychiatric nature (Max
et al., 2000, Hoofien et al., 2001, Yeates et al., 2002, Davis and Dean, 2010), and these
highlight the need for further research into how to facilitate better outcomes (Anderson et
al., 2005, Giza et al., 2007).

Introduction to Blood-Brain Barrier (BBB)
The BBB is a dynamic interface comprising of various cell types and molecules
that work in concert to physically and chemically separate the brain parenchyma from
the systemic circulation and its cargo (Hawkins and Davis, 2005). It comprises of a
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physical and chemical barrier to diffusion of peripheral blood content into the brain, as
well as a transport barrier, and a metabolic barrier (Ballabh et al., 2004, Abbott et al.,
2006). Three cellular elements form the foundation of the BBB: the capillary endothelial
cells, the astrocytic endfeet, and the pericytes (Ballabh et al., 2004). The tight junctions
(TJs) between adjacent capillary endothelial cells form the major ‘physical barrier’ to
paracellular transport (Abbott et al., 2006). The molecular constituents of TJs are
discussed elaborately in section 2.2 below. The presence of specific transporters and
transport systems on the luminal (e.g. breast cancer resistance protein [BCRP]) and
abluminal (e.g. lipoprotein receptor-related protein 1 [LRP1]) surfaces of the capillary
endothelium ensures selective transcellular transport of compounds in either direction
between peripheral blood and brain (Zlokovic, 2008). The selectiveness of these
transport systems gives the brain a much less degree of transcytosis and endocytosis
than peripheral endothelium, and forms the basis of the ‘transport barrier’ function of the
BBB (Abbott et al., 2006). The ‘metabolic barrier’ function of the BBB is spearheaded by
intracellular and extracellular enzymes (e.g. peptidases and nucleotidases which can
metabolize unwanted peptides and ATP, and cytochrome P450 which can inactivate
various neuroactive and toxic compounds) (el-Bacha and Minn, 1999, Abbott et al.,
2006) marshaled against unwanted substrates. The perivascular endfeet of astrocytes
ensheathes more than 99% of the cerebrovascular surface (Iadecola and Nedergaard,
2007). It provides a communication route between brain endothelium and neurons,
thereby facilitating the coupling of vascular and neuronal activities in several of the
brain’s blood vessels (Iadecola and Nedergaard, 2007, Dunn et al., 2013). Pericytes
enclosed within endothelial basal laminal perform maintenance, regulatory and repair
roles crucial to the integrity of the BBB (Winkler et al., 2011).
Contrary to the belief in previous decades that the BBB of neonates and infants
is structurally and/or functionally immature (Barcroft, 1938, Saunders et al., 1999),
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growing evidence suggests that tight junctions of the human BBB is fully formed at birth
(Abbott et al., 2010, Saunders et al., 2012), although there is progressively increase in
the expression of some efflux transporters (e.g. p-glycoprotein) during development (Ek
et al., 2010, Ek et al., 2012, Saunders et al., 2012). By the 14th week of gestation, the
key TJ proteins – claudin-5 and occludin – are detectable in the fetal capillary
endothelium and show the same distribution pattern as seen in adult brain (Virgintino et
al., 2004). Furthermore, pioneering studies in the 1950s showed that there is a postmortem BBB to trypan blue in stillborn human fetuses by the 12th week of gestation
(Grontoft, 1954). Observations in rodents corroborate these findings. In experimental
mice, BBB begins to form between E11 and E17 with identifiable TJs and restriction of
transendothelial movement of polar solutes (Abbott et al., 2010). The high
transendothelial electrical resistance (TEER) characteristic of adult BBB is exhibited by
E21 using in situ measurements of TEER in cerebral blood vessels of anaesthetized rats
(Butt et al., 1990, Butt, 1995). Recent experimental data from stroke even suggests that
the neonates’ BBB may be less permeable compared to adults following induction of
ischemic event (Fernandez-Lopez et al., 2012). In spite of the presence of intact BBB at
birth however, the developing cerebral vessels are still believed to be more fragile than
adult vessels, which could render the brain more susceptible not only to drugs and
toxins, but also to neuropathologic conditions underlying cerebral damage and
neurological disorders (Saunders et al., 2012). The after-birth loss of placental efflux
transporters (Ek et al., 2010, Ek et al., 2012, Saunders et al., 2012) and the vulnerability
of blood vessels in the white matter to systemic inflammatory insults at this critical stage
of development (Stolp et al., 2005a, Stolp et al., 2005b, Stolp and Dziegielewska, 2009)
are possible contributors to this vulnerability.
TJ proteins are crucial to the BBB and play a significant role in the evolution of
secondary brain injuries (Castejon, 2012, Thal et al., 2012). As such, limiting and

8

reversing TJ damage following TBI have become important therapeutic avenues for
halting the progression of some secondary injury mechanisms (Ballabh et al., 2004,
Hawkins and Davis, 2005, Shlosberg et al., 2010). A brief review of the structural and
molecular constituents of brain endothelial TJs under physiological condition follow.

Structural and Molecular Constituents of Brain Endothelial Tight
Junction
Endothelial TJ forms a major physical and structural barrier that impedes the
movement of substances from the periphery into brain parenchyma between adjacent
endothelial cells – paracellular permeability (Reese and Karnovsky, 1967, Brightman et
al., 1970, Ballabh et al., 2004). It consists of three main integral membrane protein
families (occludins, claudins and junctional adhesion molecules [JAMs]) and several
cytoplasmic accessory proteins (including zonula occludens [ZO-1, ZO-2, and ZO-3],
cingulin, etc.) (Vorbrodt and Dobrogowska, 2004, Liebner et al., 2011). In addition to
tight junctions, adherens junctions – which comprise of cadherin-catenin complexes and
their associated proteins – further strengthen the mechanical attachments between
adjacent endothelial cells and contribute to the regulation of TJ proteins (Schulze and
Firth, 1993, Wolburg and Lippoldt, 2002, Taddei et al., 2008, Komarova and Malik,
2010). The main TJ proteins as well as key accessory proteins are described below.

Claudins
The first proteins in the claudin family (claudins-1 and 2) were reported in 1998
(Furuse et al., 1998a, Furuse et al., 1998b). The list soon grew to include up to 24 more
claudin proteins (Morita et al., 1999, Furuse et al., 2002). Particularly abundant in brain
endothelial TJs are claudins-5 and -12 (Ohtsuki et al., 2008, Guerra, 2011). Unlike
occludins, there is a strong consensus that claudins are the indispensable protein
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molecules responsible for establishing the physical and structural barrier properties of
TJs (Furuse et al., 1999, Morita et al., 1999, Wolburg and Lippoldt, 2002, Liebner et al.,
2011). The ~22 kDa claudin proteins show the same structural pattern – four membranespanning regions, two extracellular loops and two cytoplasmic domains, a short Nterminus and a long C-terminal sequence (Heiskala et al., 2001). There is no homology
between the claudin and occludin protein families, although they are structurally similar
(Liebner et al., 2011). Functional investigations showed that transfection of one or more
claudin genes into cells that naturally do not possess TJs leads to the formation of TJ
morphology with reduced paracellular flux (Amasheh et al., 2005, Ohtsuki et al., 2007).
The TJ phenotype is maintained through homophilic and heterophilic interactions
between the extracellular loops of claudins (Morita et al., 2003). Furthermore, the
carboxyl terminals of claudins are known to bind with cytoplasmic zona occludens to
ensure structural integrity of the TJs (Ballabh et al., 2004). Claudins are hence
fundamental to both the formation and maintenance of brain endothelial TJs (See Fig.
1).

Occludins
Furuse and colleagues (1993) were the first to describe the 65-kD occludins in 1993
as being localized to the TJs of epithelial and endothelial cells. Occludins are made up of
two extracellular loops, four transmembrane domains, and C- and N-terminal
cytoplasmic domains (Feldman et al., 2005) (See Fig. 1). Experiments have revealed
that the morphology and functional capacity of TJs are not compromised in occludindeficient mice (Saitou et al., 2000), although these mice developed some undesirable
conditions including chronic inflammation and hyperplasia of gastric epithelium, and
calcifications in the brain parenchyma and blood vessels. (Saitou et al., 2000, Wolburg
and Lippoldt, 2002). These observations suggest that occludins are not primarily
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required for TJ formation at the onset (Saitou et al., 2000). However, phosphorylation of
occludin is known to regulate TJ permeability in both G-protein-dependent and independent manner in mature endothelial cells, independent of cytoskeletal changes
(Hirase et al., 2001). Furthermore, the external loops, as well as the transmembrane and
C-terminal cytoplasmic domains of occludin were found to be important in regulating
paracellular permeability, while the N-terminus was determined to be essential for
neutrophil migration during inflammation (Sakakibara et al., 1997, Lacaz-Vieira et al.,
1999, Huber et al., 2000, Hirase et al., 2001). Moreover, occludin was demonstrated to
be responsible for sealing of TJs (Lacaz-Vieira et al., 1999). These reports suggest that
occludin is needed by mature endothelial cells for regulating rather than establishing
their barrier properties (Wolburg and Lippoldt, 2002).

Junctional Adhesion Molecules (JAMs)
JAMs (JAM-A, JAM-B and JAM-C) contribute to the assembly of TJ
structures(Bazzoni, 2003). They belong to the immunoglobulin superfamily and possess
a single transmembrane domain with two immunoglobulin-like loops in their extracellular
portion (Ballabh et al., 2004). JAMs codistribute with and help regulate homophilic and
heterophilic interactions among TJ component molecules (Martin-Padura et al., 1998,
Wolburg and Lippoldt, 2002). Homophilic interactions among JAMs linking adjacent
endothelial cells help stabilize intercellular junctions and organize tight junctional
structures (Bazzoni, 2003) (See Fig. 1). During pathological conditions however,
heterophilic interactions between JAMs and leukocyte integrins help facilitate leukocyte
transmigration (Wolburg and Lippoldt, 2002). JAMs contribute to the regulation of
paracellular permeability. Knocking down JAM-A results in increased barrier permeability
together with concomitant reduction in claudins in intestinal epithelial cell cultures
(Severson and Parkos, 2009). In rat cold cortical injury, there was an acute decrease in
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JAM-A which was concomitant with BBB breakdown (Yeung et al., 2008). Mechanisms
through which JAMs regulate endothelial permeability include: control of endothelial
actomyosin contractility, modulation of myosin light chain (MLC) phosphorylation, and
interactions with TJ scaffolding proteins ZO-1, cingulin, etc. (Orlova et al., 2006,
Stamatovic et al., 2008).

Accessory Proteins – Zona Occludens (ZOs), Cingulin, and
Integrins
Zona Occludens (ZOs)
Zona Occludens were so named because early micrographs revealed them as a
zone or band between adjacent epithelial cells whose membranes have joined together
and formed a virtually impermeable barrier to fluid, and therefore, the ZOs ‘occlude’ the
space between the adjacent plasma membranes (Brightman and Palay, 1963, Farquhar
and Palade, 1963). ZO-1 (220 kDa), ZO-2 (160 kDa), and ZO-3 (130kDa) have major
sequence similarities and belong to the membrane-associated guanylate kinase-like
protein family (MAGUKs) (Wolburg and Lippoldt, 2002). They all have three PDZ
domains (PDZ1, PDZ2, and PDZ3), one SH3 domain, and one guanyl kinase-like (GUK)
domain (Wolburg and Lippoldt, 2002). These domains function as protein binding
molecules to facilitate signal transductions and help anchor tight junction proteins to the
cytoskeleton (Wolburg and Lippoldt, 2002, Ballabh et al., 2004) (Fig. 1). The PDZ1
domain of ZO-1, ZO-2, and ZO-3 has been reported to bind directly to the C-terminus of
claudins (Itoh et al., 1999). Furthermore, occludin interacts with the GUK domain on ZO1 (Mitic et al., 2000). Importantly, actin, the primary cytoskeleton protein, binds to Cterminal of ZO-1 and ZO-2, and this complex cross-links transmembrane elements and
thereby provides structural support to the endothelial cells (Haskins et al., 1998, Ballabh
et al., 2004).
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Cingulin
Cingulin has been reported to be expressed in endothelial cells of the BBB, and
the junction-associated coiled-coil protein (JACOP) in other endothelial and epithelial
cells (Wolburg et al., 2009). Its structure and organization is conserved throughout the
vertebrates. Cingulin is an important component of BBB in that it interacts with actin and
myosin, ZO-1 and several other TJ proteins (Bazzoni et al., 2000). Cingulin binds to
these tight junction-associated proteins through conserved domains on the targets and
therefore help to stabilize tight junctional structures (Heiskala et al., 2001, Wolburg and
Lippoldt, 2002, Hawkins and Davis, 2005).

Integrins
Integrins were first described in 1987 (Hynes, 1987). Functionally, they serve as
receptors for cell adhesion to extracellular matrix (ECM) proteins, play crucial roles in
cell-to-cell adhesions and cell motility, and maintain transmembrane connections to the
cytoskeleton (Bazzoni et al., 2000, Juliano, 2002) (See Fig. 1). They are vital in the
maintenance of signal transduction within and the structural stability of endothelial tight
junction (Juliano, 2002). Integrins exist in various affinity states for their ligands, and
these affinity states are regulated by calcium ions and R-Ras and Rap1 small GTPases
(Juliano, 2002). Knock-out studies of some integrins isoforms resulted in hemorrhage,
lack of platelet aggregation, impaired leukocyte recruitment, impaired inflammatory
responses, vessel dilation, and cerebral hemorrhage (Chen and Sheppard, 2007,
Wolburg et al., 2009). Endothelial integrins also play crucial roles during development in
the establishment of proper connections between endothelial cells and astrocytes
(gliovascular unit) under physiologic conditions, and are also crucial for angiogenesis
(Wolburg et al., 2009).
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Changes in Brain Vascular Structure and Functions following
Juvenile TBI
There is paucity of clinical data on changes occurring specifically in the
endothelial TJ protein structures and in the BBB in general following TBI in juvenile
humans (Graham, 2001). A few postmortem studies have provided some insights into
macrostructural changes in jTBI. Intracranial hemorrhages – including subdural (SDH),
subarachnoid (SAH), extradural (EDH), and intracerebral (ICH) hemorrhages – are
common in postmortem studies of the brains of childhood victims of TBI resulting from
falls, with SDH being the most frequently seen (Chadwick et al., 1991, Kim et al., 2000,
Agarwal et al., 2005). In addition, Adelson and colleagues reported low cerebral blood
flow (CBF) (i.e. hypoperfusion) in the early period after severe TBI in young children
which was associated with poor functional outcome measured with Glasgow Outcome
Score (GOS) (Adelson et al., 1997, Adelson et al., 2011). Alterations in CBF in the
juvenile TBI patients contribute to ischemia and disruption of the BBB (Verive et al.,
2012).
Furthermore, as earlier noted in section 1.3 (par. 4), one of the pathologic
features of diffuse cerebral swelling (DCS) seen as a clinical presentation of severe jTBI
is vascular congestion (Adelson, 2009). Vascular congestion may be indicative of
thrombosed cerebral blood vessels (Adams et al., 1982, Adelson et al., 1996) and
portends occurrence of further cerebrovascular dysfunctions (Reithmeier et al., 2005).
Vascular congestion is preceded and facilitated by cerebral autoregulatory dysfunction
and hyperemia (Reithmeier et al., 2005). Clinical and experimental studies both highlight
increased intracranial pressure (ICP) as another key consequence of cerebral
autoregulatory dysfunction post-jTBI (Barie et al., 1993, Biagas et al., 1996) and cerebral
edema (Vink and Van Den Heuvel, 2004).
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Experimentally, cerebral autoregulatory dysfunction in the developing brain is
linked to excessive activation of N-Methyl D-Aspartate (NMDA) receptor by glutamate
(Armstead et al., 2011a), hyperactivation of mitogen activated protein kinase (MAPK)
pathways including c-Jun N-terminal Kinase (JNK) (Armstead et al., 2011a), impairment
to ATP- and calcium-sensitive potassium (K+) channels on cerebral vessels (Armstead,
1997, Armstead et al., 2011b), and altered nitric oxide (NO) bioavailability (Verive et al.,
2012) and vasodilatory function (Armstead, 2000). Other Endothelium-dependent
systems (Verive et al., 2012) such as caveolae and their constituent caveolin proteins in
lipid rafts (Prisby et al., 2006) also affect cerebral autoregulation in pediatric head
trauma. Interestingly, caveolins, which are known to influence other factors of cerebral
autoregulation such as endothelial nitric oxide synthase (eNOS) and nitric oxide (NO)
(Bucci et al., 2000, Bernatchez et al., 2005), and possibly JNK (Tourkina et al., 2008),
have not been well-researched in juvenile TBI.
Findings from microdialysis show that pro-inflammatory cytokines such as
interleukin-1-β (IL-1β) and tumor necrosis factor-α (TNF-α) are elevated in the CSF of
children with moderate to severe TBI (Morganti-Kossman et al., 1997, Buttram et al.,
2007, Cederberg and Siesjo, 2010). These cytokines have been shown experimentally
to induce BBB disruption following TBI via upregulation of hypoxia inducible factor-α
(HIF-1α) and vascular endothelial growth factor-A (VEGF-A) (Argaw et al., 2006). In a
follow-up study, caveolin-1 and eNOS were shown to mediate the BBB disruption effects
of VEGF-A, and the systemic administration of cavtratin – a selective eNOS inhibitor –
abrogates this VEGF-A-induced BBB disruption and ameliorates neurologic deficits in a
CNS inflammatory model in young adult mice (Argaw et al., 2012). There is also a
possibility of developmental differences in cytokines sampled from cerebral microdialysis
between juvenile and adult TBI patients (Friess et al., 2012), but more studies need to
be designed and carried out to fully compare these two groups.
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In experimental juvenile TBI in rodents, genes associated with
neuroinflammation, cytokine activities and immune processes were found to be
invariably upregulated acutely, while genes associated with development,
neurotransmission, neuroplasticity, and, to some extent, metabolism were found to be
mostly downregulated (Babikian et al., 2010). These suggest that juvenile brain is
assaulted acutely by neuroinflammation following brain injury and it may be more
vulnerable to neuroinflammatory insults compared to adult brain (Swaiman et al., 2012).
Inflammatory response in the developing brain is more robust than in adult brain and is
characterized by greater disruption of the BBB and elaboration of cytokines (Potts et al.,
2006). Various studies have determined an increased vulnerability of the juvenile BBB to
oxidative stress following jTBI, possibly due to much lower activities of antioxidant
enzymes (such as glutathione peroxidase [GPx] and manganese superoxide dismutase
[MnSOD]) in the juvenile brain compared to adult brain (Bauer et al., 1999, Bayir et al.,
2002, Fan et al., 2003, Babikian et al., 2010).
Activated matrix metalloproteinases (MMPs) are known to cause degradation of
vascular basal laminal matrix proteins (e.g. collagen, fibronectin, laminin) and
breakdown of tight junction proteins (including claudins and occludins) following injury to
adult brain (Morita-Fujimura et al., 2000, Asahi et al., 2001). MMP-2 was found to have
increased expression and activity between 12 and 72 hours post-injury in an
experimental model of jTBI to P7 rats (Sifringer et al., 2007). In contrast to the
prominence of MMP-2 in juvenile TBI, MMP-9 was found to be more prominent in adult
rodents with TBI (Wang et al., 2000, Asahi et al., 2001). Baseline activity of MMP-9 was
also detectable in infant rodent brains unlike in adult brains (Sifringer et al., 2007). These
suggest that the temporal expression and activity profiles for various MMPs may differ
dependent on age, and these developmental differences should be considered in
therapeutic efforts aimed at MMPs.
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From the points reviewed in this section, it is clear that the juvenile brain has a
number of vulnerabilities with regards to changes occurring in its cerebral vascular
structure and functions following brain trauma. Key molecular targets that could be
investigated for pharmacological manipulation aimed at arresting secondary brain
damage arising from cerebrovascular dysfunctions also emerged. These include the
endothelial caveolins and c-Jun N-terminal kinases.

Changes in Brain Vascular Structure and Functions following
Adult TBI
Adult TBI patients (as well as experimental animals) share several similarities as
well as differences from juvenile patients in terms of structural and functional changes in
the brain vasculature following TBI. A wave of molecular changes that alter both
structure and function of brain vasculature is unleashed by the initial TBI impact in the
adult brain (Shlosberg et al., 2010, Chodobski et al., 2011). BBB disruption, which is
characterized by breakdown of TJ proteins and increased permeability, is typically
biphasic in nature according to experimental TBI data in adult rodents (Baldwin et al.,
1996, Baskaya et al., 1997). This is also suggested in some clinical data in adult TBI
patients (Tomkins et al., 2001, Tomkins et al., 2008). The delayed arm of BBB disruption
has been linked with transcriptional changes in the neurovascular unit which precipitates
delayed neuronal dysfunction, cell death, and degeneration (Shlosberg et al., 2010).
Apoptosis of some endothelial cells following TBI also promotes increased BBB
permeability and eventual neuronal loss (Nag et al., 2005). These events have been
proposed to influence long-term TBI complications such as cognitive and psychological
impairments (Zlokovic, 2008, Shlosberg et al., 2010).
Endothelial structures that form the physical and mechanical barriers to
paracellular diffusion or permeability undergo active breakdown in adult TBI (Zhao et al.,
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2007, Khan et al., 2009, Chodobski et al., 2011). The levels of expression of claudin-5
and occludin decrease at acute time points following TBI (Zhao et al., 2007).
Experimental evidence further suggest that transcellular permeability may also be
enhanced following adult brain trauma (Preston et al., 2001), possibly through increased
number and activity of caveolae (the caveolins-based, cave-like structures in the
endothelial lipid rafts) (Nag et al., 2007, Nag et al., 2009) which facilitate transcytosis –
the vesicle-mediated transfer of substances across the cell through binding of ligands to
membrane receptors or surface charges, followed by internalization – among other
functions (Abbott et al., 2006, Komarova and Malik, 2010). Ultrastructural morphology
consistent with increased pinocytotic activity (such as swollen endothelial cells, clearer
cytoplasm, increased vacuolization, and increase in number of pinocytotic vesicles) was
reported in brain microvessels of adult TBI patients (Vaz et al., 1997). There have been
calls (Minshall et al., 2003, Yuan and Rigor, 2010) for more studies to further investigate
the role of caveolae and caveolins in the regulation of endothelial barrier permeability in
both pediatric and adult TBI.
Compromise of BBB permeability following TBI in the adult brain results in many
secondary phenomena which include multi-focal, intraparenchymal hemorrhages in both
ipsilateral and contralateral brain regions (Chodobski et al., 2011). There is also a lower
regional cerebral blood flow to the pericontusional area (Schroder et al., 1998, von
Oettingen et al., 2002). BBB damage following TBI in adult brains results in leakage of
blood-borne factors and proteins such as albumin (Shapira et al., 1993), immunoglobulin
G [IgG] (Hooper et al., 2005), fibrinogen (Tyagi et al., 2008), thrombin (Xi et al., 2003),
extravasation of red blood cells (RBCs) (Chodobski et al., 2011), and aggregation of
platelets and leukocytes (Stein et al., 2002, Schwarzmaier et al., 2010).
Each of these leaked or released factors and cells further effect changes in brain
vascular structure and function following adult TBI. Extravasated albumin has been
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linked with neuroinflammatory processes such as increased calcium concentration and
proliferation of microglial cells (Hooper et al., 2005, Chodobski et al., 2011), activation of
MAPK pathways and synthesis of proinflammatory cytokines such as IL-1β in microglia
and astrocytes (Ralay Ranaivo and Wainwright, 2010), increase in microglial production
of NO which is mediated by MAPK pathway (Hooper et al., 2009), and induction of
MMPs (Ralay Ranaivo et al., 2012) which can further degrade the endothelial
extracellular matrix. Invading leukocytes can also release degrading MMPs to the
traumatized brain parenchyma (Borregaard et al., 2007, Chodobski et al., 2011).
Fibrinogen could induce further endothelial barrier permeability by signaling
through the MAPK pathway (Tyagi et al., 2008). Fibrinogen causes rearrangement of
microglial cytoskeleton, increases their size and phagocytic activity, thereby influencing
post-traumatic neuroinflammation (Adams et al., 2007). Fibrinogen may also inhibit
neurite outgrowth and promote post-traumatic astroglial scar formation (Schachtrup et
al., 2007, Chodobski et al., 2011).
Although pretreatment with low dose of thrombin is neuroprotective in vivo
(Chodobski et al., 2011), release of thrombin in high concentration post-TBI exacerbates
BBB disruption and edema formation, and causes apoptosis of neurons and astrocytes
(Xi et al., 2003). Thrombin stimulates microglial release of pro-inflammatory mediators
by signaling through MAPK including c-Jun N-terminal kinases (JNKs) (Waetzig et al.,
2005). Thrombin also augments oxidative stress by causing increase in microglial
expression of inducible nitric oxide synthase (iNOS) and inducing release of NO (Ryu et
al., 2000) which is a potent vasodilator and an inducer of endothelial hyperpermeability
(Yuan and Rigor, 2010). It has also been demonstrated in vitro that thrombin directly
induces contraction of brain endothelial cells which could result in increased paracellular
permeability (Nagy et al., 1995).
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Release of blood-borne factors and cells into brain parenchyma is a hallmark of
what has been traditionally termed ‘vasogenic edema’ (Donkin and Vink, 2010). Edema
in brain pathologies has for several decades been classified as either ‘cytotoxic edema’
– characterized by swelling of astrocytes and neurons due to failure of sodiumpotassium pump and resultant retention of sodium and water while the BBB remains
intact – or ‘vasogenic edema’ – characterized by BBB breakdown and flow of normally
excluded intravascular proteins into the parenchyma (Klatzo, 1967, Unterberg et al.,
2004, Donkin and Vink, 2010). Recently, however, the complexity of cerebral edema has
necessitated the addition of variants of these two traditional categories. These variants
include: ionic edema – which occurs when plasma osmolality falls below brain osmolality
and results in net movement of water from vasculature into brain interstitial fluid, all in
absence of gross BBB breakdown (Simard et al., 2007, Donkin and Vink, 2010); anoxic
edema – which occurs within minutes of cessation of CBF to a brain region, depriving it
of oxygen and glucose, and characterized by swelling of astrocytes and neurons (Badaut
et al., 2011); and hydrostatic edema – which occurs when cerebral perfusion pressure
increases to the level where autoregulatory mechanisms fails (Donkin and Vink, 2010).
Debates in scientific literature over which classes of edema predominate following TBI
has persisted for decades (Donkin and Vink, 2010). The complexity and heterogeneity of
TBI which is impossible to replicate in a single experimental model has precluded a
consensus regarding the temporal profile of edema following brain injuries. Most
researchers, however, agree that post-TBI, edema occurs as a continuum that starts
with vasogenic edema (with observable tight junction and BBB breakdown) which occur
within hours of TBI, followed by cytotoxic edema which develops over days and may
persist for weeks (Barzo et al., 1997, Marmarou, 2003, Donkin and Vink, 2010).
The brain microvessels surrounding major white matter tracts and in the
hippocampi are especially vulnerable to damage and leakage following TBI to adult
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brains (Dietrich et al., 1994, Chodobski et al., 2011). Hemorrhagic contusions were
found at the gray-white matter interphase under somatosensory cortex in lateral fluidpercussion injury model in adult rats (Dietrich et al., 1994). Microvessels coursing the
subcortical white matter such as the corpus callosum are also highly susceptible to
damage following TBI (Chodobski et al., 2011). Vascular mechanisms is also frequently
advanced to explain the selective vulnerability of the hippocampus (especially in the
CA1, CA3, and dentate gyrus) to damage following TBI in adult humans and in
nonhuman primates (Kotapka et al., 1991) and in rodents (Gao et al., 2011) and other
animals (Kirino, 1982). Selective damage to both white matter and hippocampi
contribute significantly to sensorimotor and cognitive deficits following adult TBI (Gao et
al., 2011, Alwis et al., 2012). Clear-cut vulnerability of the hippocampi and white matter
in the juvenile brain compared to those in the adult brain has not been unequivocally
demonstrated despite some evidence pointing toward this (Pullela et al., 2006).
Vasogenic edema particularly spreads and is more frequently observed in the structured
cerebral white matter rather than the less ordered grey matter (Kimelberg, 1995, Vink
and Van Den Heuvel, 2004). This is because the movement results from pressure
gradients involving the least tissue resistance. The profuse swelling along white matter
tracts impacts the structural and functional integrity of the fibers (Feigin et al., 1973, Huh
et al., 2008).
Several molecular mediators in the neurovascular unit following TBI to the adult
brain demonstrate time-dependent, biphasic effects on the brain, with the acute or
chronic phase displaying either beneficial or detrimental impact on the brain’s vascular
structure and function (Xing et al., 2012). For instance, MMPs degrade neurovascular
matrix, damage the BBB, exacerbate edema and hemorrhage, and leads to neuronal
death in the acute phase of TBI in patients (Grossetete et al., 2009) and animals (MoritaFujimura et al., 2000, Wang et al., 2000). MMPs have however been found to promote
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neurovascular remodeling in the delayed phases (7 – 14 days) of experimental brain
injury in adult rodents (Zhao et al., 2006, Zhang et al., 2010). This biphasic effects are
yet to be studied in juvenile rodents. Other mediators displaying these time-dependent
effects include trophic factors released by reactive astrocytes (e.g. VEGF, bFGF, PDGF,
BDNF, etc.) and NMDA-type glutamate receptors (Xing et al., 2012).
BBB disruption contributes significantly to the development of secondary
complications of TBI, one of which is disrupted neurovascular coupling (Golding, 2002,
Iadecola and Nedergaard, 2007, Lok et al., 2007). Neurovascular coupling denotes the
association of neural activity in a particular brain locale to concomitant changes in
cerebral blood flow (CBF) (Pasley and Freeman, 2008). The magnitude and spatial
location of blood flow changes are tightly linked to changes in neural activity through a
complex sequence of coordinated events involving neurons, glia, and vascular cells
(Golding, 2002). In normal brain, local release of metabolic by-products such as carbon
dioxide (CO2), NO, adenosine, lactate, hydrogen ion (H+) and potassium ion (K+)
influence local CBF to match or ‘couple’ neural activity to blood flow (Lok et al., 2007,
Peterson et al., 2011). Following TBI, however, uncoupling often occurs whereby local
cerebral glucose utilization increases while local CBF decreases (Golding, 2002, BorSeng-Shu et al., 2012). Breakdown in normal activities and interactions between cells
making up the neurovascular units (which include endothelium, astrocytes, pericytes,
microglia and neurons) results in neurovascular uncoupling (Shlosberg et al., 2010).
Influx and release of several vasoactive factors due to BBB disruption (Hawkins and
Davis, 2005) and disturbance of cerebral autoregulation (Bor-Seng-Shu et al., 2012)
further exacerbate neurovascular uncoupling.
Post-traumatic epilepsy is another well-documented complication of TBI which
disruption of BBB contributes to (Tomkins et al., 2001, Tomkins et al., 2008, David et al.,
2009). Abnormal brain electrical activities observed on electroencephalogram (EEG)
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(which is indicative of abnormal neuronal signaling) were localized to brain regions with
clear signs of BBB disruptions in brains of patients suffering from post-traumatic epilepsy
(Tomkins et al., 2011). Experimental studies have implicated astrocytic dysfunction
together with altered potassium and glutamate homeostasis in this post-traumatic
epilepsy (Gupta and Gupta, 2006, David et al., 2009). Hemoglobin/Iron toxicity (Iudice
and Murri, 2000) has also been implicated in post-TBI epilepsy. Children who are victims
of severe TBI appear to have a lower risk of developing post-traumatic epilepsy
compared to their young adult (Pitkanen and McIntosh, 2006) and aged (Herman, 2002)
counterparts. In a retrospective population-based study conducted on data from a very
large sample of patients (n = 1.6 million people) in Denmark spanning three-and-a-half
decades, long-term risk (up to 10 years or longer) of post-traumatic epilepsy was found
to be increased with increased injury severity, age, and family history of epilepsy
(Christensen et al., 2009). Children are, however, reported to have a slightly higher risk
of early (i.e. occurring within 7 days of injury) post-traumatic epilepsy compared to adults
following severe TBI (Khan and Banerjee, 2010).
Disruption of BBB has notable negative consequences (besides neurovascular
uncoupling) on all major cell types within the brain following adult TBI. Reduced CBF
results in the creation of an oxygen- and nutrients-starved zone (Shlosberg et al., 2010),
with concomitant neuronal death (Park et al., 2008). Astrocytes (Chodobski et al., 2011)
and pericytes (Dore-Duffy et al., 2000) respond to breakdown of BBB following brain
trauma (Al Ahmad et al., 2009). Astrocytic foot processes swell due to high intake of
potassium ions, and this leads to failure of glutamate transporters and reversal of
glutamate uptake (Kimelberg et al., 1995, Park et al., 2008). Reversal of glutamate
uptake floods the extracellular space with excessive glutamate, which is a major culprit
in neuronal excitotoxicity (van Landeghem et al., 2006, Park et al., 2008). Astrogliosis,
marked by abnormal proliferation of the astrocytes, occurs in response to release of
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factors (thrombin, albumin, cytokines, etc.) and migration of peripheral cells into the
parenchyma following BBB disruption (Chodobski et al., 2011), and neuronal cell death
(Myer et al., 2006). Reactive astrogliosis occurs in a graduated fashion depending on
injury severity, and is linked with both detrimental and beneficial effects on neurons
which may be time-dependent (Myer et al., 2006, Laird et al., 2008, Wu et al., 2010).
NMDA and AMPA receptors on neurons are hyperactivated by the excessive
glutamate present in the parenchyma, leading to excessive Ca2+ and Zn2+ influx – a
hallmark of excitotoxicity that eventually kill the cells (Yi and Hazell, 2006, Park et al.,
2008, Zhu et al., 2009). Ca2+ influx activates several enzymes including proteases such
as calpains that damage components of neuronal and axonal cytoskeleton (Saatman et
al., 2010). Events such as cellular depolarization, increased oxidative stress,
mitochondrial dysfunction and caspase activation are linked to excitotoxicity (Zhao et al.,
2003, Park et al., 2008).
Following BBB disruption, intraparenchymal microglial cells become activated
and motile, migrating to the injured site within a rapid time frame (Nimmerjahn et al.,
2005, Ramlackhansingh et al., 2011). The rapid time frame in which microglia react to
BBB disruption suggests involvement of blood-borne and chemoattractive factors
(Chodobski et al., 2011). Microglial activation was found to persist in some clinical cases
for several years (up to 17 years) after TBI, even at regions distal from the focal impact
area (Ramlackhansingh et al., 2011). This highlights chronic inflammatory response that
evolves over time and the potential for intervention to be beneficial for long intervals after
TBI. It has been linked with both beneficial and deleterious effects.
Blood-derived leukocytes that infiltrate into brain parenchyma following BBB
disruption in adult TBI further exarcebate inflammatory response with consequent
deleterious effect on BBB integrity, observed as increased permeability and aggravation
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of edema (Wedmore and Williams, 1981, Lindbom, 2003, Schmidt et al., 2007, Kenne et
al., 2012).

Search for Therapeutic Avenues for Controlling BBB Disruption
and Edema in Juvenile TBI
As highlighted in the preceding sections, BBB disruption is central to acute and longterm secondary brain damage following TBI (Shlosberg et al., 2010). The gradual
evolution and biphasic nature of BBB breakdown allow a therapeutic window of
opportunity to halt the progression of secondary injury on its track (Beauchamp et al.,
2008, Park et al., 2008). To this end, the restoration of BBB integrity (Shlosberg et al.,
2010) and abrogation of edema formation (Huh and Raghupathi, 2009, Fukuda et al.,
2012) are emerging targets for brain protection following juvenile TBI.
Most of past research efforts aimed at investigating interventions for brain trauma
have been focused on adult TBI (Adelson et al., 2003), which is reflected in the common
use of adult rodents and primates (Prins and Hovda, 2003). Scientific observers have
therefore called for more studies focusing on juvenile TBI (Adelson et al., 2003, Taylor,
2004), especially given that majority of TBI cases occur in children and young adults
(Langlois et al., 2006, Rutland-Brown et al., 2006, Giza et al., 2007).
Although preclinical studies on drug agents such as corticosteroids, non-steroidal
anti-inflammatory drugs (NSAIDs), monoaminergic substances, cyclosporine, and
cannabinoids for combating post-TBI secondary damage were highly promising,
randomized control trials on these agents have had mostly negative results (Edwards et
al., 2005, Beauchamp et al., 2008, CRASH-2, 2011). One of the factors responsible for
failure of most of these trials may be the inability of the tested drugs to ameliorate BBB
disruption and edema formation on the brain post-TBI (Vink and Van Den Heuvel, 2004).
Trials targeting pediatric TBI patients (which are scarce) have also not met with much
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success (Natale et al., 2006). A search for safe and potent pharmacological agents that
could act at the level of brain vasculature and ameliorate post-traumatic BBB disruption
(Shlosberg et al., 2010) is therefore warranted, particularly for the under-researched
young demographic. It is not a guarantee that a drug that limits BBB disruption and
edema in juvenile TBI will also be effective in adult TBI, due to potential differences in
the severity, duration, and mechanisms of BBB disruption and edema following injury to
the juvenile brain versus adult brain (Giza et al., 2007, Huh and Raghupathi, 2009).
Another desirable property for any potential pharmacological agent targeting BBB
damage and edema in jTBI is the ability to act in more than one cell type and attenuate
multiple secondary injury factors (Vink and Van Den Heuvel, 2004). This is important
because juvenile TBI, not unlike adult TBI, is a multifactorial and multifaceted
pathological phenomenon (Anderson and Yeates, 2010) that affects all major cell types
in the brain (Potts et al., 2006, Chodobski et al., 2011). Moreover, BBB is a dynamic
interface that is part of the neurovascular unit, and damage to the BBB elicits responses
from all cell types that are part of that unit (e.g. endothelial cells, astrocytes, microglia,
pericytes, and neurons [see sections 2.3 and 2.4 above]) (Chodobski et al., 2011). Posttraumatic cerebral edema and neuroinflammation also affect all cell types in the
neurovascular unit (Chodobski et al., 2011). Therefore, while the search is not for a
‘panacea’ – an unrealistic universal drug that ameliorates or cures all pathophysiological
problems associated TBI in every cell of the developing brain – it is nonetheless
desirable that potential drugs have multiple targets and regulate signaling cascades that
are not limited to only one cell type in the brain (Vink and Van Den Heuvel, 2004).
Yet another coveted property which a new drug should possess if it to be used in
juvenile TBI cases is the ability to reverse the neurological and cognitive deficits that
characterize trauma to the developing brain (Adelson et al., 2000, Ajao et al., 2012). The
long-lasting nature of some of these deficits highlighted earlier in section 1 often leaves
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survivors of moderate to severe TBI saddled with residual and emergent functional
problems of sensorimotor, cognitive and psychiatric nature (Max et al., 2000, Yeates et
al., 2002, Davis and Dean, 2010). The ability to reverse these deficits and restore normal
function long-term will be suitable for a drug to be used in jTBI cases.
Two groups of proteins that are of primary interest to this dissertation with respect to
their potential to influence endothelial barrier permeability, edema formation, and a few
other pathological processes in the neurovascular unit (such as neuronal apoptosis and
disruption in cerebral blood flow autoregulation) are caveolins (cav-1, cav-2 and cav-3)
and c-Jun N-terminal kinases (JNK-1, JNK-2, and JNK-3). Varied isoform mix of
caveolins and JNKs are present in most of the cell types constituting the neurovascular
unit (endothelial, neuronal, astrocytic, etc.) and both affect signaling cascades and
processes in these cell types under physiological and pathological conditions.
Pharmacological agents that mimic caveolins (see section 4) or inhibit JNKs (see section
5) are available for use in in vitro and in vivo studies investigating these proteins. These
agents have potentials for clinical translation. Ultimately, the main focus of this project is
investigating the roles of caveolins and JNKs in regulating BBB disruption and edema
formation, and how drugs mimicking or targeting these molecules might correct
neurological and cognitive deficits following juvenile TBI both short-term and long-term.
The next two sections provide background information and elaborate on the importance
of caveolins and JNKs to BBB regulation.

Caveolae and Caveolins in Brain Pathologies
Caveolae were first identified and morphologically described almost
simultaneously by Eichi Yamada (who gave the name ‘caveolae’ which means ‘little
caves’) (Yamada, 1955) and the late Nobel laureate and cell biologists George E.
Palade (Palade, 1953) in the early 1950s. Caveolae appear under electron microscope
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as vesicular plasma membrane invaginations that are usually 50 – 100 nm in diameter
(Palade, 1953). They are early components of what are later called ‘lipid rafts’ –
specialized membrane microdomains that are highly enriched in cholesterol,
glycosphingolipids and glycolipoproteins (Simons and van Meer, 1988, Lajoie and Nabi,
2010). George Palade proposed the first functional hypothesis for caveolae –
transcytosis (Travis, 1993), but definitive proof of this was delayed by technical restraints
for decades until caveolae could be isolated and their structural units examined.
Caveolins, the integral membrane structural proteins that form oligomeric assemblies
necessary for the characteristic shape and functions of the caveolae in brain lipid rafts
(Sargiacomo et al., 1995, Predescu et al., 2007), were discovered in the early 1990s in
the lab of Dr. Richard G. Anderson (Rothberg et al., 1992). The lab was able to raise
antibodies which label the caveolae membrane proteins. Research into the molecular
structure and functions of caveolins blossomed from there onwards.
The caveolin gene is conserved across various species of metazoan (vertebrate
and invertebrate animals). It has being studied in some invertebrate (e.g. Apis mellifera,
honeybee; C. elegans, roundworm; Crassostrea gigas, pacific oyster; etc.) and nonmammalian (e.g. Danio rerio, zebrafish; Xenopus laevis, frog; etc.) systems. Amongst
mammals, caveolin gene and protein products have been studied notably in mice, rats,
pigs, monkeys and humans (Tang et al., 1997, Schlachetzki and Pardridge, 2003, Spisni
et al., 2005, Kirkham et al., 2008). There are three main isoforms of caveolins –
caveolins-1, 2 and 3 – and their presence has been reported in humans and in nonhuman species (Scherer et al., 1997, Razani et al., 2002a, Shin et al., 2003). The three
isoforms enjoy a wide distribution in various tissues and organs of the human body
(Virgintino et al., 2002, Das et al., 2007a, Tourkina et al., 2008). Whereas all three
caveolin isoforms are present in the brain, their localization differs. Caveolins-1 and 2
usually form hetero-oligomers and predominantly localize to the caveolae (Cohen et al.,
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2004, Schwencke et al., 2006) and some cytosolic organelles such as endoplasmic
reticulum, mitochondria and Golgi (Li et al., 2001, McCaffrey et al., 2007) in brain
endothelial cells (Cameron et al., 1997, Virgintino et al., 2002). However, caveolin-1 has
been found in smaller concentrations in some neurons, astrocytes and ependymal cells
under both physiological and pathological conditions (Galbiati et al., 1998b, Shin et al.,
2005, Head et al., 2008, Head et al., 2010). Caveolin-3 is predominantly found in
astrocytes in the brain (Ikezu et al., 1998, Virgintino et al., 2002), and in skeletal,
cardiac, and smooth muscles in the periphery (Song et al., 1996).
Early transcription of caveolin gene and expression of its isoforms have been
observed in several animal models. Cav-1 immunoreactivity in human fetal tissues
has been observed from mid to late gestation (14 to 39 weeks) in patterns similar to that
of adult tissues (Barresi et al., 2006). There were, however, some positive staining
pattern in the fetal tissues (e.g. in urothelium) not seen in adult tissue, which suggests
novel roles for cav-1 during embryogenesis (Barresi et al., 2006). Cav-1 mRNAs have
been shown to localize in primitive blood vessels of embryonic mice lungs starting at
E10 (Ramirez et al., 2002), suggesting that the caveolins are intact at birth in rodents.
The level of cav-1 mRNAs in rodent cortex peaks at P12 – during active brain
development (Cameron et al., 1997) – and decreases with age (Head et al., 2010). In
chicken, cav-3 immunoreactivity was observed as early as E4, when it is localized to the
neural tube and myotome, and seen in glia of chicken brain at E6 (Shin et al., 2003).
Cav-3 immunoreactivity changes at various stages of embryogenesis in a non-linear
manner, suggesting that the gene and protein play active roles in early development
(Shin et al., 2003). Caveolin-1 was shown to be required for proper dorsoventral
patterning in zebrafish embryogenesis (Mo et al., 2010). The abnormal phenotypes in
zebrafish embryos caused by ablation of Cav-1 – which include weak dorsalization, early
tailbud protrusion, curved bodies, deformed notochord and somites, and shortened tails
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– were rescued by the expression of human Cav-1, suggesting that cav-1 function is
conserved in both species (Mo et al., 2010).
Meanwhile, the caveolins scaffold several signaling molecules through their
scaffolding domain (CSD) (Sargiacomo et al., 1995, Cameron et al., 1997, Couet et al.,
1997a, Couet et al., 1997c, Garcia-Cardena et al., 1997, Razani et al., 2002b, Lajoie and
Nabi, 2010). The CSD binds well-defined caveolin-binding motifs (CBM) present in
signaling proteins, such as protein kinases (Galbiati et al., 1998a, Okamoto et al., 1998)
and in enzymes such as endothelial nitric oxide synthase (eNOS) (Garcia-Cardena et
al., 1996, Couet et al., 1997a, Bucci et al., 2000). For instance, in peripheral endothelial
cells, cav-1, via its CSD, functions as a potent endogenous inhibitor of the p42/44-MAPK
and JNKs (Wang et al., 2006, Tourkina et al., 2008, Tourkina et al., 2010).
Furthermore, the binding of caveolin to eNOS through CSD-CBM interaction
(Garcia-Cardena et al., 1997) is widely implicated in the control of endothelial
permeability both in the periphery (Bucci et al., 2000, Siddiqui et al., 2011) and in the
brain (Gu et al., 2011). Synthesis of NO by eNOS is negatively regulated by caveolin-1
in both brain and peripheral endothelia (Bucci et al., 2000, Bernatchez et al., 2005).
Thus, cav-1 regulates the concentration of NO – the most potent endogenous
vasodilator known (Cooke and Dzau, 1997) and a mediator of increased endothelial
permeability (Lal et al., 2001, Yuan and Rigor, 2010) (See Fig. 2). A synthetic peptide
(called Cav-AP, cavtratin, or CSD peptide), made by fusing the CSD of caveolin-1 with a
transporter sequence, is being used to investigate mimicry of cav-1 function in
experimental studies (Bucci et al., 2000, Argaw et al., 2012).
Caveolin-1 mRNAs, protein levels, and activation states are changed in response
to brain injuries such as cold cortical injury (Nag et al., 2007, Nag et al., 2009), brain
ischemia (Jasmin et al., 2007), and experimental spinal cord injury (Shin et al., 2005,
Shin, 2007). Decrease in cav-1 has been implicated in neurodegenerative disorders
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such as Alzheimer’s disease (Head et al., 2010). Increase in cav-1 (Nag et al., 2007)
and its phosphorylated forms (Nag et al., 2009) was observed up to four days following
cold cortical injury model in adult rats, and in the clip compression model of spinal cord
injury in rats (Shin, 2007). These reported changes in cav-1 are usually associated with
BBB or blood-spinal cord barrier breakdown and vasogenic edema (Shin et al., 2005,
Nag et al., 2007, Gu et al., 2011, Li et al., 2012). In both the brain and in peripheral
organs, Cav-1 has been recognized as a potent tumor-suppressor in many forms
metastatic cancers (Engelman et al., 1998, Gratton et al., 2003, Cohen et al., 2004,
Williams and Lisanti, 2005). The Cav-1 gene is localized in a tumor suppressor locus at
7q31.1(Sloan et al., 2004). There are, however, a few models in which Cav-1 may
function as a tumor promoter (Williams et al., 2005, Williams and Lisanti, 2005).
Endothelial caveolins have been associated with various structural components
and signaling pathways of the BBB [See (Komarova and Malik, 2010) for a recent review
detailing the roles of caveolins in regulating brain endothelial permeability]. It is wellestablished that caveolins regulate the transcellular route of endothelial permeability via
transcytosis (Komarova and Malik, 2010, Yuan and Rigor, 2010). Transcytosis is a
process in which solutes can traverse the interior of endothelial cells via receptormediated vesicle endocytosis – a form of transcellular transport – originating at caveolae
(Predescu and Palade, 1993, Simons and Ikonen, 1997, Predescu et al., 2007) (See
Fig. 2). However, caveolins also influence the paracellular route of endothelial
permeability. For instance, claudins and occludins are found in isolated caveolae, where
they interact with caveolins (Nusrat et al., 2000, McCaffrey et al., 2007, Song et al.,
2007, Stamatovic et al., 2009, Itallie and Anderson, 2012) (See Fig. 2). The level of
oligomeric claudin-5 and occludin seen in normal brain endothelial caveolae (McCaffrey
et al., 2007) is reduced during pathological conditions such as hypoxia-reoxygenation
(McCaffrey et al., 2009). Such reduction engenders tight junction and BBB disruption
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(McCaffrey et al., 2008). Several receptors and signaling molecules that are known to
mediate endothelial permeability possess caveolin binding motifs (CBMs) and are
morphologically and/or biochemically linked with caveolins within the caveolae (See
Table 1) (Couet et al., 1997a, Couet et al., 1997b, Okamoto et al., 1998, Razani et al.,
2002b, Komarova and Malik, 2010).
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Table 1: Caveolae-Localized and Caveolin-Interacting Molecules Implicated in
Mediating Endothelial Permeability. Adapted from (Razani et al., 2002b).
Molecule with
Caveolar
Localization
Receptor Tyrosine
Kinase (RTK), e.g.
VEGFR-2

Class

M

Endothelial
Receptor

+

Interact
with
B
Caveolins
+
+

G-Protein Coupled
Receptors (GPCR),
e.g. Bradykinin B2
receptor

Endothelial
Receptor

+

+

Integrin Receptor

Endothelial
Receptor

+

+

+

Calcium

Intracellular
Second
Messenger

+

+

Cyclic AMP (cAMP)

Intracellular
Second
Messenger

+

+

(Schwencke et al.,
1999, Razani and
Lisanti, 2001)

NO-Cyclic GMP
(NO-cGMP)

Intracellular
Second
Messenger

+

+

(Garcia-Cardena et
al., 1996, Linder et
al., 2005)

Myosin Light-Chain
Kinase/Phosphotase
(MLCK/MLCP)

Protein
Kinase /
Phosphotase

+

+

Protein Kinase C
(PKC)

Protein
Kinase

+

+

(Somara et al., 2011,
Cunningham and
Turner, 2012, Rigor et
al., 2012)
(Lisanti et al., 1994,
Oka et al., 1997,
Rybin et al., 1999)

Focal Adhesion
Kinase (FAK)

Protein
Kinase

+

+

Rho Family
GTPases

Protein
Kinase

+

+

+

+

Matrix
Metalloproteinases
(MMPs), e.g. MMP2 and MMP-9

+

Protease
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References
(Feng et al., 1999a,
Feng et al., 1999b,
Labrecque et al.,
2003)
(Haasemann et al.,
1998, Ju et al., 2000,
Chini and Parenti,
2004)
(Echarri and Del
Pozo, 2006, Ning et
al., 2007, Shi and
Sottile, 2008)
(El-Yazbi et al., 2008,
Pani and Singh,
2009)

(Lee et al., 2002,
Pelkmans et al.,
2005)
(Somara et al., 2011)
(Puyraimond et al.,
2001, Phillips and
Birnby, 2004)

A Disintegrin and
Metalloproteases
(ADAMs)

Protease

+

Fibrinogen

Extracellular
Matrix Protein

Bradykinin

Endogenous
Vasoactive
substance

+

+

(Liu et al., 2010)

Vascular Endothelial
Growth Factor
(VEGF)

Endogenous
Vasoactive
substance

+

+

(Feng et al., 1999a,
Feng et al., 1999b,
Bauer et al., 2005)

Nitric Oxide (NO)

Endogenous
Vasoactive
substance

+

+

(Garcia-Cardena et
al., 1996, Bernatchez
et al., 2005, Linder et
al., 2005)

Endothelial Nitric
Oxide Synthase
(eNOS)

Endogenous
Vasoactive
substance

+

+

(Garcia-Cardena et
al., 1997, Bucci et al.,
2000)

Sphingosine-1Phosphate (S1P)

Endogenous
Vasoactive
substance

+

+

(Rosen and Goetzl,
2005, Singleton et al.,
2006, Yuan and
Rigor, 2010)

Angiopoietin-1
(Ang-1) & Tie-2

Endogenous
Vasoactive
substance

+

+

(Yoon et al., 2003)

+

+

+

+

(Kurozumi et al.,
1983)

M = morphological evidence; B = biochemical evidence
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(Wilke and Bubeck
Wardenburg, 2010)

Strong evidence has also emerged from several in vivo and in vitro brain
endothelial and brain disease models that support beneficial roles for caveolins in the
maintenance of TJ proteins (Jasmin et al., 2007, Song et al., 2007, Gu et al., 2011). In
an in vivo brain inflammatory model, VEGF-A was found to reduce claudin-5 expression
and induce BBB disruption by signaling through VEGF-2 receptor (VEGFR2) and eNOS
(Argaw et al., 2012). Both VEGFR2 and eNOS are negatively regulated by caveolin
(Garcia-Cardena et al., 1996, Feng et al., 1999a) and by cavtratin (Bucci et al., 2000,
Gratton et al., 2003). Cavtratin also reverses VEGF-mediated decrease in claudin-5
expression (Argaw et al., 2012). This observation, however, is by no means universal, as
some reports have suggested that caveolin-1 could play a less beneficial role (e.g.
redistribution of claudin-5 and occludin, which may lead to transient increase in BBB
permeability early on after brain insults) at least transiently in some models such as in
vitro inflammatory and drug-stimulated models of brain endothelial cells (Stamatovic et
al., 2009, Park et al., 2011) and in early ischemic stroke models (Liu et al., 2012). This
highlights the need to investigate the physiologic roles of caveolins and their potential
roles in human pathology (Minshall et al., 2003, Sellers et al., 2012).
Interestingly, cav-1 knockouts (-/-) mice display unique defects that include
impaired angiogenic response (Woodman et al., 2003), aberrations in endotheliumdependent relaxation, contractility and vascular tone (Drab et al., 2001, Razani et al.,
2001), and, importantly, microvascular hyperpermeability (Schubert et al., 2002). The
increased microvascular permeability was observed in peripheral organs (lung, heart,
spleen, kidney, liver, and skeletal muscle) and in the brain (there is a two-fold increase in
the level of extravasated radio-iodinated BSA in the brains of cav-1 knockout mice)
(Schubert et al., 2002). In vivo knockdown of cav-1 expression in mouse lung endothelia
with siRNA resulted in dilated interendothelial junction, with concomitant increase in lung
vascular permeability to albumin and increased plasma NO concentration (Miyawaki-
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Shimizu et al., 2006). In an ischemic stroke study in mice, cav-1 knockouts have worse
outcome than the wild-type (WT), with increased cerebral volume of infarction, impaired
cerebral angiogenesis, and increased cerebral apoptotic cell death (Jasmin et al., 2007).
Stimulation of brain microvascular endothelial cells (BMECs) with the chemokine
CCL2 reduces expression of cav-1, accompanied with decrease in the expression of
occludin (Song and Pachter, 2004, Song et al., 2007). Although, a sharp increase in
cav-1 level has been reported to precede the decrease in expression of claudin-5 and
occludin in cold cortical injury models in adult rats (Nag et al., 2007), there are no
definitive proofs that increase in cav-1 in this model is altogether detrimental.
Furthermore, in a cerebral ischemic-reperfusion injury model, Gu and colleagues
demonstrated extensively that Cav-1 plays a critical role in protecting BBB integrity
through inhibition of MMPs activity in brain microvessels and other brain tissues (Gu et
al., 2011, Gottschall and Barone, 2012). This is through cav-1’s inhibition of eNOS
activity and resultant reduction of NO production – overproduction of NO has been
shown to increase MMP-9 activity (Gursoy-Ozdemir et al., 2000, Gursoy-Ozdemir et al.,
2004). Exposure of human brain endothelial cells (HBMEC) to high concentration of
unconjugated bilirubin (a model to mimic hyperbilirubinemia) acutely increases the
expression of endothelial caveolin-1 with intact tight junction integrity, whereas
prolonged exposure results in reduction in caveolin-1 expression and tight junction
compromise (Palmela et al., 2012). The putative beneficial role of cav-1 in these models
is possibly related to its regulation of the phosphorylation states, distribution, and
oligomerization of TJ proteins, all of which are essential in maintaining functional interendothelial TJs (Kachar and Reese, 1982, McCaffrey et al., 2007, Stamatovic et al.,
2009, Wolburg et al., 2009).
Regulation of brain endothelial permeability is undoubtedly a complex process
with intricately interwoven molecular players and mechanisms (Abbott et al., 2006,
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Shlosberg et al., 2010, Yuan and Rigor, 2010). In addition to factors that have been
mentioned previously, JNK activation appears to contribute tremendously to TJ and BBB
disruption in some brain disease models (Tai et al., 2010, Tu et al., 2011). The 3 JNK
isoforms are known to have well-conserved caveolin-binding motif (CBM) (Okamoto et
al., 1998). Cav-1 inhibits JNK activation endogenously in the periphery, such as in
models of fibrotic lung disease (Tourkina et al., 2008) and in cardiac ischemicreperfusion (IR) injury (Das et al., 2007b). Such JNK inhibition has been shown to result
in increased expression and strengthening of tight junction proteins in the periphery
(Kojima et al., 2010, Samak et al., 2010). Furthermore, cav-1 inhibits the expression of
proinflammatory cytokines in macrophages and endothelial cells in part by regulating
JNK activation (Wang et al., 2006). A drug that restored caveolin-1 expression in a
mouse model of pulmonary inflammation and fibrosis was also found to simultaneously
inhibit MAPK activation, including JNK activation (Meng et al., 2012). This evidence
opens up the possibility that endogenous interaction between cav-1 and JNK within brain
endothelial cells may influence BBB permeability. The role of caveolin-1 in mediating
JNK inhibition is yet to be researched in brain trauma models.
The roles of caveolin in regulating both transcellular and paracellular routes of
endothelial permeability continues to be under investigation in some models (Minshall et
al., 2003, Komarova and Malik, 2010). However, to date, there are no reported studies
that characterize the expression of brain endothelial caveolins in a juvenile model of TBI
in association with BBB dysfunctions. There have also been no reports on how drugs
that target or mimic the caveolins (e.g. cavtratin) impact histological, neurological and
cognitive outcomes following juvenile TBI.
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The c-Jun N-terminal Kinases (JNKs): Expression and Inhibition
following Brain Injuries
The c-Jun N-terminal kinases (JNKs) were first described in the early 1990s as
consisting of serine/threonine protein kinases which phosphorylate the N-terminal
transactivation domain of the c-Jun transcription factor upon activation by stress stimuli
(Pulverer et al., 1991, Derijard et al., 1994). JNKs are members of a mitogen activated
protein kinase (MAPK) subfamily. The other two MAPK subfamilies are p38 and ERK
(Widmann et al., 1999, Plotnikov et al., 2011). There are three JNK genes – JNK1, JNK2
and JNK3 (Pulverer et al., 1991, Derijard et al., 1994, Kallunki et al., 1994, Gupta et al.,
1996). Alternative splicing of these genes yield 10 identified JNK isoforms (Waetzig and
Herdegen, 2005). All 3 JNK genes are highly conserved across various species ranging
from yeast to mammals (Goberdhan and Wilson, 1998, Kirkham et al., 2008).
In mammals, JNK1 and JNK2 are ubiquitously expressed, while JNK3 is primarily
expressed in the heart, brain, endocrine pancreas and testis (Waetzig et al., 2006).
JNKs are found in various cell types in the brain, including neurons (Lannuzel et al.,
1997, Herdegen et al., 1998), endothelial cells (Etienne et al., 1998, Waetzig et al.,
2006), and astrocytes (Migheli et al., 1997, Xie et al., 2004). Basal JNK activity level in
the brain is 15 to 30-fold higher than in other tissues under physiological conditions (Xu
et al., 1997, Coffey et al., 2000). JNKs in the brain are activated even further following
external stimuli and pathological events (Borsello and Bonny, 2004).
JNKs are activated by dual phosphorylation of threonine (Thr) and tyrosine (Tyr)
residues within a unique Thr-Pro-Tyr motif located in subdomain VIII of the kinases (Ip
and Davis, 1998). This phosphorylation is catalyzed by upstream kinases – MKK 4 and 7
(Widmann et al., 1999, Kyriakis and Avruch, 2001, Waetzig et al., 2006). A wide range of
environmental and biological stressors are capable of activating JNKs, and these include
UV light, inflammatory cytokines, reactive oxygen species (ROS), growth factors, protein
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synthesis inhibitors, as well as physical and biomechanical perturbations (Davis, 1999,
Borsello and Bonny, 2004). JNKs can also be deactivated by some specific
phosphatases (Palacios et al., 2001, Masuda et al., 2010).
In terms of function, JNKs are essential for normal brain development and
organogenesis in general during embryonic development (Haeusgen et al., 2009).
Postnatally, JNKs play various roles ranging from regulation of cell survival and
apoptosis to proliferation (Nishina et al., 2004, Waetzig and Herdegen, 2005, Waetzig et
al., 2006, Haeusgen et al., 2009). They are also activated under pathological conditions
both in the brain (Brecht et al., 2005, Bogoyevitch, 2006) and in the periphery (Cui et al.,
2007, Chaudhury et al., 2010).
Most of the studies on JNK pathway in rodent brains have focused predominantly
on neuronal activation triggered by excitotoxic events (Lennmyr et al., 2002, Borsello et
al., 2003, Cui et al., 2007, Haeusgen et al., 2009). There is however increasing evidence
that JNK is also activated in glial cells (Xie et al., 2004) and brain endothelial cells (Lo et
al., 2005, Kacimi et al., 2011), and that such activation in non-neuronal cells negatively
impacts neuronal cell death and function (Xie et al., 2004). Zhu and colleagues (2003)
reported the hyperactivation of JNK in murine cerebral microvascular endothelial
(bEND.3) cells in vitro. Such overt JNK hyperactivation in brain endothelial cells has
been implicated in clinical pathologies including Alzheimer’s disease, strokes and
multiple sclerosis (Vukic et al., 2009, Grammas, 2011). Kusaka et al (2004) reported an
acute hyperactivation of JNK following subarachnoid hemorrhage (SAH) in rat brain
endothelium. Benakis et al (2010) reported the modulation of non-neuronal inflammatory
processes in the brain by DJNKI-1, a competitive JNK inhibitor that was injected
peripherally. Studies have indicated that DJNKI-1 crossed the BBB and penetrated the
cerebral cortex within 1.5 hours after intraperitoneal (i.p.) injection in rodents, and could
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remain stable in brain parenchyma for at least 3 weeks (Repici et al., 2007, Ploia et al.,
2011, Sclip et al., 2011).
Experimental and clinical observations show that JNK phosphorylation initially
drops, but begins to rise at 1.5 hours and peaks at 9 hours after stroke (Gao et al.,
2005). Phosphorylation of c-Jun, a JNK substrate, follows a similar pattern, peaking at 8
hours post-stroke (Borsello et al., 2003, Gao et al., 2005). Activation of JNK in ischemic
strokes has been linked with mitochondrial apoptotic pathway and nuclear translocation
of MADD (MAP kinase-activated death domain-containing protein) in neurons (Putcha et
al., 2003, Centeno et al., 2007). Increase of Phospho-JNK was also reported in the brain
tissues from 6 TBI patients, and experimental reports have confirmed this increase from
1 to 48 hours post-injury in a CCI model in adult mice (Ortolano et al., 2009).
Hyperactivation of JNK in CNS pathologies has been linked with BBB disruption (Tu et
al., 2011).
The inhibition of JNK pathway has been shown to be beneficial in some models
of adult and juvenile brain damage. Borsello et al (2003) reported that the competitive
JNK-inhibitor, DJNKI-1, protects against NMDA-induced neurotoxicity in hippocampal
neurons cultured from 2-day old rat pups. Using the drug (DJNKI) after TBI in newborn
piglets, Armstead et al (2011a) showed that inhibiting the JNK pathway mitigates
cerebral hemodynamic dysfunctions observed in jTBI. Moreover, deletion of JNK3 gene
protects neonatal mice against cerebral hypoxic-ischemic (HI) injury (Kuan et al., 2003,
Pirianov et al., 2007). Tu et al (2011) also showed that in overweight rat pups (P7 and
P21), experimental HI brain injury results in BBB breakage strongly mediated by JNK
overactivation.
Experimental evidence suggests that JNK hyperactivation will likely increase
endothelial hyperpermeability both in the periphery (Chen et al., 2006, Hu et al., 2013)
and in the brain (Yatsushige et al., 2007, Tu et al., 2011) (See Fig. 3). Activated JNK
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and its substrates (e.g. phosphorylated c-Jun) are strong regulators of TJ proteins in the
periphery (Betanzos et al., 2004, Carrozzino et al., 2009, Kojima et al., 2010, Samak et
al., 2010). For example, inhibition of JNK pathway in mammary epithelial cells enhances
TJ barrier function through modulation of claudin-5 expression (Carrozzino et al., 2009).
Furthermore, the protein c-Jun, a substrate phosphorylated by JNK, exerts regulatory
control on TJ proteins in epithelial cells (Betanzos et al., 2004). In human pancreatic
cells, JNK strongly regulates TJ proteins at the tricellular contacts (Kojima et al., 2010).
With regard to brain endothelial cells, activation of JNK and c-Jun has been shown in
vitro to increase cerebral endothelial cell permeability through disruption of
interendothelial TJ complexes (Etienne et al., 1998, Adamson et al., 1999, Wolburg and
Lippoldt, 2002).
Meanwhile, certain molecular mediators of endothelial hyperpermeability known
to interact with caveolins are also linked with increased JNK activation under
pathological conditions such as inflammation. These include VEGF and VEGFR2 (Upon
ligand binding, VEGFR2 activates multiple protein kinase-dependent signaling including
JNK pathway to induce hyperpermeability) (Kumar et al., 2009), protein kinase C (PKC)
(Yuan and Rigor, 2010), and src-kinase (Yoshizumi et al., 2000) (See the preceding
section above for literature evidence of links between JNKs and caveolae/caveolins).
Inhibitors of JNK pathway have been shown to reduce and reverse TJ disruption in
injured brain-derived endothelial cells through decreased inducible nitric oxide synthase
(iNOS) activation and NO production (Kacimi et al., 2011). Furthermore, under
inflammatory condition in human lung microvascular endothelial cells, bradykinin
potentiates eNOS-derived NO generation in part through JNK signaling (Lowry et al.,
2013). Hence, mounting evidence suggests that caveolins and JNKs both play key roles
in mediating the eNOS-NO pathway in the endothelium (Minshall et al., 2003, Balligand
et al., 2009). JNK is also highly activated in laminar shear stress experiments performed
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on endothelial cells (Yoshizumi et al., 2003) with concomitant increase in caveolins and
caveolae number (Frank and Lisanti, 2006).
Recovery of neurological and cognitive function in both the short- and long-term
is a desirable property for any pharmacological agent to be used for juvenile TBI. To this
end, it is important to note that DJNKI-1, a competitive JNK inhibitor (see below), has
been shown to ameliorate behavioral deficits in experimental models of stroke (Esneault
et al., 2008), neuroinflammation (Palin et al., 2008), and spinal cord injury (Repici et al.,
2012) in adult rodents, even when injected peripherally. D-JNKI-1 was also successfully
used to arrest the progression of hearing loss in a model of cochlear implantation trauma
(Eshraghi et al., 2006). The action of DJNKI-1 in various forms of CNS injuries possibly
extend beyond brain endothelial cells (where it could reduce BBB disruption) (Tu et al.,
2011, Repici et al., 2012) to neurons (where it reduces excitotoxicity and neuronal cell
death) (Borsello et al., 2003), astrocytes (Huang et al., 2009, Kang et al., 2011), and
microglia (Repici et al., 2012). Hence, DJNKI-1 could potentially mitigate several aspects
of secondary brain damage in various cells simultaneously to maximize recovery.
Meanwhile, the possibility of systemic mode of action for DJNKI-1, which is beneficial to
recovery, has been raised in some in vivo experimental studies (Lehnert et al., 2008,
Touchard et al., 2010, Benakis et al., 2012).
The drug, DJNKI-1, is a synthetic, protease-resistant and cell-penetrating peptide made
by linking HIV-TAT transporter peptide sequence to the 20-amino acid JNK-binding motif
of JIP-1 (Borsello et al., 2003). The D-retro-inverso synthesis (i.e. made with D-amino
acids) of DJNKI-1 gives it strong resistance against proteolytic degradation and
increases its stability in the body (Borsello et al., 2003, Borsello and Bonny, 2004). The
peptide functions through competitive inhibition of all JNK isoforms (see Fig. 3). DJNKI1 selectively blocks access of JNK to c-jun and other downstream substrates such as
JunB, JunD, and c-myc by competing for the JNK-binding site of JIP-1(Borsello et al.,
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2003, Borsello and Forloni, 2007) (see Fig. 3). The potential for therapeutic
effectiveness of DJNKI-1 in jTBI is pegged on its ability to modulate upstream and
downstream arms of the secondary injury cascade, including excitotoxicity, hypoxiaischemia, BBB disruption, edema, neuroinflammation and apoptosis (Yang et al., 1997,
Kuan et al., 2003, Tu et al., 2011).

Research Aims
Juvenile TBI is a field that has not been well-researched, and in which no
pharmacological agent has been successfully translated for clinical use. A reliable and
reproducible animal model of jTBI is needed as a starting point to test various
hypotheses. A controlled cortical impact (CCI) model of TBI [modeled after one
described by Brody et al. (2007)] in juvenile (P17) rats has been developed for this
purpose (Ajao et al., 2012). This model could be used to probe the effects of juvenile TBI
on neurobehavioral function, brain morphology and molecular structures. Effects of jTBI
on brain structures and functions at both acute and latter time point(s) need to be
thoroughly studied to enhance the clinical relevance of the model. For instance, effect of
TBI on the morphology and function of the developing white matter is not well studied.
Neurological and cognitive tests could also be carried out longitudinally to establish
functional deficits resulting from brain injury in this model.
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Having established the relevance of caveolin-1 and JNK activation to secondary
events that occur in juvenile brain injury in the preceding sections, the CCI model could
be used to study changes in protein expression of caveolin-1 and activation of JNK
following jTBI. Moreover, the potential therapeutic effects (functional and/or histological)
of pharmacological mimicry of caveolin function and inhibition of JNK could be examined
with the use of cavtratin and DJNKI-1 respectively on jTBI animals. The role caveolin-1
and JNK activation are playing in aggravating or reversing BBB disruption could be
studied with the use of cavtratin and DJNKI-1 respectively.
Literature evidence reviewed so far suggest parallel molecular pathways that link
endothelial caveolins and JNKs to the control of paracellular and transcellular
permeability pathways, which may have important consequences on BBB integrity and
TBI outcome. This theory has never been examined in the context of jTBI. We therefore
hypothesize that:

Following juvenile TBI, upregulation and activation of caveolins-1 in brain
endothelial cells endogenously attenuate BBB disruption and edema, while JNK
hyperactivation exacerbates BBB disruption, with concomitant morphological
damage and functional deficits in the short- and long-term.

This hypothesis will be tested in controlled cortical impact (CCI) model of TBI in
juvenile (P17) rats. The questions raised above will be explored under the following
three aims.

Aim 1: Characterize the acute and long-term neurological, electrophysiological
and histological changes following juvenile TBI.
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Hypothesis: Induction of controlled cortical impact injury in P17 rat pups will engender
observable adverse outcomes on neurological function and on brain tissue properties
that will last for weeks after the initial insult.
A battery of neurological and cognitive tests will be carried out longitudinally on rats
subjected to CCI and on their sham counterparts. Electrophysiological profiles of these
rats as well as their histology will be observed from juvenile period into early adulthood.
Lesion volume and T2 changes will also be measured.

Aim 2: Characterize changes in the expression pattern and immunoreactivity of
caveolins-1, 2, and 3 after juvenile TBI in conjunction with BBB disruption and
edema formation.
Hypothesis: Decrease in the tight junction protein levels and resultant opening of the
BBB will be associated with increase in the expression of caveolins-1, 2 and 3 in brain
endothelial cells following juvenile TBI.
The expression level of caveolins will be determined via immunohistochemistry and
immunoblotting at 1, 3, 7 and 60 days post-jTBI. BBB disruption will be confirmed via
IgG staining and edema formation will be assessed with MRI.

Aim 3: Examine the effect of DJNKI-1 treatment (JNK Inhibition) and cavtratin
treatment (pharmacological mimicry of caveolin scaffolding domain) on BBB
integrity and caveolin-1 expression following juvenile TBI.
Hypothesis: Inhibition of JNK pathway and treatment with cavtratin will reduce and
reverse damage to tight junction proteins and prevent BBB disruption.
A cohort of rats will receive i.p. injection of DJNKI-1 after jTBI. A separate cohort of
rats will be treated with cavtratin following jTBI. Changes in the expression of the TJ
proteins, caveolin-1 and BBB properties will be assessed at 1, 3, 7, 60 days after injury.
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MRI will be used to assess brain water diffusion and edema formation.

The diagrammatic representation below (Fig. 4) highlights the key players examined
in this project, and illustrates the hypothesized mechanism and effects of the two
pharmacological agents used – DJNKI-1 and cavtratin (CSD peptide).
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PROLOGUE TO CHAPTER 2A
TRAUMATIC BRAIN INJURY IN YOUNG RATS LEADS TO
PROGRESSIVE BEHAVIORAL DEFICITS COINCIDENT WITH
ALTERED TISSUE PROPERTIES IN ADULTHOOD
Chapter 2 describes the progressive behavioral deficits resulting from juvenile
brain trauma, and their associated morphological and molecular changes, in a rodent
model. The clinical relevance of emergent motor and behavioral impairments that
persists for months in rodents that were subjected to focal brain injury is emphasized.
The chapter highlights the vulnerability of the developing brain to TBI.
The aim of this chapter is to characterize the acute and long-term histological
and neurological changes that occur in juvenile TBI using a customized controlled (CCI)
model in P17 rats. Morphological and molecular changes in both gray (e.g. at the lesion
and perilesion cortex) and white matter (especially the corpus callosum) structures were
examined over a 60-day (d) post-injury period. Changes in injury volume across 60 postinjury days, as well as electrophysiological changes were also investigated. A battery of
tests was employed to examine neurological and behavioral outcomes following juvenile
TBI over the 60d period. The hypothesis for this chapter is that induction of CCI in P17
rat pups will engender observable and testable adverse outcomes on neurological and
behavioral functions, and on brain tissue properties, which will last for weeks following
the initial insult. The chapter justifies the suitability of the CCI model for carrying out
testing of drugs aimed at limiting secondary injury processes, and improving histological
and functional outcomes.
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This chapter has been published as a scientific article in the July 20, 2012 edition
of the Journal of Neurotrauma (volume 29, pages 2060 - 2074) under the same title as
above. It is complete with abstract, introduction, methods, results and discussion
sections. There are 8 figures with detailed figure legends in the manuscript. The authors
of the manuscript and their professional affiliations are listed on the first page.

52

CHAPTER 2A
TRAUMATIC BRAIN INJURY IN YOUNG RATS LEADS TO
PROGRESSIVE BEHAVIORAL DEFICITS COINCIDENT WITH
ALTERED TISSUE PROPERTIES IN ADULTHOOD

David O. Ajao1, Viorela Pop2, Joel E. Kamper3, Arash Adami7,
Emil Rudobeck8, Lei Huang4, Roman Vlkolinsky4, Richard E.
Hartman3, Stephen Ashwal2, Andre Obenaus2, 4-6, and Jerome
Badaut1, 2
Departments of 1Physiology, 2Pediatrics, 3Psychology, 4Radiation Medicine, 5Biophysics
and Bioengineering, and 6Radiology, Loma Linda University, Loma Linda, California.
Departments of 7Neuroscience and 8Physics, University of California–Riverside,
Riverside, California.

Running Title: BEHAVIORAL AND WHITE MATTER CHANGES
AFTER JTBI
Address correspondence to:
Jerome Badaut, Ph.D.
Departments of Pediatrics, Pharmacology, and Physiology
Loma Linda University School of Medicine
Coleman Pavilion, Room A1120
11175 Campus Street
Loma Linda, CA 92354
E-mail: jbadaut@llu.edu

JOURNAL OF NEUROTRAUMA 29:2060–2074 (July 20, 2012)
© Mary Ann Liebert, Inc.
DOI: 10.1089/neu.2011.1883

53

Abstract
Traumatic brain injury (TBI) affects many infants and children, and results in
enduring motor and cognitive impairments with accompanying changes in white matter
tracts, yet few experimental studies in rodent juvenile models of TBI (jTBI) have
examined the timeline and nature of these deficits, histologically and functionally. We
used a single controlled cortical impact (CCI) injury to the parietal cortex of rats at postnatal day (P) 17 to evaluate behavioral alterations, injury volume, and morphological and
molecular changes in gray and white matter, with accompanying measures of
electrophysiological function. At 60 days post-injury (dpi), we found that jTBI animals
displayed behavioral deficits in foot-fault and rotarod tests, along with a left turn bias
throughout their early developmental stages and into adulthood. In addition, anxiety-like
behaviors on the zero maze emerged in jTBI animals at 60 dpi. The final lesion
constituted only ~3% of brain volume, and morphological tissue changes were evaluated
using MRI, as well as immunohistochemistry for neuronal nuclei (NeuN), myelin basic
protein (MBP), neurofilament-200 (NF200), and oligodendrocytes (CNPase). White
matter morphological changes were associated with a global increase in MBP
immunostaining and reduced compound action potential amplitudes at 60 dpi. These
results suggest that brain injury early in life can induce long-term white matter
dysfunction, occurring in parallel with the delayed development and persistence of
behavioral deficits, thus modeling clinical and longitudinal TBI observations.

Key words
Behavior; CNPase; juvenile traumatic brain injury; magnetic resonance imaging; myelin;
neurofilament-200
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Introduction
Traumatic brain injury (TBI) in children is a major cause of death and disability
(Schneier et al., 2006, Kuppermann et al., 2009), and it has been suggested that
developmental neuroplasticity assists in the recovery of younger individuals (Jane and
Francel, 1996, Giza and Prins, 2006). However, clinical and experimental reports
indicate that TBI results in lasting structural and functional damage. Clinically, TBI to the
frontal cortex has been associated with disruptions in motor function, problem solving,
spontaneity, memory, judgment, impulse control, and social behavior (Levin et al., 1987).
Although the underlying cellular and molecular pathophysiology is not fully understood,
post-TBI behavioral deficits such as aggressive behavior, anxiety, and depression, as
well as an increased risk for epilepsy may last for months to years (Fujii and Ahmed,
2002, Giza and Prins, 2006, Lippert-Gruner et al., 2006). Only a small number of
experimental TBI studies have evaluated and shown extended behavioral deficits (Prins
and Hovda, 1998, Adelson, 2000, Huh and Raghupathi, 2007). Little is known about
changes in the tissue properties in association with behavioral modifications.
Several clinical and experimental observations have shown that white matter
tracts are highly vulnerable to TBI-induced secondary injury, and that their damage may
contribute to cognitive deficits after TBI (Huh and Raghupathi, 2007, Levin et al., 2007,
Wagner et al., 2007). Post-natal day (P) 17 in rats, which corresponds to the juvenile
population, is a critical myelination period, as it marks the peak of myelin basic protein
(MBP) synthesis in the developing rat brain (Bjelke and Seiger, 1989, Akiyama et al.,
2002). Previous studies have shown changes in myelination after environmental stress
in rats at P17, including changes in MBP (Kodama et al., 2008). Early life stress, such as
premature weaning at P17, has been associated with increased anxiety and increased
MBP in adulthood (Kodama et al., 2008). To date, experimental juvenile TBI studies
have not focused on the timeline of the behavioral deficits seen in association with
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alterations in white and gray matter tissue properties using a combinatorial approach of
magnetic resonance imaging (MRI), immunohistochemistry, and electrophysiology.
The clinical literature led us to hypothesize that an early-life injury such as TBI
would elicit enduring behavioral deficits associated with functional and morphological
changes in the brain tissue that persist into adulthood. We used a single controlled
cortical impact (CCI) injury to the parietal cortex of P17 rats, at an age of active myelin
sheath formation, and evaluated the animals over a period of 60 days post-injury (dpi).
We carried out a large battery of behavioral tests to assess a wide spectrum of motor
and cognitive functions, and each of the tests that we employed measured a unique
aspect of the spectrum of deficits reported after juvenile TBI (jTBI) in humans. We used
MRI to evaluate anatomical changes (areas of lesion and corpus callosum [CC]). Tissue
was collected to assess morphological and molecular changes in gray and white matter,
as well as for in vitro axonal conductivity. We present findings of extended behavioral
deficits coincident with significant changes in white matter tract properties observed in
adulthood, and characterized using MRI, immunohistochemistry, and electrophysiology.

Methods
Animals
All protocols and procedures were approved by the Institutional Animal Care and
Use Committee of Loma Linda University, and are in compliance with the U.S.
Department of Health and Human Services Guide. Juvenile male Sprague-Dawley rats
(P17; Harlan, Indianapolis, IN) were housed with their dams on a 12-h light-dark cycle at
constant temperature and humidity. Pups were weaned at P24, housed two rats per
cage, and fed with standard lab chow and water ad libitum. All groups of animals used in
the study had identical sham or CCI surgical parameters. One group of animals (n = 8
sham, n = 7 CCI) was studied longitudinally for MRI (3, 30, and 60 dpi), and all
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behavioral tests (3, 7, 30, and 60 dpi). At 60 dpi, a final immunohistochemistry study was
carried out on sham (n = 5) and CCI (n = 6) animals. Additional groups of animals were
evaluated at each time point for immunohistochemistry at 3 dpi (n = 3 sham, n = 4 CCI),
7 dpi (n = 5 sham, n = 5 CCI), and 30 dpi (n = 5 sham, n = 5 CCI), and for
electrophysiology at 60 dpi (n = 4 sham, n = 4 CCI).

Juvenile Traumatic Brain Injury Model
CCI was induced in juvenile rats as previously described in our adult experiment
(Obenaus et al., 2007). Briefly, P17 juvenile rats were anesthetized with isoflurane
(Webster Veterinary Supply, Inc., Sterling, MA) and placed in a mouse stereotaxic frame
(David Kopf Instruments, Tujunga, CA). Following a midline skin incision over the skull, a
5-mm craniotomy was performed over the right fronto-parietal cortex (bregma: 1mm
anterior-posterior and 2mm medial-lateral). CCI was accomplished using a 3-mm
rounded-tip metal impactor fixed to an electromechanical actuator and centered over the
exposed dura at a 20o angle to be parallel to the cortical surface (Leica Microsystems
Company, Richmond, IL). The CCI was delivered at a 1.5-mm depth from the cortical
surface with impact duration of 200 msec at a velocity of 6 m/sec. The surgical site was
sutured after recording any bleeding or herniation of cortical tissues. Body temperature
was maintained at 37oC during surgery. Buprenorphine (0.01 mg/kg; dilution: 0.01
mg/mL) was injected subcutaneously for pain relief before the animals were returned to
their dams. The sham animals underwent identical procedures except for the cortical
impact.

Magnetic Resonance Imaging and Analysis
MRI was performed in vivo at 3 and 30 dpi followed by high resolution ex vivo
imaging at 60 dpi as previously described (Badaut et al., 2007). For in vivo MRI, rats
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were anesthetized using isofluorane (1-2%), placed in a temperature controlled cradle
containing a volume radiofrequency (RF) coil and imaged on a 11.7T MRI (8.9 cm bore,)
or on a larger bore (40 cm) 4.7T MRI (Bruker Biospin, Billerca, MA) based on the size of
the animals. T2 weighted imaging (T2WI) to determine TBI volume was acquired using:
a repetition time/echo time (TR/TE) = 3278.3/20 ms; 256 X 256 matrix; 1 mm slice
thickness; 1 mm interleaved; average of 2 acquisitions; number of slices = 20; and a field
of view (FOV) = 2.2 cm for a total imaging time of 28 min on 11.7T MRI; and a repetition
time/echo time (TR/TE) = 3563.4/20 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm
interleaved; average of 2 acquisitions; number of slices = 25; and a field of view (FOV) =
2.8 cm for a total imaging time of 30 min on 4.7T MRI. The utilization of two different
field strengths did not alter the measurements performed in our experiments (Obenaus
et al., 2011).
For ex vivo MRI, animals were transcardially perfused with 4% paraformaldehyde
(PFA) prepared in phosphate buffered saline (PBS), the brains were immersed in same
solution overnight, and then transferred to PBS with sodium azide (0.1%) before ex vivo
scanning using the 11.7T magnet. T2WI was acquired using: a repetition time/echo time
(TR/TE) = 3278.3/20 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm interleaved;
average of 2 acquisitions; number of slices = 20; and a field of view (FOV) = 2.2cm for a
total imaging time of 28 min on 11.7T MRI. We previously reported no volumetric
differences between in vivo and ex vivo MRI (Obenaus et al., 2011). Volumetric analyses
of the total brain volume and percent lesion/brain volume were performed on T2WI using
Cheshire image processing software (Hayden Image Processing Group, Waltham, MA)
and Amira (Mercury Computer Systems, Visage Imaging, Inc., San Diego, CA, USA).
Lesion volume was defined as those regions containing abnormal hypo- and/or hyperintense signals. All tissue below the skull level was included, but in the rare instances
when tissue herniated and extended above the level of the skull, it was excluded. Injury
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volume was adjusted using total brain volume to correct for individual differences and
age-related brain growth. Area measurements of the CC at 60 dpi were selected from
the MR images at bregma level +1 mm, anterior to the lesion, and included all visible
portions of the CC. The coronal section with the same visible anatomical landmarks was
chosen for analysis for all animals by a blinded experimenter.
Behavioral Testing
All behavioral tests at each time-point were carried out on sham and CCI animals
within a 3-hour morning time-block (8 – 11 am). Sham and CCI animals were interleaved
in testing sequence.

Foot-fault
Foot-fault testing was carried out on an elevated wire mesh (2.5 cm X 30 cm
rectangular holes/grid spacing) raised 76 cm above the floor at 1, 3, 7, and 60 dpi. Rats
were placed in the middle of the wire mesh and movements were video-recorded for a
period of 60 sec in two separate trials, 30 min apart (Schmanke et al., 1996). When a
rodent’s paw slipped completely through the wire mesh, it was considered as an
individual fault. The average foot-fault score was calculated from the total number of
faults from two 60 sec trials, and a percentage was calculated from sham levels.

Beam Balance
A square Plexiglas beam balance (61 cm long) labeled in 2.5 cm increments was
employed in these experiments. Juvenile animals were tested on a 0.65 cm wide beam
at 1, 3, and 7 dpi, and adult animals were tested on a 2.5 cm wide beam at 30 and 60
dpi according to size requirements. Animals were placed at the midpoint of the beam,
perpendicular to the longitudinal axis, and allowed to walk unrestricted in either direction
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for 60 sec, with two trials 20 min apart. The number of falls, total time spent on the
beam, and the distance covered by each animal was recorded.

Rotarod
Rotarod evaluation was performed on all the animals at 30 and 60 dpi (Rotamex5, Columbus Instruments, Columbus, OH). A rotating 7 cm-wide spindle, accelerating at
a rate of 2 RPM every 5 sec until the animals fell off, was used to evaluate performance
during two trials (15 min apart). Latency to fall was recorded as a measure of motor
coordination and balance (Recker et al., 2009), and the two fall latencies were averaged.

Open Field
Open field testing assessed general exploratory behavior and activity levels at 30
and 60 dpi. Each animal was placed in an empty plastic bin (50 cm long, 36 cm wide, 45
cm high), and activity was video-recorded for 30 min (Noldus Ethovision, Noldus
Information Technology, Inc., Leesburg, VA). Total distance traveled was assessed as a
measure of overall activity levels.

Zero Maze
An elevated zero maze apparatus was used to evaluate anxiety levels at 30 and
60 dpi. The circular apparatus was composed of a 10 cm wide track (100 cm outerdiameter) with walls (30 cm high) enclosing half of the track with the other half remaining
open and brightly lit. Animals were given 1 trial of 5 min duration and the percentage of
time spent in the enclosed half was recorded. Generally, spending more time in the dark
quadrants of the track is associated with increased anxiety-like behaviors.

Morris Water Maze (MWM)
Cued and spatial water maze performance was assessed over 3 days as a
measure of learning and spatial memory functions at 30 and 60 dpi. A computerized
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tracking device (Noldus Information Technology, Inc., Leesburg, VA) recorded the
rodent’s swim path (Hartman et al., 2005). The water maze consisted of a 110 cm
diameter metal tank filled with opaque water. An escape platform (11 cm diameter) was
adjusted so that the platform’s surface was 2 cm above the water surface for cued
testing, and submerged 1 cm below the water surface for the spatial learning and
memory tasks. In the cued task, the platform was placed in one of four quadrants, and
the location of the platform changed for each block of trials. Animals were given 10 trials
(60 sec maximum) in 5 blocks of 2 consecutive trials with a 5 sec inter-trial interval. For
each trial, the rat was released into the tank opposite the platform location and allowed
to search for the platform. If the rat had not located the platform within 60 sec, it was
guided to it. Animals were allowed to remain on the platform for 15 sec after each trial.
For the spatial testing, the platform remained in the same location for all 10 trials
and the rat was released into the tank at one of four release points and allowed to find
the platform. A probe trial was administered 1.5 hrs later, in which the platform was
removed from the tank, and the rats were allowed to swim for 60 sec. The percentage of
time spent in the quadrant where the platform was previously located was calculated.
Left/right turn bias and swim speed was also calculated during the probe trial with the
percentage of left and right turns measured for each rat.

Tissue Processing and Immunohistochemistry
Rats were transcardially perfused with 4% PFA prepared in PBS at 3, 7, 30 and
60 dpi, the brains were immersed in same solution overnight, and then transferred to
PBS with sodium azide (0.1%). Brains were immersed in 30% sucrose at 4oC for 48
hours and then frozen on dry ice and stored at -20oC. Sham and CCI brains were cut as
coronal cryostat sections (50µm) throughout the entire length of the brain (Leica
CM1850, Leica Microsystems GmbH, Wetzlar, Germany). All antibody incubations were
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carried out in PBS (Fisher Scientific, Pittsburg, PA) containing 0.25% Triton X-100 and
0.25% bovine serum albumin (BSA) (both from Sigma-Aldrich Co., St. Louis, MO). After
washes in PBS, sections were blocked for 1.5 hours in PBS with 1% BSA, and then
incubated overnight at 4°C with mouse anti-neuronal nuclei (mouse anti-NeuN – 1:500,
Chemicon International, Temecula, CA), anti-myelin basic protein (mouse anti-MBP –
1:1000 for classical or 1:200 for infra-red analysis, Chemicon International, Temecula,
CA; rabbit anti-MBP – 1:1000 for classical or 1:200 for infra-red analysis, Abcam Inc.,
Cambridge, MA), oligodendrocyte marker anti-CNPase (1:1000 for classical or 1:400 for
infra-red analysis, Abcam Inc., Cambridge, MA) or anti-neurofilament-200 (NF200 –
1:1000 for classical or 1:250 for infra-red analysis; Sigma-Aldrich Co., St. Louis, MO)
antibodies. After rinsing in PBS, sections were incubated for 2 hours at room
temperature with goat anti-mouse secondary antibody coupled with Alexa-Fluor-488
(1:500 or 1:1000; Molecular Probes, Invitrogen) or with goat anti-mouse secondary
antibody coupled with Alexa-Fluor-800 and goat anti-rabbit secondary antibody coupled
with Alexa-Fluor-680 for infra-red analysis (1:1000; Molecular Probes, Invitrogen) and
subsequently washed in PBS 3x10 min. Sections for classical immunofluorescence were
mounted on glass slides and coverslipped with anti-fading medium vectashield
containing DAPI (Vector, Vector Laboratories, Burlingame, CA). Sections for infra-red
analysis were mounted on glass slides and dried. Negative control staining where the
primary antibody was omitted showed no detectable labeling. Immunostaining was
carried out the same day with the same antibody mix for both sham and CCI animals for
each time point.
Automated counting of NeuN positive nuclei was performed as previously
described (Badaut et al.) in the dorsal parietal cortex (close to injury) and in the piriform
cortex (distant from the injury) in coronal sections that exhibited a visible TBI lesion
cavity. NeuN is a specific marker of neuronal nuclei only, allowing the opportunity to
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count the number of positive neurons stained with NeuN, but not other cell types such as
astrocytes, oligodendrocytes, or microglia (Mullen et al., 1992). The region of interest
(ROI) for the ipsilateral parietal cortex (ipsi-parietal cortex) was drawn close to the lesion
cavity (Figure 5) and contralateral parietal cortex (contra-parietal cortex) was a mirror
image of the ipsi-parietal cortex outline in the contralateral hemisphere. Similar regions
were drawn in sham animals at the same anatomical regions. All values were collected
using an epifluorescent microscope (Olympus, BX41, Center Valley, PA USA) and each
ROI contained 80-95 different fields (422 µm x 338 µm) quantified using Mercator
software (Explora-Nova, La Rochelle, France). The threshold and morphological userdefined parameters were selected to maximize visualization of NeuN-positive staining in
the regions of interest, and parameters were kept consistent for all animals. The
Mercator program automatically counted only NeuN positive nuclei (Figure 4A).
Accuracy of counting was previously tested on slices from control rats stained with
NeuN, and no significant differences were observed between the two hemispheres (data
not shown).
NF200, MBP, and CNPase coronal sections that were immunostained with infrared secondary antibodies were scanned using the same parameters for sham and CCI
with a Licor-Odyssey scanner at 21 µm/pixel resolution (Licor Bio-science, Lincoln, NE,
USA). The infra-red method proposed to quantify the immunohistochemistry has been
recently described by different authors (Wong, 2004; Brunet et al., 2011) and by our
group (Badaut et al., 2007; Badaut et al., 2011). For surface area measurements of the
CC with NF200 (Figure 5C) and MBP (Figure 6E), an average area was obtained from
fields-of-interest drawn with the Licor-Odyssey analysis software around the entire CC
on at least 3 coronal sections located anterior to the injury site at a distance from the
disrupted CC directly below the injured area. Tissue processing after MRI and prior to
immunohistochemistry (sucrose fixation, freezing, cryosectioning) may result in a
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different degree of decrease in CC area from immunohistochemistry compared to MRI.
Alternatively, slice thickness on MRI (1mm) compared to immunohistochemistry (50 m)
could also account for these differences. For infra-red analysis on specific regions,
integrated intensity (I.I.) values were obtained from 4 – 8 coronal sections spaced at
least 1.2 mm apart throughout the longitudinal brain axis (as available per brain region).
For NF200 and CNPase, identical fields-of-interest were drawn using Licor-Odyssey
software on both ipsilateral and contralateral hemispheres only for an analysis on the
medial CC (near longitudinal fissure, adjacent to injury) and lateral CC (dorsal to rhinal
fissure, ventral to injury) and a global I.I. average value was calculated for the CC only.
For MBP, identical fields-of-interest were drawn using Licor-Odyssey software on both
ipsilateral and contralateral hemispheres for the following brain regions: anterior
commissure, medial CC (near longitudinal fissure, adjacent to injury), lateral CC (dorsal
to rhinal fissure, ventral to injury), cingulate cortex, medial parietal cortex, lateral parietal
cortex (dorsal to rhinal fissure, ventral to injury), and temporal/entorhinal cortex (ventral
to rhinal fissure, ventral to injury). For MBP, statistical comparisons revealed no within
group differences across bregma levels or ipsilateral versus contralateral hemispheres,
meaning there was similar immunoreactivity for all white matter structures, and similar
immunoreactivity for all gray matter structures within individual sham and CCI groups.
Therefore, a global I.I. average value was calculated for the white matter tracts (anterior
commissure, medial and lateral CC) and the cortical gray matter (cingulate, medial and
lateral parietal, temporal/entorhinal cortices).

Electrophysiology
At 60 dpi, a separate cohort of rats was anesthetized with 3.5% isoflurane,
decapitated and their brains dissected to prepare coronal slices of the CC. Slices (400
µm thick) were cut using a vibratome (Electron Microscopy Sciences, Hatfield, PA, USA)
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in ice-cold artificial cerebrospinal fluid (ACSF) composed of (in mM): 130 NaCl, 3.5 KCl,
1.25 NaH2PO4xH2O, 10 MgSO4x7H2O, 0.50 CaCl2, 24 NaHCO3, 10 glucose and
saturated with carbogen (95% O2 + 5% CO2) at a pH of 7.4. Slices were prepared from
a brain region anterior to the injury site (bregma +0.5mm), transferred to a recording
chamber, and superfused for at least 80 minutes with carbogen-saturated ACSF with
Mg2+ concentration reduced to 1.5 mM and Ca2+ concentration elevated to 2.0 mM.
During all electrophysiological recordings, slices were continuously perfused at a rate of
2-3 ml/min and maintained at 25oC. A stimulation electrode was placed in the callosal
fiber tract ipsilateral to the lesion ~0.5 mm lateral to the longitudinal fissure to deliver
square current pulses 0.05 ms in duration at 0.02 Hz (see inset Figure 8). Compound
action potentials (CAP) were recorded with glass electrodes (tip resistance 1–3 MΩ)
filled with 3 M NaCl and positioned in the contralateral CC, 1.0 mm from the stimulation
electrode, and the depth was adjusted to yield a maximal CAP (~140 µm depth).
Responses were amplified (Axoclamp, Axon Instruments, Foster City, CA) and digitized
at a sampling rate of 10 kHz, and analyzed using Clampfit (Axon Instruments) and
MiniAnalyses (Synaptosoft) software. The CAP is characterized as a biphasic waveform
produced by fast-conducting, myelinated axons representing the N1 peak and slower,
unmyelinated axons representing the N2 peak. The excitability of the myelinated fibers
was assayed by evaluating the amplitude of the N1 peak of the CAP at incrementally
increasing stimulation intensities (0.5 mA increments) until the maximal CAP amplitude
was reached. Maximal CAP amplitude was used from each animal and averaged.

Statistical Analyses
All data are presented as mean ± SEM, and statistical analyses were done using
GraphPad InStat version 3.05 (GraphPad Software, San Diego CA) and
Sigmastat/Sigmaplot (SPSS Inc.). For behavioral data, a Kolmogorov and Smirnov test
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was first performed to assess the Gaussian distribution, and parametric data were
analyzed using unpaired Student t-tests and ANOVA testing followed by Tukey-Kramer
for multiple comparisons, while non-parametric data was evaluated with Wilcoxon and
Kruskal-Wallis tests to assess group differences. Repeated measures ANOVAs were
used in cases where longitudinal data were collected on the same groups. MRI and
immunohistochemical findings were assessed by unpaired Student t-tests for normally
distributed data, or Mann-Whitney U analysis.

Results
All juvenile TBI (jTBI) rats survived the CCI injury (P17) from 1 day to 2 months
post-TBI (adulthood; P77). There were no significant weight differences between the CCI
and sham groups during the study.

Behavioral Testing
Because the TBI lesion was located in the parietal cortex, which contains
somatosensory processing areas, a series of motor tests were performed to evaluate the
functional impact of jTBI two months after the initial injury. We found significant
impairments on the foot-fault task, with an increased number of faults at 7 dpi (p<0.05)
and 60 dpi (p<0.001) (Figure 1A) compared to shams. In the CCI animals, we observed
temporal changes from 1 dpi to 60 dpi (repeated ANOVA, p<0.001) in the number of
faults (Figure 1A), supporting the concept of progressive motor impairments over time.
The beam balance results show impaired performance in CCI animals, with less
distance traveled compared to shams from 1 to 60 dpi (Figure 1B, *p<0.05, **p<0.01)
and no changes within each group’s performance over time. Sensorimotor coordination
was assessed using the rotarod (Figure 1C) and revealed that CCI animals were unable
to stay on the rotating cylinder as long as shams at 30 dpi (p<0.05). CCI animals
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appeared to recover from this deficit by 60 dpi, indicating impaired coordination that
resolved over time (Figure 1C). Analysis of turn bias from MWM tests demonstrated a
significant left turn bias in CCI rats at 30 dpi (p<0.05) that was maintained at 60 dpi
(p<0.05) (Figure 1D). Taken together, these results reveal impaired sensorimotor skills
of CCI animals that persisted until adulthood.
We also administered a comprehensive battery of tests to assess exploratory
behavior (open field), anxiety-like behaviors (zero maze), and learning and memory
(MWM) abilities at 30 and 60 dpi. In open field testing, the total distance traveled in 30
min by the CCI group was significantly less than in sham animals at 30 dpi (p<0.05) but
not at 60 dpi (Figure 2A). These and the above rotarod data (Figure 1C) suggest that
certain aspects of motor function recovered after TBI, whereas others did not. Analysis
of the first 3 minutes of the open field test, as a marker of exploratory behavior in a novel
environment (Figure 2B), showed that CCI animals moved significantly less when initially
placed into the novel environment compared to sham groups at 60 dpi (p<0.05),
consistent with decreased motor/exploratory behaviors. Both CCI and sham animals
explored less during the first 3 minutes at 60 dpi than at 30 dpi (p<0.001), suggesting an
effect of general maturation and/or repeated exposure to the open field. Similarly, the
zero maze-test revealed no group differences in anxiety-like behaviors (measured as
increased time spent in the enclosed half of the track) at 30 dpi, but a significant
increase in anxiety-like behaviors in CCI animals at 60 dpi (p<0.05) (Figure 2C). Our
open field data suggest reduced motor performance at 30 dpi, whereas reduced
exploratory behavior may be related to the emerging anxiety-like behaviors in the
elevated zero maze occurring at 60 dpi.
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FIG. 1. (A) Sensorimotor functions were tested with the foot-fault test. There was a
significant increase in the number of faults in controlled cortical impact (CCI) rats
compared to their sham counterparts at 7 and 60 dpi (*p < 0.05, **p < 0.01). (B)
Balance and coordination skills were measured with the beam balance test. The
distance covered by CCI animals was significantly decreased compared to sham
animals at 1, 3, 7, and 60 dpi. (C) Balance and coordination skills were tested with
the rotarod test. Fall latency was significantly lower in CCI animals at 30 dpi (*p <
0.05). (D) Turn bias measurements indicated that the percentage of left turns
(contralateral to the injury) at 30 and 60 dpi was significantly increased in CCI
compared to sham animals (*p < 0.05; SEM, standard error of the mean).
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FIG. 2. (A) During open-field testing, the overall distance traveled over 30 min (10
blocks of 3 min each) revealed a significant decrease in activity in the controlled
cortical impact (CCI) group compared to sham animals at 30 dpi (*p < 0.05).
(B) The first 3-min block of activity was evaluated in sham and CCI animals, as this
time would normally be used to explore the new environment into which they have
been placed. At 60 dpi (but not at 30 dpi) there was a significant difference in the
distance traveled in CCI compared to sham animals (*p < 0.05), when the CCI
animals showed decreased exploratory activity. (C) The zero maze was used to
assess anxiety-like behaviors, and in this test more time spent in the dark is thought
to correlate with increased anxiety. We observed a significant increase in the time
spent in the dark at 60 dpi (*p < 0.05). (D) Cumulative distance traveled by the rats to
find the platform at 30 and 60 dpi was no different between the CCI and sham
groups in the Morris water maze spatial test.
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Learning and memory abilities after jTBI were evaluated on the cued and spatial
versions of the MWM at 30 and 60 dpi (Figure 2D). Although both groups improved over
time, no performance differences in overall swim speed, cued learning or spatial learning
/ memory were observed between sham and CCI at either time point.

MRI-Derived Lesion Volumes and Surface Area of Corpus
Callosum
MRI at 3, 30 and 60 dpi was used to non-invasively measure lesion volumes (Figure 3)
and the area of the CC (Figure 5A, B). The relative lesion volume measured from the
T2WI might be influenced by edema formation, inflammation and cell death. Sham
animals had little or no abnormalities at the site of the craniotomy, whereas CCI animals
demonstrated brain injury as evidenced by increased tissue edema (Figure 3A, arrows at
3 and 30 dpi). No prominent midline shift was observed in the MR images in this model
and there were only a few CCI animals that exhibited herniation of brain tissue. At 30
and 60 dpi, MRI revealed a cortical cavity that circumscribed the TBI site in frontoparietal cortex (Figure 3A), and a 3D reconstruction (Figure 3B) revealed the rostrocaudal extent of the lesion cavity in the parietal cortex 60 days after jTBI. Lesion
volumes were significantly increased in CCI animals compared to sham controls at 3 dpi
(3.5% vs. 0.4% of brain volume; p<0.001), 30 dpi (3.0% vs. 0.3%; p<0.001), and 60 dpi
(2.9% vs. 0.1%; p<0.001) (Figure 3C). Lesions volumes, as defined using the
parameters of hyper- and hypo-intensity described in the Methods, decreased across the
3 time-points within the CCI and sham groups (p<0.05, Figure 3C). Decreased lesion
volume may be a consequence of decreased edema and inflammation over time. MRI at
60 dpi was used to analyze the surface area of the CC, measured at bregma +1mm
anterior to the site of the injury in CCI animals and in a comparable coronal section in
shams, and showed a global decrease of 21% compared to shams (p<0.05) at 60 dpi
(Figure 5A, B).
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FIG. 3. (A) Magnetic resonance imaging (MRI) at 3, 30, and 60 dpi identifies the
lesion (arrows) as an increase in the signal intensity at 3 and 30 dpi, and as a hole
at 60dpi, corresponding to the formation of the lesion cavity. (B) A three-dimensional
reconstruction of the brain (gray) and lesion (red) at 3 dpi extends to include*3%of
the total brain volume. (C) The lesion volumes were significantly larger in controlled
cortical impact (CCI) rats compared to their sham counterparts receiving craniotomy
only (**p < 0.001) at all time points during our 60-day observation period.
Color image is available online atwww.liebertonline.com/neu

71

Immunohistochemical Changes following CCI
The consequences of jTBI on gray and white matter were studied at 60 dpi using
immunostaining for a neuronal marker (NeuN), neuronal process marker (NF200),
oligodendrocyte marker (CNPase) and myelin basic protein (MBP), both at the level of
and remote from the site of injury. In sham animals, an intact cortex was observed
(Figure 4A, 5A left, 6A left), whereas a cavity at the lesion site extending to the level of
the CC was seen in the CCI animals (Figure 4C, arrow). This lesion impacted a
relatively small portion of the parietal cortex (in accordance with the results obtained
from MRI), and may be directly responsible for some of the observed behavioral deficits.
In Figure 4, NeuN staining reflects the numerical index of NeuN-positive nuclei
used to assess neuronal number and DAPI staining shows no difference in cell density
in images co-labeled with NeuN. The positive DAPI cells without NeuN are those of nonneuronal cells in the cortex such as astrocytes, microglia, and endothelial cells.
Quantitative analyses of NeuN positive cells near the injury, in the ipsilateral and
contralateral parietal cortex, revealed a 35% decrease in CCI compared to sham
animals (p<0.05) (Figure 4B, D, E). Quantification of NeuN in the piriform cortex, a
cortical region distant from the injury site, did not show any changes in the number of
neurons between groups (688 ± 117 positive NeuN cells/mm2 in sham versus 545 ± 60
positive NeuN cells/mm2 in CCI). At 60 dpi, our NeuN staining intensity did not change
significantly (Figure 4A, C) in contrast to studies showing increased brain NeuN during
the first days after injury (Liu et al., 2009). Therefore, while the intensity level, or actual
brightness of NeuN staining is unchanged, the NeuN-positive nuclei reflecting neuronal
number is decreased after injury. At 60 days, the observed loss of parietal neurons may
be a contributing factor to sensorimotor dysfunction.
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FIG. 4. (A–D) Neuronal nuclei (NeuN) immunohistochemistry at 60 dpi in the sham (A
and B) and controlled cortical impact (CCI; C and D) groups showed the lesion cavity
in the parietal cortex (arrow in C). The number of NeuN-positive neurons (green) was
decreased in CCI (D) compared to sham (B) animals in the parietal cortex (Par Cx) at
close proximity to the injury site, in tissue adjacent to the cavity. Nuclei of all cell types
were stained with DAPI (blue in B and D), and automated counting of the NeuNpositive cells in the parietal cortex (E) showed a significant reduction in CCI compared
to sham animals in the ipsilateral and contralateral hemispheres (*p < 0.05; scale bars
in A and C= 200 µm; in B and D= 50 µm; DAPI, 4,6-diamino-2-phenylindole).

73

Similar to MRI analysis (Figure 5A, B), area measurements of the CC from infrared NF200 stained coronal sections (Figure 5A, C) at 60 dpi showed a significant
decrease after 7 dpi in the CC (31±1% of sham, p<0.01) that was still present at 60 dpi
(42±4% of sham, p<0.005, Figure 5C). CC area measurements from MBP
immunostaining also showed a similar decrease in CCI animals compared to shams
(p<0.05, Figure 6E). CC area changes from MRI were highly correlated with
measurements from infra-red NF200 (r2= 0.505, p<0.05) or infra-red MBP (r2= 0.433,
p<0.05). Differences in the size of the decrease in CC area between CCI and shams
from MRI and immunostaining are potentially due to tissue processing and analysis
(details in Methods). However, it is clear that both quantification methods demonstrate a
significant decrease in CC area at 60 dpi following CCI.
In addition to these gross morphological changes to the CC surface area
following jTBI, infra-red NF200 (Figure 5), infra-red CNPase (Figure 7) and infra-red
MBP (Figure 6) immunoreactivities were quantified to address the question of whether
NF200, CNPase and MBP immunoreactivities were altered. Quantification of NF200
infra-red staining intensity in the CC was not significantly changed between sham and
CCI at 60 dpi (Figure 5A, H). Classical immunostaining with NF200, including higher
magnification images of the CC, showed similar morphological staining patterns between
sham and CCI (Figure 5D-G). NF200 appears more punctate in the gray matter cortex in
both sham and CCI. In the white matter, there are no obvious distorted fiber tracts, or
interrupted fiber tracts that are commonly observed in other white matter injuries and
models (e.g. optic nerve injury, Wang et al. 2011; spinal cord injury Cho et al., 2009;
Iannotti et al., 2011). In the CC, CNPase staining intensity was not significantly changed
(Figure 7A, F), in accordance with our observations at higher magnification showing no
gross changes in the pattern of staining between the sham and CCI groups (Figure 7BE). Classical CNPase immunolabeling identified occasional positive cells in the CC that
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were consistent in shape and size with expected oligodendrocyte morphology (Figure
7B-E). Although no changes were detected with these antibodies and quantification
methods, it remains possible that other axonal changes are occurring at the
ultrastructural or molecular level.
However, in contrast to the NF200 and CNPase staining, the immunostaining
and higher magnification images for MBP in Figure 6 reveal stark differences between
sham and CCI. As expected during brain development (Bjelke and Seiger, 1989,
Akiyama et al., 2002), sham animals demonstrated a significant global increase in MBP
immunoreactivity between ages 20 to 60 days in the CC (increased 25±4%, p<0.005,
data not shown). Quantification of infra-red MBP immunoreactivity in CCI (% of sham)
revealed a biphasic change, with an initial increase (25±5%) in CCI compared to sham
animals at 3 dpi, normalization at 7 and 30 dpi, and then an increase (33±9%) at 60 dpi
in white matter tracts (Figure 6D). MBP immunoreactivity was increased in CCI at 3 dpi
and 60 dpi in all anterior-to-posterior white matter tracts (average values of anterior
commissure, medial and lateral CC, from bregma +1.7 to -6.0 mm, Figure 6A, D) and
was also increased in CCI animals in the CC structure alone (average values of medial
and lateral CC only, from bregma +1.7 to -6.0 mm, Figure 6A, p<0.05, graph not shown).
MBP staining in the cortex and anterior commissure values alone were higher in CCI
compared to sham from bregma +1.7 to -6.0 mm, but did not reach significance (data not
shown). MBP staining was consistent across bregma levels within groups, and no
differences were detected for comparisons of individual white matter structures within
each individual sham or CCI group. Mosaic images and higher magnification of classical
immunostaining demonstrate increased MBP after jTBI at 60 dpi (Figure 6B, C). The
coronal slices in sham animals show uniform MBP staining throughout individual white
matter locations including the CC (Figure 6B). In contrast, CCI animals have a higher
staining intensity level in the CC (Figure 6C). Similar results were obtained using a
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FIG. 5. (A) Slices from magnetic resonance imaging (MRI) and neurofilament-200
(NF200) immunostaining show a decreased corpus callosum (CC) size on MRI
(green and yellow outlines), and NF200 immunostaining (arrows). (B) Quantification
of the CC area from the MRI at 60 dpi (mm2) showed a significant decrease in CCI
animals (*p < 0.05). (C) Quantification of the CC area from the NF200 infrared
immunostaining (% of sham animals) shows a significant decrease in the CCI group
at 7, 30, and 60 dpi (*p < 0.05). (D–G) Classical immunostaining with NF200 images
at higher magnification in the corpus callosum (CC, red dashed outlines), and
overlying cortex (Cx), showed similar morphological staining patterns, and no
changes between the sham (D and E) and CCI (F and G) groups. (H) Infrared (IR)
quantification of NF200 staining intensity in the CC was unchanged between groups
at 60 dpi (scale bar in A= 1mm; in D and F = 500 µm; in E and G= 50 µm; A.U.,
arbitrary units).
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FIG. 6. Myelin basic protein (MBP) immunostaining in the sham (A, B, and G) and
controlled cortical impact (CCI; A, C, F, and G) animals from bregma + 1.7mm to 6.0mm. (A) MBP immunoreactivity using infrared antibodies with mouse anti-MBP
(ms-MBP) was increased in the CCI animals compared to sham animals at the
anteroposterior bregma level in white matter tracts. This global increase of MBP
was also seen distant from the lesion cavity (asterisk in A). (B and C) Higher
magnification images of classical MBP immunostaining show higher intensity in the
corpus callosum (CC) compared to the striatum (STR) and cortex (CX), in (B) sham
and (C) CCI animals, and increased MBP staining in the CC white matter of CCI
animals (insets in B and C). (D) Quantification of infrared MBP staining showed a
significant increase in the white matter tracts (CC and anterior commissure) of CCI
animals compared to sham animals at 3 and 60 dpi (*p < 0.05). (E) CC area
measurements of MBP immunostaining showed a decrease in CCI animals
compared to sham animals (p < 0.05). (F) Doubleimmunolabeling with infrared MBP
antibodies recognizing two different epitopes, mouse anti-MBP (ms-MBP, green)
and rabbit anti-MBP (rb-MBP, red), showed co-localization in the merged images.
(G) The intensity of the rb-MBP was increased in the CCI compared to the sham
group, as indicated by ms-MBP (asterisks in A, F, and G indicate the lesion cavity;
scale bars in A, F, and G= 1mm; in B and C= 200 µm; in insets in B and C= 50 µm).

78

second antibody raised in rabbit against MBP (Abcam) with a different epitope located
from amino acid 150 to the N-terminus, in comparison to the antibody raised in mouse
against MBP (Chemicon) that recognizes an epitope from amino acids 116-131. Both
antibodies showed similar staining patterns and increases in CCI (Figure 6F-G).

Corpus Callosum Compound Action Potentials (CAP) following
CCI
To assess the functional consequences of jTBI on the CC, we evaluated
electrical transmission within the CC of CCI and sham animals at 60 dpi. N1 amplitudes
of CAP reflect excitability of fast conducting myelinated axons (Figure 8) and represent
the sum of all individual action potentials (Bolton and Carter, 1980, Velumian et al.). The
average N1 amplitudes in CCI animals were significantly reduced compared to
responses recorded from sham operated animals (p<0.005) (Figure 8). This suggests an
impairment of axonal conductance in the CC of CCI animals that is possibly associated
with a decrease in the thickness of the CC (surface area) and increased MBP
(immunoreactivity).
In summary, our data indicates that the CCI is a focal injury at the time of impact
with formation of a cavity under the site of the impact, but immunohistochemistry and
electrophysiology data suggest that the resulting jTBI continues to pathologically affect
the brain in a diffuse pattern, primarily along white matter tracts.

Discussion
Using a CCI model of brain injury in juvenile rats, we have demonstrated for the
first time that TBI in the developing brain is associated with acute sensorimotor deficits
that persist into adulthood and also showed the delayed appearance at 60 dpi of
abnormal anxiety-like behaviors. The morphological changes within the gray matter (the
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presence of a cavity and reduced number of neurons) and the white matter tracts
(decreased area of the CC from MRI and histology) were associated with increased
MBP immunostaining and reduced trans-callosal electrical conductance remote from the
lesion site. Our findings on the zero maze are consistent with the accepted notion that
anxiety-like behaviors involve several brain regions such as the amygdala, and the
parietal and frontal cortical areas. We believe our global analysis of gray and white
matter tissue properties also demonstrate that a local impact evolves to a global change
that may affect overall brain function. Specifically, our results suggest that TBI in juvenile
rats produces long-lasting changes in gray and white matter properties and impairments
of electrical signaling in major axonal pathways that may explain the observed
sensorimotor deficits and anxiety-like behaviors.
Our observations in this jTBI rodent model corroborate clinical reports that
highlight the persistence of neurological, cognitive, behavioral, and psychosocial
sequelae after childhood TBI (Lippert-Gruner et al., 2006, Goold and Vane, 2009). In
human subjects, these impairments last from a few months to 50 years post-injury and
impact activities of daily living (Yeates et al., 2002, Brenner et al., 2007). A wide range of
deficits have been clinically described, including slowed information processing,
impaired judgment, attention deficit hyperactivity disorder, hampered reasoning and
problem-solving skills, mood disorders, anxiety, aggression and anti-social behaviors
(Cattelani et al., 1998, Max et al., 2004, Brenner et al., 2007, Prigatano, 2008).
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FIG. 7. (A) CNPase immunolabeling along white matter tracts is shown in
representative coronal sections near the lesion (bregma - 1.8mm), and anterior
to the lesion cavity (bregma + 0.5mm), with bright levels of CNPase staining with
infrared (IR) antibodies localized to white matter tracts in the corpus callosum
(CC; groups of red arrows). (B–E) Classical CNPase staining at higher
magnification shows similar staining patterns in the CC (red dashed outlines),
and on individual oligodendrocyte cell bodies (arrows), and processes
(arrowheads) of (B and C) sham, and (D and E) controlled cortical impact (CCI)
animals. (F) Quantification of infrared staining in the CC across several coronal
slices shows no statistically significant differences between the sham and CCI
groups for CNPase staining levels (CX, cortex; asterisk in A indicates lesion
cavity; scale bar in A=1mm; in B and D= 200 µm; in insets in C and E = 20 µm;
A.U, arbitrary units).
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FIG. 8. Electrophysiology in the corpus callosum (CC) at 60 dpi shows N1
amplitudes recorded after compound action potentials (CAP) were evoked. The
stimulating electrode (S) was placed on the side of injury (or sham surgery),
located approximately 1mm from the recording electrode (R). Quantification
shows that N1 amplitudes were significantly decreased in controlled cortical
impact animals compared to sham animals (*p < 0.005).
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A focal injury to the parietal sensorimotor cortex in P17 rats resulted in a 35 mm3
lesion volume (~3% of total brain volume) at 60 dpi (Figure 3B), which is comparable to
previously published data (Prins et al., 2005). The lesion volume remained relatively
stable over 60 dpi (Figure 3C) despite the emergence of specific motor and behavioral
impairments. In fact, motor dysfunction was observed within the first week and persisted
until 60 dpi (Figure 1). Early increases in foot faults and decreased distance covered on
beam balance tests are similar to results described in a closed head injury model using
P17 mice (Adelson et al., 2000). The recovery that we observed in rotarod testing in the
CCI group at 60 dpi may be due to a combination of learning effects, age-related brain
development, and reduced sensitivity of this particular test to small deficits in motor
planning, proprioception and coordination which other tests such as foot fault can detect
(Barreto et al., 2010). In accordance with other investigators (Prins and Hovda, 1998),
we did not find major deficits in spatial learning and memory using water maze testing at
30 and 60 dpi. However, jTBI induced the development of anxiety-like behaviors that
emerged only in adulthood (Figure 2C), which was revealed by the longer time spent in
the enclosed part of the zero maze combined with reduction of the exploratory activity in
the first 3 minutes of open field testing (Figure 2B). These results are similar to clinical
observations of the delayed onset of anxiety in adult patients after TBI (WhelanGoodinson et al., 2009). The acute decrements in motor function (i.e., increased of
incidence of foot faults and asymmetric turning behavior) are likely the result of the initial
lesion and local neuronal cell death in the sensorimotor cortex (Nishibe et al., 2010)
(Figures 1 - 4). The persistence and progressive worsening of these motor functions
could possibly be due to the cavitation of the motor cortex as well as to impaired axonal
conductance associated with the global changes in white matter tracts (Figure 1, 4 - 8).
As noted above for the rotarod test, the absence of differences between the groups for
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open field testing at 60 dpi (Figure 2A) may be due to learning or habituation effects
resulting from repeated testing (Russell and Williams, 1973).
Clinical imaging studies have emphasized the vulnerability of white-matter
pathways, such as the CC and anterior commissure, after TBI (Holshouser et al., 2005,
Wilde et al., 2006, Wu et al., 2010). These structural changes may alter the level of
MBP, a primary protein involved in myelin sheath formation. Several reports have
studied MBP in human serum and cerebrospinal fluid (CSF) following pediatric and adult
TBI, as a potential biomarker of injury severity (Berger et al., 2005, Sandler et al., 2010).
For example, serum MBP was increased in children for up to 2 weeks following TBI
(Berger et al., 2005). Thus, we sought to explore the relation between white matter tract
changes using MRI, histology and electrophysiology and behavioral changes in
adulthood after jTBI. Morphological analysis of white matter tracts using MRI and
histology revealed decreased callosal thickness starting at 7 dpi that persisted to 60 dpi,
findings that are similar to white matter loss observed in humans (Kraus et al., 2007, Wu
et al., 2010). Our data show the CC is damaged in this CCI model at the site of the
impact, but also at distance from the lesion site, with no recovery over time (Fig 3-8).
The permanently decreased area of the CC over the 60-day observation period
(measured with MRI, NF200 and MBP) contrasts with the temporal callosal changes in
MBP staining that we measured by infra-red quantitative-immunohistochemistry (Figure
5, 6). We found early increased MBP staining at 3 dpi, which may reflect injury-induced
myelin changes. Indeed, increased MBP levels were previously reported in an adult rat
TBI model and attributed to MBP fragmentation at 3 dpi (Liu et al., 2006). MBP staining
was normalized to sham levels at 7 dpi and 30 dpi, despite the significant decreases in
CC thickness (Figure 5, 6). In adult TBI models, early myelin fragmentation is due to
increased calpain activity that also normalizes 7 days after TBI (Liu et al., 2006).
However, our MBP staining normalization was transient and by 60 dpi we observed a
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global increase in MBP staining in white matter tracts throughout the anterior-posterior
extent of the brain in CCI compared to sham (bregma +1.7 to -6.0 mm) (Figure 6A). We
also showed an absence of CNPase and NF200 staining changes in the CC, in parallel
with increased MBP staining at 60 dpi. Thus, increased MBP staining is likely not a result
of increased number of oligodendrocytes (CNPase) in the white matter. It remains
possible that MBP fragmentation may play a role, or overexpression associated with an
attempt of the brain to compensate for myelin loss (Ihara et al., 2010), but the exact
mechanism needs further exploration in this CCI model. Previous studies indicate that
glucocorticoids may influence MBP, as they are known to enhance the rate of myelin
formation (Chan et al., 1998) and are elevated after brain injury as part of the innate
immune response (Glezer and Rivest, 2004).
In conjunction with decreased callosal white matter thickness and increased
MBP-staining, we found electrophysiological evidence of deficient CC conductivity after
jTBI compared to shams (Figure 8), suggesting a possible functional basis for some of
the behavioral deficits. The decreased CAP suggests that the increase of MBP observed
in CCI animals is non-functional and insufficient to compensate for the loss of axons
after CCI. Our findings are similar to a recent report in mice showing that myelin
proteolipid protein (PLP1) overexpression was associated with decreased axonal
conductance velocity (Tanaka et al., 2009). Interestingly, Kodama et al (2008) used the
same mouse anti-MBP antibody (Chemicon) and found increased MBP protein levels in
adulthood following early weaning. They ascribed their MBP increase to the 21.5 kDa
isoform only, which suggests that increased MBP observed in their study and our jTBI
model may not be necessarily localized in the myelin sheath. This hypothesis is
supported by our electrophysiological data that showed decreased axonal conductance
in spite of increased MBP staining, but additional electron microscopy studies would be
needed for confirming precise localization. Further, our data showing decreased CC

86

thickness post-TBI is consistent with a decrease in the number of fibers that may
contribute to a decrement in function.
Morphological and functional changes in white matter tracts after jTBI may
explain the persistence of motor dysfunction and the development of anxiety-like
behaviors in adulthood. Clinically, non-mechanical stressors early in life are associated
with long-term behavioral changes and can also result in altered myelin development
and reduced size of white matter tracts. For example, children with post-traumatic stress
disorder have a smaller CC volume compared to healthy subjects when they reach
adulthood (Bremner et al., 1995). In rodent models, early weaning of rats pups at P17
induces an increase in MBP and development of anxiety-like behaviors (Kodama et al.,
2008). Our induction of a cortical mechanical-stress (CCI) at the same developmental
age also induced an increase in MBP immunoreactivity and development of anxiety-like
behaviors that emerged during adulthood. In the rodent, P14-P21 is a critical maturation
period for central axonal myelination (Akiyama et al., 2002), and it is likely that a stressor
(early weaning or TBI) during this critical period may induce long-term changes in
myelination and behavior. The developmental changes in myelin proteins (MBP, PLP)
were associated with a physiological response to stress and emotional states, including
anxiety and depression in adulthood (Kodama et al., 2008, Ono et al., 2008, Tanaka et
al., 2009). Thus, despite the presumed neuroplasticity of the juvenile brain after jTBI,
there is likely insufficient cortical reorganization or compensation to completely reverse
injury-induced deficits.

Conclusion
Our findings showed that a focal TBI results in lasting behavioral deficits
(decrements in motor function and late emergence of anxiety-like behaviors) similar to
those seen in human TBI patients, as well as global alterations in white matter
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(decreased thickness of white matter tracts, increased MBP immunoreactivity), leading
to long-term changes in neuronal function (decreased neuronal number and axonal
conduction). A mechanical stress to the cortex during a sensitive developmental window
of myelin formation resulted in long-term changes in the morphology of white matter
tracts as seen with changing MBP immunoreactivity that appear concurrently with
decreased axonal output and behavioral changes. However, the molecular mechanisms
and changes in oligodendrocytes underlying MBP increases in adulthood after TBI have
yet to be determined, and would suggest new avenues for development of novel
pharmacological therapies.
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PROLOGUE TO CHAPTER 2B
EARLY BRAIN INJURY ALTERS THE BLOOD–BRAIN BARRIER
PHENOTYPE IN PARALLEL WITH Β-AMYLOID AND COGNITIVE
CHANGES IN ADULTHOOD
This second section of chapter 2 describes alterations to blood-brain barrier
(BBB) phenotype which are detectable in adult rodents that had been subjected to
juvenile traumatic brain injury (jTBI) at a developmental time period (P17). This change
in BBB phenotype was studied in conjunction with: (a) accumulation of β–amyloid (Aβ),
and (b) changes in cognitive function. The section demonstrates that there are both
structural and functional changes in the BBB at long-term, brought about by jTBI at a
developmental time period. It provides some evidence in support of the theory that TBI
at a young age could predispose the brain’s blood vessels as well as the BBB to
detrimental long-term changes with possible functional deficiencies, such as alteration in
clearing of Aβ and lowering of cognitive abilities. BBB alterations may therefore be
explored as a therapeutic avenue in jTBI.
The customized controlled cortical impact (CCI) injury model in P17 rats
(reported in section 2A) was used as a developmental model of TBI. Morris Water Maze
(MWM) test was customized to assess not only spatial learning and spatial memory, but
also preferred swim strategies used by the tested rodents at 30 and 60 days post injury
(dpi). Immunohistochemical methods were used to test for both BBB marker proteins
such as claudin 5 and Immunoglobulin G (IgG). Immunolabeling and western blotting
techniques were also employed to assess Aβ accumulation. The hypothesis for this
section is that acquisition of TBI in early life may yield detectable long-term changes in
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BBB components, such as tight junctions and influx/efflux transporters, in parallel with
aberrant Aβ accumulation and cognitive dysfunction.
This section of chapter 2 has been published as a scientific article in the
November 14, 2012 edition of the Journal of Cerebral Blood Flow & Metabolism (volume
33, pages 205 - 212) under the same title as above. It is complete with abstract,
introduction, methods, results and discussion sections.
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Abstract
Clinical studies suggest that traumatic brain injury (TBI) hastens cognitive decline
and development of neuropathology resembling brain aging. Blood–brain barrier (BBB)
disruption following TBI may contribute to the aging process by deregulating substance
exchange between the brain and blood. We evaluated the effect of juvenile TBI (jTBI) on
these processes by examining long-term alterations of BBB proteins, β-amyloid (Aβ)
neuropathology, and cognitive changes. A controlled cortical impact was delivered to the
parietal cortex of male rats at postnatal day 17, with behavioral studies and brain tissue
evaluation at 60 days post-injury (dpi). Immunoglobulin G extravasation was unchanged,
and jTBI animals had higher levels of tight-junction protein claudin 5 versus shams,
suggesting the absence of BBB disruption. However, decreased P-glycoprotein (P-gp)
on cortical blood vessels indicates modifications of BBB properties. In parallel, we
observed higher levels of endogenous rodent Aβ in several brain regions of the jTBI
group versus shams. In addition at 60 dpi, jTBI animals displayed systematic search
strategies rather than relying on spatial memory during the water maze. Together, these
alterations to the BBB phenotype after jTBI may contribute to the accumulation of toxic
products, which in turn may induce cognitive differences and ultimately accelerate brain
aging.

Keywords
Amyloid; claudin 5; endothelial; juvenile; P-glycoprotein; traumatic brain injury
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Introduction
Traumatic brain injury (TBI) is defined as damage resulting from a direct or
indirect biomechanical force on the brain, and pathophysiological outcomes emphasize
damage to neurons and glia. However, the blood-brain barrier (BBB) and vascular
integrity are also compromised following TBI. Primary injury occurs at the moment of TBI
impact, with disruption of blood vessels and the BBB, contributing to vasogenic edema
formation (Pop and Badaut, 2011). BBB disruption precedes several downstream events
contributing to secondary injuries, such as changes in cerebral blood-flow and hypometabolism, brain swelling and increased intracranial pressure, hypoxia/ischemia, and
related molecular events such as cell death, inflammation, oxidative stress, and
pathology (Pop and Badaut, 2011). BBB disruption normalizes within one week in
several injury models, yet recent studies show BBB permeability up to 30 days after
ischemic insult (Strbian et al., 2008). Collectively, these observations suggest that BBB
integrity represents a complex and dynamic sequelae meriting attention during acute
and delayed stages post-TBI.
Vascular dysfunction is a critical element of brain aging and neurodegeneration,
especially in Alzheimer disease (AD) (Nicolakakis and Hamel, 2011). Age-related brain
Aβ accumulation may depend on progressively impaired clearance mechanisms, as
measured by in vivo kinetics of Aβ in cerebrospinal fluid of AD and control patients
(Mawuenyega et al., 2010). At the endothelial interface, the central molecular
participants in the bidirectional flow of substances are the transporters P-glycoprotein (Pgp) and low-density lipoprotein-related receptor protein 1 (LRP1) for brain-to-blood
efflux, and the receptor for advanced glycation end products (RAGE) for blood-to-brain
influx (Ueno et al., 2010). In fact, decreased P-gp or LRP1 on endothelial cells are linked
to increased Aβ and neurodegeneration in human brain aging, AD, and aging rodents
(Silverberg et al., 2010). In addition, P-gp knock-out mice administered intra-cerebral Aβ
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peptides have decreased brain-to-blood clearance and increased brain Aβ (Cirrito et al.,
2005), suggesting P-gp as a key player in parenchymal Aβ clearance. After brain
trauma, little is known about the pathophysiological timeline of vascular damage and
healing, or whether BBB changes affect long-term TBI outcome.
Clinically, several lines of evidence demonstrate long-term pathological and
behavioral modifications after TBI. These long-term changes may lead to premature
aging and neurodegenerative processes like AD with higher risk for aberrant Aβ protein
accumulation (Johnson et al., 2010). In support of this, brain Aβ immunolabeling was
detected within hours after clinical TBI (Ikonomovic et al., 2004) and in long-term
survivors (1 to 47 years) of a single injury (Johnson et al., 2012). As for patient outcome,
many TBI survivors endure lifelong consequences, with 3.2 to 5.3 million US residents
currently suffering physical and/or mental disability which can result in long-term
complications (Zaloshnja et al., 2008). Young children, followed by adolescents and
older adults, are at greatest risk for incurring TBI (Faul et al., 2010). Therefore, long-term
studies on cellular and molecular changes after TBI are needed in juvenile experimental
models, especially regarding collective changes in the BBB phenotype, neuropathology,
and behavior.
We hypothesized that an early life juvenile TBI (jTBI) may result in several brain
changes. We evaluated BBB components (tight junctions, influx/efflux transporters) in
parallel with neuropathology and aberrant protein accumulation (Aβ) and cognitive
outcomes (learning and memory). A controlled cortical impact (CCI) was delivered to the
parietal cortex of juvenile (17 day old) rats and outcomes are described in adults at 60
days post injury (dpi).
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Materials and Methods
Animals
All protocols and procedures were approved by the Institutional Animal Care and
Use Committee of Loma Linda University. Juvenile (Literature descriptions for “juvenile”
include a broad range of post-natal ages (Babikian et al., 2010). Based on previous
publications and our recently published data (Ajao et al., 2012) , we used post-natal day
17 as “juvenile” which is identical to methods in the present manuscript.) (17 day old)
male Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed with their dams on a
12-hour light-dark cycle at constant temperature and humidity. Only male rats were
selected, as prior studies suggest the existence of gender differences following TBI
(Wagner et al., 2004). Pups were weaned 7 days after the surgery, housed 2 rats per
cage, and fed with standard lab chow and water ad libitum. At 60 dpi, animals were
euthanized, and brain tissue was collected for immunohistochemical studies (n=8 sham
and n=8 jTBI). An additional group of animals (n=10 sham, n=10 jTBI) was studied
longitudinally in the water maze (30 and 60 dpi).

Juvenile Traumatic Brain Injury Model
Controlled cortical impact (CCI) was induced in rats as previously described
(Ajao et al., 2012). Briefly, rats were anesthetized with isoflurane (Webster Veterinary
Supply, Sterling, MA) and given a 5 mm diameter craniotomy over the right frontoparietal cortex (1 mm posterior, 2 mm lateral from Bregma) and CCI was delivered to
jTBI animals using a 3 mm impactor at a 20° angle to cortex, 1.5 mm depth, 200 ms
impact duration, 6 m/s velocity. Body temperature was maintained at 37°C during
surgery. A subcutaneous buprenorphine injection was administered for pain relief
(0.01mg/ml/kg at 1 hr and 24 hrs post-surgery) and animals were returned to their dams.
All Sham animals underwent the same procedures as jTBI animals, except for the CCI.
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Table 1.
Learning
Strategy

Spatial

Systematic

Looping

Description of MWM swim strategies observed after jTBI
Swim pattern

Description

Spatial direct

Animal swims directly to the
platform

Spatial indirect

Animal swims to the platform with
slight deviation from a true course

Focal correct

Animal swims to and searches in
proximal quadrant for platform

Scanning

Animal searches the interior
portion of the tank without spatial
bias

Random

Animal searches entire tank
without spatial bias

Focal incorrect

Animal swims to and searches in
an incorrect portion of the tank

Chaining

Animal swims in repetitive loops in
the middle of the tank

Peripheral
looping

Animal swims in repetitive loops
around the tank’s perimeter

jTBI, juvenile traumatic brain injury; MWM, Morris Water Maze
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Water Maze Design and Testing
Water maze (WM) testing has been previously described for this model (Ajao et
al., 2012). Briefly, testing occurred at 30 and 60 dpi over a 3-day paradigm, with 5 blocks
of 2 trials each (10 total trials) including cued testing (visible platform), spatial learning
(hidden platform) and probe trials for spatial memory (no platform). Swim strategy
analysis (Brody and Holtzman, 2006) revealed 8 different swim patterns grouped into
three general learning strategies (Table 1 and Figure 5A): Spatial strategy (spatial direct,
spatial indirect, focal correct), Systematic strategy (scanning, random, focal incorrect), or
Looping strategy (chaining, peripheral looping).

Brain Tissue Processing and Immunohistochemistry
At 60 dpi, rats were anesthetized with a combination of Ketamine (Ketaject
100mg/ml, Phoenix, St. Joseph, MO) and Xylazine (AnaSed 100mg/ml, Lloyd
Laboratories, Shenandoah, IA) at the appropriate dose/body weight, and then
transcardially perfused with 4% paraformaldehyde. Brains were excised and
cryoprotected in 30% sucrose solution for 48 hrs, and frozen on dry ice. Coronal cryostat
free floating sections (50 µm) were cut and collected as serial sections spaced 1.2 mm
apart, then processed for standard immunohistochemistry experiments as previously
described (Ajao et al., 2012).

Immunoglobulin G Extravasation Staining for Blood–Brain
Barrier
Sections were rinsed in PBS and blocked for 1 hour in 1% bovine serum albumin
(BSA) (Sigma-Aldrich Co., St. Louis, MO) made in PBS, pH=7.4 (Fisher Scientific,
Pittsburg, PA) prior to incubation for 2 hrs at room temperature with Alexa-Fluor-800
biotin conjugated affinity purified goat anti-rat IgG (1:500, Rockland Immunochemicals,

97

Gilbertsville, PA) in PBS containing 0.25% Triton X-100 and 0.25% BSA (Sigma-Aldrich
Co., St. Louis, MO) made in PBS, pH=7.4. After washing, sections were scanned on an
Odyssey infra-red scanner to quantify fluorescence in the cortex and striatum.

Immunolabeling of Blood–Brain Barrier Proteins
For P-gp staining, sections were pre-treated for antigen retrieval using 33%
acetic acid + 66% EtOH solution for 10 min at 20°C (Fisher Scientific, Pittsburg, PA). For
claudin 5, glial fibrillary acidic protein (GFAP), P-gp, LRP1, and RAGE, sections were
blocked for 1 hour in 1% BSA in PBS prior to overnight primary antibody incubation at
4°C. All antibody incubations were in 0.25% BSA with 0.25% Triton X-100 made in PBS,
pH=7.4. For immunolabeling, we used mouse anti-claudin 5 (1:500, Life Technologies:
Invitrogen, Grand Island, NY), mouse anti-P-gp (1:100, Abcam Inc., Cambridge, MA and
Calbiochem, EMD Chemicals, Merck KGaA, Darmstadt, Germany), mouse anti-LRP1
(1:1000, Calbiochem, EMD Chemicals, Merck KGaA, Darmstadt, Germany), rabbit antiRAGE (1:500, Abcam Inc., Cambridge, MA) and chicken anti-GFAP (1:1000, Millipore,
Temecula, CA). After PBS rinses, we incubated in secondary antibody for 2 hrs at room
temperature at 1:1000 as appropriate for each primary antibody: goat anti-mouse
secondary antibody coupled with Alexa-Fluor-488 or with Alexa-Fluor-594, goat antichicken coupled with Alexa-Fluor-568, and for infra-red analysis either goat anti-mouse
secondary antibody coupled with Alexa-Fluor-800 or goat anti-rabbit secondary antibody
coupled with Alexa-Fluor-680 (all secondaries from Invitrogen, Grand Island, NY). After
washes in PBS, sections for classical immunofluorescence were mounted on glass
slides and coverslipped with vectashield anti-fading medium containing DAPI (Vector,
Vector Laboratories, Burlingame, CA). Sections for infra-red analysis were mounted on
glass slides and air-dried. Control sections for all studies in which primary or secondary
antibodies were omitted resulted in negative staining (not shown).
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Immunolabeling for Aβ
Sections for amyloid analysis were pre-treated for 4 min in 88% formic acid at
room temperature and all other immunostaining procedures were identical to the
procedure described above. We used a monoclonal antibody raised in mouse, against
rodent Aβ at the N-terminal amino acids 1-16 (1:1000, from M. Paul Murphy) and
visualized staining with goat anti-mouse secondary antibody Alexa-Fluor-488 (1:1000;
Life Technologies: Invitrogen, Grand Island, NY). Adjacent sections were co-incubated
with the mouse rodent-Aβ antibody and either the C-terminal antibody against Aβ1-42
(rabbit, 1:1000, Covance, Emeryville, CA), or the microglial marker ionized calcium
binding adaptor molecule 1 (IBA1) (rabbit, 1:1000, Wako Chemicals, Richmond, VA). To
control for non-specific binding of mouse antibodies on rat tissue (Figure 3F), sections
received only the secondary antibody, goat anti-mouse Alexa-Fluor-594 (staining was
negative), followed by a full protocol with both the rodent-Aβ antibody and goat antimouse Alexa-Fluor-488. Sections were also stained with the 6E10 anti-human-Aβ1-16
antibody (mouse, 1:5000, Covance, Emeryville, CA) or using protocols excluding primary
or secondary antibodies, resulting in negative staining (not shown).
To determine any fibrillar beta-pleated sheet structures, sections were double
stained with a rodent-Aβ (see above) followed by Thioflavin S staining. Briefly, tissue
was immersed for 5 min in double-distilled (dd) H20, followed by a 5 min incubation in
1% Thioflavin S (Sigma-Aldrich Co., St. Louis, MO) made in ddH20, and subsequent
differentiation using consecutive 5 min washes in 70% EtOH, 95% EtOH, and ddH20
(Fisher Scientific, Pittsburg, PA). Slides were then coverslipped as described above.

Quantification of Immunohistochemistry
Coronal sections immunostained with infra-red secondary antibodies (IgG and
RAGE) were scanned using the same parameters for sham and jTBI at a 21 µm
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resolution (Li-Cor Odyssey Bio-Science, Lincoln, NE) and identical regions-of-interest
(ROIs) were drawn using Li-Cor Odyssey software (Ajao et al., 2012). For IgG, average
values per animal were obtained from ROIs in the perilesional parietal cortex and
striatum in the hemisphere ipsilateral to the lesion, and analogous areas were evaluated
in the hemisphere contralateral to the lesion or craniotomy, for a total of 3-5 serial
coronal sections as available (n=4 sham, n=4 jTBI). For RAGE, average values per
animal were obtained from ROIs in the parietal and temporal cortex in hemispheres both
ipsilateral and contralateral to the lesion or craniotomy from 4 coronal sections at
bregma levels -1.6 mm, -2.8 mm, -4.0 mm, and -5.2 mm (n=3 sham, n=3 jTBI).
For quantification of classical immunolabeling of claudin 5, P-gp, LRP1, and Aβ,
images were evaluated and collected using an epifluorescent microscope (Olympus,
BX41, Center Valley, PA). The threshold and morphological user-defined parameters
were selected to maximize visualization of positive staining in the ROIs for each protein
staining pattern. These parameters were kept consistent for all animals during image
acquisition. For claudin 5, P-gp, and LRP1 a series of images were taken in the parietal
and temporal cortex, both above and below the rhinal fissure on each hemisphere
ipsilateral and contralateral to the lesion or craniotomy using a 20X objective (422 µm X
338 µm). For claudin 5, images of large intra-parenchymal vessels (30-100μm diameter)
and a separate analysis on microvessels (10-20μm diameter) were acquired from two
serial coronal sections at bregma level -2.8 mm and -4.0 mm (n=4 sham, n=4 jTBI; 8
images/animal for large vessels and 8 images/animal for small vessels). For P-gp,
images were acquired from four serial coronal slices at bregma level -2.8 mm, -4.0 mm, 5.2 mm, and -6.4 mm (n=6 sham, n=6 jTBI; 24 images per animal). For LRP1, images
were acquired from two serial coronal slices at bregma level -4.0 mm and -5.2 mm (n=3
sham, n=3 jTBI; 8 images per animal). Individual images were analyzed with MorphoPro
software (Explora-Nova, La Rochelle, France), using the following procedure: 1) Top Hat
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morphologic filter to outline vascular staining, 2) user-defined thresholding value applied
to each image, 3) calculation of area of staining from background for each protein of
interest (claudin 5, P-gp, or LRP1). Final values are represented as a percentage of the
sham group.
For quantification of rodent-Aβ immunoreactivity, we used 8 whole serial coronal
slices per animal spaced 1.2 mm apart, from bregma levels +3.2 mm to -5.2 mm as
shown in Figure 4 (n=8 sham, n=6 jTBI; 112 total individual values). Mercator software
2

(Explora-Nova, La Rochelle, France) was used to automatically calculate the area (µm )
2

of positive staining that was normalized to the total area (µm ) of each respective
coronal slice and presented as % of Aβ load.

Brain Tissue Processing for Western Blotting
A Protein FFPE extraction kit (Qiagen, Hilden, Germany) was used to process
perfused brain slices for Western blotting. Parietal and temporal cortical tissue above the
rhinal fissure was excised from three coronal sections at bregma levels -1.6 mm, 2.8
mm, and -4.0 mm, that were adjacent to slices of interest used for
immunohistochemistry. Briefly, tissue was homogenized and processed according to kit
instructions, and then samples were assayed for total protein concentration by
bicinchoninic assay (BCA, Pierce Biotechnology Inc., Rockford, IL). The human Aβ1-40
and Aβ1-42 peptides (Biopeptide Co., San Diego, CA) were prepared using a 1mg
sample that was reconstituted to obtain 231µM Aβ1-40 and Aβ1-42 peptides in NaOH
(Sigma-Aldrich Co., St. Louis, MO). Peptides were then incubated overnight at 37°C and
aliquoted for storage at -80°C, then thawed on ice when ready for use. For gel
electrophoresis, all samples were prepared with loading sample buffer and reducing
agent (Invitrogen, Carlsbad, CA) for a total of 40 µg of rat protein, 4 µg of Aβ1-40
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peptide, and 0.5 µg of Aβ1-42 peptide, loaded on a 4-12% SDS polyacrylamide gel
(Nupage, Invitrogen, Carlsbad, CA). Proteins were transferred to a polyvinylidene
fluoride membrane (PVDF, PerkinElmer, Germany), blocked for 1 hr in Odyssey blocking
buffer (Li-Cor Bio-Science, Lincoln, NE), and incubated with the same monoclonal
antibody against rodent-Aβ used in immunohistochemistry (1:2000; from Dr M. Paul
Murphy, University of Kentucky) or a monoclonal antibody anti-human-Aβ 6E10 (1:750;
Covance, Emeryville, CA). P-gp and claudin 5 antibodies were used as in the
immunostaining, namely mouse anti-P-gp (1:100, EMD Chemicals, Merck KGaA,
Darmstadt, Germany) and mouse anti-claudin 5 (1:200, Life Technologies: Invitrogen,
Grand Island, NY), and these blots were incubated with Biotin-SP-conjugated goat antimouse (1:5000; Jackson ImmunoResearch Laboratories, West Grove, PA) for 1.5 hours
at room temperature, followed by PBS washes. The blots were then incubated for 1 hour
at room temperature with Streptavidin-conjugated-IRDye 800 (1:10000; Li-Cor BioScience, Lincoln, NE), before scanning. Each western blot was co-incubated with a
rabbit polyclonal antibody against beta-actin (1:1250; Sigma-Aldrich Co., St. Louis, MO)
in Odyssey blocking buffer (Li-Cor Bio-Science, Lincoln, NE) overnight at 4°C. After PBS
washes, proteins were visualized using a co-incubation with goat anti-mouse secondary
antibody coupled with Alexa-Fluor-800 (1:10,000; Rockland Immunochemicals,
Gilbertsville, PA) and goat anti-rabbit secondary antibody coupled with Alexa-Fluor-680
(1:10,000; Life Technologies: Molecular Probes, Grand Island, NY) for 2 hrs at room
temperature. After PBS washes, the PVDF membrane was visualized using the Li-Cor
infra-red scanner.

Statistical Analyses
All data are presented as mean ± SEM, statistical analyses were done using
SPSS, and graphs obtained using SigmaPlot. For the Aβ analyses, we utilized a
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repeated measures ANOVA with group (jTBI, sham) x bregma level (8 serial coronal
sections) and a conservative Huyhn-Feldt adjustment to the degrees of freedom was
used to protect against any violations of the sphericity and compound symmetry
assumptions underlying this ANOVA model. For the behavioral strategy analysis, data
were analyzed using independent samples t-tests to test between-group differences at
each time point, and paired-samples t-test to analyze within-group effects across time
points. All other histological data between sham and jTBI animals met statistical
assumptions and were analyzed using student t-tests.

Results
Blood–Brain Barrier Phenotype
While disruption of the BBB after jTBI lasts only for a short period of about 7 days
(Pop and Badaut, 2011), little is known about its recovery and structural properties at a
delayed post-jTBI time point. We evaluated several BBB markers at anatomical sites
near the lesion, as well as on coronal slices at a distance from the injury site at 60 dpi.
IgG extravasation staining (Figure 1A, B) and quantification (Figure 1C) did not
show any difference between sham and jTBI groups in perilesional parietal cortex and
striatum, suggesting that the BBB is no longer disrupted. IgG extravasation was
observed as expected in regions without a BBB, such as the median eminence (Figure
1A, B). In accordance with this result, claudin 5 immunolabeling was positive and
outlined the elongated endothelial membrane structure of large vessels (Figure 1D,E)
and microvessels (Supplemental Figure 1A-B) of both sham and jTBI animals. Claudin 5
staining was significantly increased in the large intracortical blood vessels of jTBI
animals compared to sham (Figure 1F, p<0.045), but no changes were observed in
microvessels (Supplemental Figure 1C). Collectively, these data indicate that although
BBB disruption is no longer present at 60 dpi, protein expression within the BBB is

103

changed long after injury.
To further address phenotypic changes at the BBB, we characterized the
distribution of P-gp, LRP1, and RAGE proteins known to be involved in BBB trafficking.
P-gp immunostaining was observed primarily on endothelial cells, in both jTBI and sham
animals co-labeled with the astrocytic marker, GFAP (Figure 2D-F).
Sham animals exhibited more intense and widespread staining patterns on microvessels
(Figure 2D), whereas jTBI had more diffuse vascular staining of P-gp (Figure 2E).
Quantification of images from the parietal and temporal cortices revealed significantly
decreased levels of P-gp immunoreactivity in jTBI cortical vessels compared to sham
(Figure 2F, p<0.05). Similarly, western blot analysis revealed significantly lower P-gp
protein levels in jTBI compared to sham, as shown in representative cases (Figure 2G)
and blot quantification (Figure 2H, p<0.05). LRP1 immunostaining in the parietal and
temporal cortices showed a positive signal in both neuronal and vascular compartments
(Figure 2A-B), that are consistent with prior reports of LRP1 staining in neurons,
endothelial cells, and astrocytes (Silverberg et al., 2010). Quantification of LRP1
immunoreactivity showed a decrease in jTBI animals without reaching significance
(Figure 2C, p<0.1). RAGE immunolabeling also revealed a ubiquitous staining pattern
encompassing several cell types. No differences were found in RAGE immunoreactivity
between sham and jTBI in the parietal and temporal cortex, as measured using infra-red
immunolabeling (data not shown). Altogether, our data indicate jTBI alters BBB proteins
involved in efflux (P-gp) without significant changes to LRP1 or influx (RAGE) at the
endothelial interface between the blood and brain.
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Figure 1. Changes in endothelial tight junctions 2 months after juvenile traumatic
brain injury (jTBI). (A, B) Immunoglobulin G (IgG) extravasation using infrared
immunolabeling showed higher staining intensity at the median eminence and glia
limitans of both (A) sham and (B) jTBI. (C) IgG levels were unchanged as
quantified in the bilateral parietal cortex and striatum, thus indicating an overall
lack of overt blood–brain barrier (BBB) leakage. (D, E) Endothelial tight-junction
protein claudin 5 (Cld5) was observed on endothelial cells of intraparenchymal
vessels in both (D) sham and (E) jTBI and (F) Cld5 quantification in the parietal
and temporal cortices shows that jTBI have significantly increased Cld5 staining
(p< 0.05), perhaps as a restorative mechanism to improve BBB function (*p< 0.05;
values are represented as mean±s.e.m.; IR, infrared; Cld5, claudin 5; white
arrowhead in B = lesion cavity; scale bar in (D, E) = 50 μm).
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Figure 2. Juvenile traumatic brain injury (jTBI) changes proteins involved in cellular
trafficking at the blood-brain barrier. (A, B) LRP1 immunostaining is demonstrated
in both the vascular walls (white arrowheads in D, E) as well as neuronal
compartments (white arrows in A, B) in the cortex of a representative sham. (C)
Quantification of LRP1 immunostaining in the parietal and temporal cortex shows
that jTBI animals have lower overall staining of LRP1, but no significant differences
were found between groups. (D, E) P-gp immunostaining is specific for endothelial
cells (green), as shown in close proximity to the end-feet of GFAP-positive
astrocytes (red) in both (D) sham and (E) jTBI. (F) P-gp quantification in the
parietal and temporal cortices shows a significant decrease in vascular P-gp
transporter in jTBI compared to sham (p<0.05). (G, H) Protein levels of jTBI are
also significantly lower than sham, as shown in representative cases and
quantification (p<0.05). (*p<0.05; values as mean +/-SEM; BBB, blood-brain
barrier; jTBI, juvenile traumatic brain injury; LRP1, lipoprotein receptor-related
protein 1; P-gp, p-glycoprotein; GFAP, glial fibrillary acidic protein; scale bar in A =
20 µm; B, D, E = 50 µm)
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Widespread Aβ Accumulation
Using a rodent-Aβ antibody specific to the N-terminus and a formic acid pretreatment, we detected a diffuse pattern of immunoreactivity that is both extracellular
(Figure 3 A, C-H) and perivascular (arrowheads in Figure 3C, E-H). Examples of positive
rodent-Aβ immunolabeling are shown at a distance from the injury, such as the frontal
(Figure 3C, E-H), temporal (Figure 3A), and parietal cortex (Figure 3D). Positive staining
was also detected in the entorhinal cortex, striatum, and thalamus (Figure 4A), with no
staining using the secondary antibody alone (Figure 3A).
Western blot showed that the rodent-Aβ antibody was specific for rat tissue but
not for human Aβ1-40 and Aβ1-42 peptides, while the anti-human 6E10 antibody
detected bands for human Aβ peptides, but no signal for rat tissue (Figure 3B). The
6E10 antibody detected monomeric Aβ species (4kDa) in both human Aβ1-40 and Aβ142 peptide preparations, and several Aβ aggregates that are more abundant in the Aβ142 preparation (Figure 3B). In the rat tissue, the rodent-Aβ antibody reveals a betaamyloid precursor protein (APP) signal near the expected region ~110kDa and several
additional bands, possibly APP fragments or Aβ aggregates of various sizes (Figure 3B).
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Figure 3. Immunoreactivity patterns with a rodent-Aβ antibody. (A-H) Positive
staining is detected in several brain regions following formic acid pre-treatment and
classical immunostaining using the specific rodent-Aβ antibody, as shown in
representative sections from jTBI animals. (A) Temporal cortex shows specificity of
the rod-Aβ antibody (labeled with goat anti-mouse λ488 nm), with negative staining
nd
using the secondary antibody alone on the same section (2 alone, pre-incubation
protocol with goat anti-mouse λ594 nm). (B) Western blotting from the
parietal/temporal cortex shows the rod-Aβ antibody has high specificity for rat cortex,
but not for human Aβ1-40 or Aβ1-42 peptides, while the 6E10 antibody has high
specificity for human Aβ peptides at 4kDa and larger aggregates, but no signal for rat
tissue. In the rat, the rod-Aβ antibody reveals a prominent APP band and several
smaller fragments, indicating positive immunoreactivity for both Aβ aggregates or
APP fragments. (C) In an example from the frontal cortex, rod-Aβ stains a cluster of
several extracellular diffuse deposits (white arrows) and vascular labeling (white
arrowheads) near the molecular and superficial cortical layers. (D) In an example
from the parietal cortex, rod-Aβ staining is often surrounded by IBA1-positive
microglial processes with an abnormal morphology (white arrowheads) suggestive of
an immune response. (E, F, G, H) Co-incubation with both rod-Aβ antibody (raised in
mouse, secondary λ488 nm) and a C-terminal antibody against Aβ42 (raised in
rabbit, secondary λ594 nm) in the frontal cortex, shows several areas of
colocalization (white arrowheads) as well as areas without overlap, indicating the
presence of several Aβ species.
nd
(Aβ, beta-amyloid; rod-Aβ, rodent beta-amyloid antibody; 2 alone, secondary
antibody alone; APP, beta-amyloid precursor protein; M, marker; kDa, kilodalton;
IBA1, ionized calcium binding adaptor molecule 1; scale bars in A, C = 100 µm, D =
40 µm; E, F, G, H = 30 µm)
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Rodent-Aβ immunoreactivity was associated with microglial cells, stained with
IBA1. Microglia exhibited an elongated soma, little somatic cytoplasm, and multiple
thinner processes, as shown in an example from the jTBI parietal cortex (Figure 3D). No
activated microglia were detected at this time point (data not shown). Rodent-Aβ
immunoreactivity colocalized with C-terminal-Aβ1-42 staining in several brain regions,
such as the frontal cortex (Figure 3E-H). Thioflavin S staining (data not shown) is
negative despite positive rodent-Aβ immunoreactivity, suggesting a lack of fibrillar betapleated sheet structures. Overall, these data are consistent with an early Aβ
accumulation pattern having a diffuse morphology and containing Aβ1-42 species.
Total rodent-Aβ immunoreactivity was quantified using the Mercator program and
expressed as % Aβ load relative to total coronal brain area at each bregma level (Figure
4A-C). Representative jTBI animals are shown with the lesion location (black
arrowheads in Figure 4A) and outlines of positive staining at individual bregma levels
(Figure 4A). By 60 dpi, the cortical jTBI lesion cavity is apparent from bregma -1.0 mm
up to -4.0 mm (not shown) and higher rodent-Aβ immunoreactivity was observed in more
anterior and posterior levels from the lesion site (Figure 3B). Repeated measures
ANOVA showed significant changes across all coronal sections regardless of group
(Figure 4B, p<0.042), with moderate changes across bregma levels in jTBI group alone
(p<0.057), but no changes observed in sham alone (p>0.1). Similarly, the jTBI group
showed a trend for higher staining in total brain compared to sham (Figure 4C, p<0.073).
These data suggest that early brain injury may exacerbate a process of endogenous
rodent-Aβ accumulation throughout vulnerable regions over time.
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Figure 4. Anterior to posterior patterns of rodent-Aβ distribution. (A) Representative
coronal sections with outlines of rodent-Aβ positive staining in jTBI are shown at
bregma +1.7 mm, -0.4 mm, -1.4 mm, and -5.2 mm. The jTBI lesion cavity is apparent
in the parietal cortex at -1.4 mm and still visible at bregma -0.4 and -3.8 mm to a
lesser extent (black arrowheads). (B) All positive rodent-Aβ immunoreactivity was
quantified to obtain %Aβ load relative to total brain area at 8 bregma levels, with
significant changes along the anterior-to-posterior axis (p<0.042), but no significant
changes between groups at any single level. (C) Summation of total brain Aβ load
was higher in jTBI versus sham (p<0.073), with jTBI animals showing high staining
variability common in models of natural Aβ accumulation. (Values are represented
as mean +/-SEM; mm, millimeter; Aβ, beta-amyloid; jTBI, juvenile traumatic brain
injury)
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Changes in Strategy during Water Maze
As previously reported, sham and jTBI animals showed no overall performance
differences across trials on swim speed, cued learning, or spatial learning/memory at 30
or 60 dpi (Ajao et al., 2012). The cumulative distance travelled for both groups showed
no differences in spatial learning at 30 dpi (Figure 5B) and 60 dpi (Figure 5C). As
expected due to repeated testing, performance during block 1 of day 60 was better than
block 1 of day 30 (Figure 5B versus 5C, p<0.05) for both jTBI and sham animals, and
both groups traveled the same average distance for remaining blocks. In addition, we
analyzed swim patterns and learning strategies for individual spatial trials (Table 1,
Figure 5A). Generally, jTBI animals used fewer spatial strategies, and more systematic
and looping strategies, compared to sham animals at 60 dpi (Figure 5E) but not at 30 dpi
(Figure 5D). Specifically, the stacked bar graphs (Figure 5D, E) represent a breakdown
of the % spatial testing trials classified under spatial, systematic, or looping swim
strategies. We observed no significant differences between groups in any strategy
categories at 30 dpi. However, we detected significant changes at 60 dpi where shams
used more spatial strategies than jTBI animals (88.9% versus 62.5% respectively,
p<0.05). In addition, shams exhibit an increased use of spatial strategies from 30 to 60
dpi (37.5% versus 88.9% respectively, p<0.05). In contrast, jTBI animals have nearly
identical strategy groupings at both time points, displaying an inability to improve
performance over time.

Discussion
We evaluated long-term changes following TBI in a juvenile rat model to address
the concordance with clinical observations of delayed behavioral modifications, and
emerging data on changing BBB properties during brain aging and neurodegenerative
disease. Our results at a delayed two-month time point show parallel changes in
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structural BBB phenotypes of claudin 5, altered P-gp expression, rodent-Aβ
immunoreactivity, and altered water maze performance. Together, our data suggest that
an early brain injury may commence with vascular damage that promotes long-term
phenotypic changes to the BBB that can influence cognition.

Physiopathological Changes in the Blood–Brain Barrier
We explored BBB phenotypes at a delayed time point after juvenile injury as a
unique platform for addressing whether jTBI disrupts the neurovascular unit (NVU) and
contributes to brain pathophysiology. Within the first days post-injury, we observe high
IgG staining (Pop and Badaut, 2011). BBB disruption is repaired by two months in our
jTBI model, as evidenced by the absence of IgG extravasation and increases in tight
junction protein claudin 5 (Figure 1). Other studies also report that improved BBB
integrity coincides with altered expression of tight junction proteins at later time points.
Similar to our model, claudin 5 levels are up-regulated after Evans blue and IgG leakage
subsides at 1 and 2 weeks after rat cortical injury(Lin et al., 2010). Claudin 5 is also
increased, along with resolution of Evans blue staining, after 4 and 8 weeks in mice
exposed to an infectious agent targeting the BBB (Liao et al., 2008). Thus, altered levels
of claudin 5 long after jTBI suggest delayed modifications in BBB structural properties.
Furthermore, our differential observations on large and small vessels (Figure 1,
Supplemental Figure 1) indicated a more complex phenotypic response of the
endothelium which may be related to location along the vascular tree.

113

114

Figure 5. Differences in water maze strategies in adulthood. (A) Eight swim
patterns/learning strategies (red lines) were identified and divided into 3 categories
from the most (+) to the least (-) efficient: spatial, systematic, and looping. (B-C)
Water maze performance is unchanged between groups at (B) 30 days and (C) 60
days post-jTBI, however both groups improve and learn the task within each time
point (Block 1 to 5) and between testing time points (comparison of Block 1 at 30
versus 60 days). (D) Swim strategy use was evenly distributed among sham and
jTBI groups at 30 days, but not at 60 days. By 60 days, jTBI animals used strategies
similar to those used at 30 days (primarily systematic and looping patterns), but
sham controls relied on significantly more spatial memory strategies compared to
jTBI and to their prior performance at 30 days (p<0.05). (Values as mean +/-SEM;
jTBI, juvenile traumatic brain injury; + and – in A= most and least efficient,
respectively)
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We investigated the triad of endothelial cell proteins (P-gp, LRP1, and RAGE)
previously shown as potential mediators of Aβ trafficking and other proteins across the
BBB (Figure 6) (Miller, 2010, Ueno et al., 2010). P-gp is well known as an efficient
gatekeeper on the luminal side and often pharmaceutically by-passed to allow efficient
drug delivery. Its expression is influenced by several distinct molecular pathways and its
putative role in disease and injury is emerging (Kooij et al., 2010, van Assema et al.,
2012). We observed a significant decrease in P-gp in cortical vessels following jTBI by
immunostaining and protein blot analyses. Similar to our findings, brain P-gp protein
level and function decreased after irradiation of normal rats (Bart et al., 2007), in aged 3
year old rats (Silverberg et al., 2010), and in sporadic AD (van Assema et al., 2012).
Additionally, P-gp expression and function were impaired during multiple sclerosis
pathology and its dysfunction coincides with lymphocyte infiltration and inflammation in
experimental allergic encephalomyelitis (Kooij et al., 2010).
Our observed P-gp decreases may be one result of long-lasting
neuroinflammation, contributing to an increase in rodent-Aβ immunoreactivity.
Importantly, P-gp knockout mice exhibited decreased LRP1 in brain capillaries without
changes in RAGE proteins (Cirrito et al., 2005) and aged 3 year old rats showed
decreased vascular levels of P-gp and LRP1 associated with accumulation of Aβ
(Silverberg et al., 2010). We did not detect significant changes in LRP1 between sham
and jTBI, but LRP1 was positive in blood vessels and neurons within the temporal cortex
of jTBI animals. Our findings are in line with several model systems and age groups,
which emphasize the putative role of the BBB in chronic brain pathophysiology after
acute injury. Our observed P-gp decrease may have a complex relationship to
accumulation of rodent-Aβ in multiple brain areas. Frontal and temporal lobes are
vulnerable to neuropathology after TBI (Johnson et al., 2012). In our model, these same
regions exhibited reduced P-gp (Figure 1) and increased rodent-Aβ immunoreactivity in
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the brain parenchyma and vessel walls (Figure 3, 4). Clinically, our findings are similar to
low endothelial P-gp that correlated with increased parenchymal Aβ1-40 or Aβ1-42
plaques in the medial temporal lobe of aged non-demented humans (Vogelgesang et al.,
2002). Following peripheral Aβ1-42 injections in adult mice, brain endothelial cells show
downregulated expression of RAGE, LRP1 and P-gp at the mRNA level, however P-gp
immunostaining remained unchanged (Brenn et al., 2011). Collectively, these findings
highlight complex interactions between Aβ species and the BBB transporters that may
be influenced by injury type and study time point.

Aβ Accumulation and Blood–Brain Barrier Changes after
Juvenile Traumatic Brain Injury
The important consequences of cerebrovascular dysfunction and the role of the
BBB neuropathological protein trafficking are gaining momentum. In normal rodents,
classical AD-like pathology with fibrillar amyloidosis is rare. This may be due to Aβ
sequence differences of three amino acids at the N-terminal (Istrate et al., 2012).
However, we used an N-terminal specific antibody for rodent Aβ (McGowan et al., 2005),
and endogenous accumulation has been reported long after a brain insult in normal
experimental injury models. For example, increased APP and Aβ immunostaining was
observed in thalamic nuclei for up to 9 months after stroke in normal rats (van Groen et
al., 2005). In normal adult rats, intranasal nerve growth factor administration resolved
increases of Aβ1-42 for up to two weeks post-TBI (Tian et al., 2012). In a rodent model
of aging, senescence accelerated mice (SAMP8) showed increased BBB disruption at
12 months and exhibited vascular Aβ compared to their littermate controls (Del Valle et
al., 2011). These data indicate the close relationship of BBB disruption and brain
pathology in aging and post-injury.
BBB phenotypic changes at 2 months occurred in parallel with higher rodent-Aβ
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immunolabeling in the parenchyma and vasculature of jTBI animals (Figure 3, 4).
Notably, we observed diffuse Aβ deposition in regions remote to the original site of
impact, especially in the superficial cortical layers. Additionally, diffuse Aβ in superficial
cortical layers is the primary conformation present in other models of natural Aβ
accumulation, such as aged beagles (Pop et al., 2012). Diffuse Aβ is also more common
in clinical cases with mild cognitive impairment (MCI) (Jicha et al., 2006) and is
becoming recognized as an important contributor to disease progression by the National
Institute of Aging-Alzheimer’s Disease (Montine et al., 2012). Aβ load, evaluated by
immunohistochemical staining similar to our methodology, was the best predictor for
dementia in very old individuals (Robinson et al., 2011). Interestingly, we observed
sparse rodent-Aβ immunoreactivity in some shams (n=3 of 8 total) and only modest
effects of increased rodent-Aβ immunolabeling throughout the brain of jTBI animals (n=6
total). In a similar TBI model, sham animals with a craniotomy exhibited brain tissue
modifications and deficits in learning and memory post-surgery (Bertolizio et al., 2011).
Therefore, we expect that inclusion of additional animals or a more appropriate naïve
control group may improve our data variability and improve statistical power.

Parallel Changes in Vascular Phenotype and Behavioral
Dysfunction
In our injury model, we observed changes in behavioral outcome by two months
post-injury (Ajao et al., 2012), which indicate the brain may be undergoing compensatory
mechanisms. Here, we observed strategic water maze impairment without overt memory
deficits, which may reflect underlying brain-repair mechanisms occurring post-injury.
Interestingly, clinical defects of initial strategy formulation affected performance on a task
of complex visuospatial executive function in individuals with amnestic MCI who are
more likely to develop AD (Papp et al., 2011). In a CCI study in adult mice, sham and

118

TBI animals exhibited similar water maze outcomes after two months, but TBI animals
exhibited thigmotaxic strategy impairment with increased percent time swimming along
maze walls, similar to our looping category (Blaiss et al., 2011). In comparison with adult
models, juvenile rats may be especially vulnerable due to a lack of cognitive reserve.
While the neural correlates are unclear, clinically it is thought that having increased
cognitive reserve from education and other life experiences may be protective against
brain aging and disease (Honer et al., 2012). Thus, brain injury at a developmental stage
may influence underlying mechanisms and reduce cognitive reserve. Our observations
of delayed impairments in jTBI suggest a parallel with acceleration of brain aging and
disease due to trauma.

Concluding Remarks
Juvenile traumatic brain injury may induce initial BBB dysfunction which
progresses over time to affect protein trafficking at a time point relevant for cognition.
Our data are consistent with clinical and experimental findings in studies of TBI and Aβ
in transgenic models, as well as studies on BBB dynamics with aging and non-traumatic
brain injuries. However, only the use of further target-specific studies may address
whether these changes are interconnected, or whether they are independent parallel
events in the same trauma-affected brain. In this study, we described lasting effects of
jTBI with phenotypic BBB changes after two months, including a lack of IgG
extravasation and compensatory increases in structural tight junction protein claudin 5
(Figure 6) (Andras et al., 2010). However, the reduction in P-gp may be sufficient to
impair normal Aβ clearance and promote its accumulation inside the brain. Overall, we
show the presence of continued modifications in the BBB phenotype long after injury,
and propose the BBB as a meaningful therapeutic target for resolving detrimental posttraumatic dysfunction.
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Figure 6. Summary of parallel changes in adulthood after early brain injury. A
schematic representation of events two months after jTBI shows phenotypic
alterations to the BBB changes occurring in parallel with molecular and behavioral
dysfunction. Specifically, lack of IgG extravasation from the blood into the tissue
and increased levels of tight-junction marker Cld5 indicate an intact BBB during
adulthood. However, in an environment with decreased levels of P-gp, and
unchanged levels of LRP1 and RAGE, proper metabolism of toxic proteins such as
Aβ can be hindered. As a result, the BBB phenotype impairs normal clearance of
rod-Aβ and may promote its abnormal accumulation inside the brain in the
parenchyma and vascular walls (figure adapted from Andras et al., 2010).
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PROLOGUE TO CHAPTER 3
LONG-TERM INCREASE OF CAVEOLINS IN THE ENDOTHELIUM
AND IN ASTROCYTES AFTER JUVENILE TRAUMATIC BRAIN
INJURY
A reproducible juvenile TBI (CCI in P17 rat pups) model and the histopathological
features and functional deficits resulting from the injury at both acute and chronic time
points have been described in chapters 2. In keeping with the experimental aims of this
project, chapter 3 focuses on caveolins and their association with BBB disruption, and
possibly with other secondary processes following juvenile TBI. Caveolin-1, -2, and -3
are a family of integral membrane proteins that constitute the coat of caveolae – small
invaginations of plasma membrane in lipid rafts – and perform various roles ranging from
transcytosis and endocytosis to cholesterol metabolism and modulation of numerous
intracellular signaling pathways. Regulation of tight junction permeability is suspected to
be one of the functions of caveolins in the developing brain following TBI.
The relevance of caveolin expression and activation to the secondary
pathophysiology of juvenile TBI has been reviewed in chapter 1 (and is also reviewed in
the introductory section of this chapter 3). In chapter 4, the therapeutic potential of
cavtratin – an injectable peptide mimetic of the caveolin scaffolding domain is
investigated with respect to slowing and/or reversing BBB disruption and cerebral
edema, and also in terms of improving functional outcomes.
The aim of this chapter is to characterize changes in the expression pattern and
immunoreactivity of caveolin-1, -2 and -3 following juvenile TBI in conjunction with BBB
disruption and edema formation. The hypothesis is that decrease in tight junction protein
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levels and the resultant opening of BBB will be associated with increased expression of
caveolins-1, 2, and 3 in brain endothelial cells and other cells following juvenile TBI.
The chapter follows the blueprint of a scientific manuscript. It contains 5 figures
with detailed figure legends. Authors’ names and affiliations are on the first page.
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CHAPTER 3
LONG-TERM INCREASE OF CAVEOLINS IN THE ENDOTHELIUM
AND IN ASTROCYTES AFTER JUVENILE TRAUMATIC BRAIN
INJURY

David O. Ajao1, Andrew M Fukuda1, Dane Sorensen1, 2, Jérôme
Badaut1, 2*
Departments of Physiology1 and Pediatrics2, Loma Linda University, Loma Linda, CA.

Running Title: Expression of caveolins after juvenile TBI
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1) Long-term change in blood-brain barrier after jTBI
2) Distribution of the 3 isoforms of caveolin after jTBI
3) Time course of protein expression for the 3 caveolin isoforms after jTBI
4) Increase of caveolin-1 in cerebral endothelia
5) Increase of caveolin-1 and -3 in astrocytes
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Abstract
Caveolins are structural proteins involved in caveolae formation as well as in
modulating the activities of a wide variety of signaling molecules. Three isoforms of
caveolin are known to be present in the mammalian brain and hypothesized to be
involved in blood-brain barrier (BBB) dysfunctions after brain injury with vascular
phenotypic changes. Traumatic brain injury (TBI) is one of the major causes of death
and disability in children and adolescents, and results in a complex cascade of events
including the disruption of BBB. Juvenile TBI (jTBI) induces long-term alterations on
endothelial phenotypes such as increase of claudin-5 and a decrease in p-glycoprotein.
In the present study, we explored the changes of the caveolin expression and
distribution after jTBI. Using a controlled cortical impact on post-natal 17 day-old rats as
a model of jTBI, BBB was observed to be disrupted from 1 to 3 days after injury and
went back to normal at day 7. Caveolin (cav)-1 was increased from day 1 to 60 after
injury in the endothelial cells and in the reactive astrocytes. In contrast, cav-2
expression, only present in the endothelium, was not modified over time after injury.
Cav-3 was observed in astrocytes and increased in the border of the lesion in the
reactive astrocytes at 1 and 3 days after injury. The long-term change observed in cav-1
after jTBI makes this a good molecular candidate for controlling endothelial phenotypic
changes after injury. Increase of cav-1 and 3 in the astrocytes also raises an interesting
question regarding their roles in the reactive astrocytes after jTBI.
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Introduction
Traumatic brain injury (TBI) affects about 1.7 million people annually and
accounts for about 30.5% of all injury-related deaths in the United States. Children and
adolescents aged between 0 to 14 years represent a vulnerable population with half a
million TBI-related emergency department visits annually (Faul et al., 2010). As such,
juvenile TBI (jTBI) is a leading cause of death and disability in children and adolescents
in the United States (Schneier et al., 2006). TBI is defined as brain damage that results
from an external mechanical force (e.g. rapid acceleration or deceleration), blast waves,
penetration by a projectile, or direct impact, and it is often accompanied by a post-injury
concussion or similar form of altered consciousness (Maas et al., 2008). In connection
with the primary injury, TBI is associated with secondary events, which include
hemorrhage, disruption of blood-brain barrier (BBB), and vasogenic edema (Pop and
Badaut, 2011). TBI in the juvenile population has been associated with greater risks of
cerebral hemodynamic dysfunction, hypoxic-ischemic injury, and diffuse cerebral edema
compared to adults (Armstead, 1999, Suh et al., 2001, Giza et al., 2007, Freeman et al.,
2008). In an experimental model of jTBI, we have previously shown an increase in brain
water content during the first week post-injury using T2-weighted MRI (Fukuda et al.,
2012). Further post-traumatic secondary events include brain swelling, decrease in
cerebral blood flow (CBF), perturbation of ionic homeostasis that induce dysfunction in
neuronal firing, excitotoxicity, apoptosis, oxidative stress, and inflammation (Baethmann
et al., 1988, Armstead, 1999, Sahuquillo et al., 2001, Gaetz, 2004, Zweckberger et al.,
2006). All these events contribute to neurological deterioration, leading to mortality and
morbidity after TBI.
TBI-induced vascular changes have been shown to alter endothelial phenotypes
both acutely and chronically after injury (Pop and Badaut, 2011, Pop et al., 2012). In
addition to early breakdown of BBB and edema formation, we have observed a
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compensatory increase in the expression of claudin-5, a protein involved in tight junction
formation, and a decrease in p-glycoprotein (P-gp), an ATP-binding protein, at 2 months
post-injury (Pop et al., 2012). The molecular mechanisms contributing to these long-term
endothelial phenotypic changes are still unknown. However, recent studies showed that
the caveolins are involved in molecular signaling and contribute to the changes in
claudin-5 and P-gP (McCaffrey et al., 2007, McCaffrey et al., 2012).
Caveolins are structural proteins that form the backbone of the caveolae, which are
known to function in endocytosis, transcytosis, and exocytosis in endothelial cells
(Predescu and Palade, 1993, Jodoin et al., 2003, Salaun et al., 2005, Choudhury et al.,
2006, Predescu et al., 2007). Three isoforms of caveolin are known to be present in the
mammalian brain (Cameron et al., 1997, Virgintino et al., 2002). Caveolins-1 (cav-1) and
2 were mostly observed in brain endothelial cells (Lisanti et al., 1994, Virgintino et al.,
2002) although cav-1 has also been observed in some neurons and astrocytes
(Cameron et al., 1997, Virgintino et al., 2002, Head et al., 2010). Cav-3 has been
predominantly described in the astrocytes (Virgintino et al., 2002, Shin et al., 2005).
Besides facilitating the caveolae sequestration of several receptors and ligands, the
caveolins also serve as active modulators of activities of a wide variety of signaling
molecules, including inhibition of endothelial nitric oxide synthase (eNOS) (Bucci et al.,
2000, Bauer et al., 2005, Lajoie et al., 2009). This modulation is performed via the
caveolin scaffolding domain (CSD), a 19-amino acid sequence (amino acids 82 – 109)
that binds proteins via a binding site, caveolin-binding motif (CBM), that are present on
proteins such as eNOS (Sargiacomo et al., 1995, Cameron et al., 1997, Lajoie et al.,
2009).
Despite abundant literature on the role of cav-1 in modulating eNOS and its
physiological consequences in the periphery (Bernatchez et al., 2005), little is known
about the potential roles of caveolins after brain injury (Nag et al., 2007). In an adult rat
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model of cold cortical injury, the level of expression of cav-1 is increased in the
endothelium for several days following injury (Nag et al., 2007, Nag et al., 2009). Similar
increases have been reported in models of brain ischemia (Jasmin et al., 2007) and
experimental spinal cord injury (Shin et al., 2005, Shin, 2007). Although cav-1 increase
in some of these brain injury models was associated with BBB or blood-spinal cord
barrier breakdown (Nag et al., 2007, Nag et al., 2009), the exact role of these changes in
cav-1 is still unclear. Experiments using cav-1 knockout (cav-1-/-) mice suggest beneficial
roles for cav-1 in rodent models of brain disorders (Jasmin et al., 2007, Gu et al., 2011).
In fact, cav-1-/- mice presented higher vascular permeability (Schubert et al., 2002,
Miyawaki-Shimizu et al., 2006, Siddiqui et al., 2011) and intriguingly have a worse
outcome than the wild-type (WT) with increased cerebral volume of infarction after stroke
(Jasmin et al., 2007). Interestingly, claudin-5, a protein involved in tight junction (TJ)
formation, was shown to bind to cav-1 and be stabilized by it in some cases (McCaffrey
et al., 2007, Stamatovic et al., 2009). It is therefore plausible that increase in cav-1
expression may be contributing to the recovery of TJ and BBB functions after injury.
However, cav-2 is also abundant in the endothelial cells, and cav-2-/- mice showed a
decreased lesion volume compared to WT (Jasmin et al., 2007). This suggests that cav2 may have a detrimental role in brain injury, in contrast with cav-1.
Lastly, cav-3 expression was also shown to change in spinal cord astrocytes in a
model of experimental autoimmune encephalomyelitis (Shin et al., 2005). The changes
in expression of these caveolins are potentially contributing to the neurovascular
dysfunctions observed after jTBI (Fukuda et al., 2012, Pop et al., 2012). The expression
and distribution profiles of cav-1, 2, and 3 within the neurovascular unit after jTBI in
conjunction with BBB disruption have not been investigated. The goal of this present
study is, therefore, to report changes in the level of expression of cav-1, 2, and 3 after
jTBI, in parallel with the changes in the BBB.
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Materials and Methods
Animals
All animal related protocols and procedures in this study were approved by the
Institutional Animal Care and Use Committee of Loma Linda University. Male SpragueDawley rat pups at postnatal day 10 (P10, Harlan, Indianapolis, IN) were housed on a
12-hour light-dark cycle at constant temperature and humidity for one-week prior to
surgery to allow sufficient time for acclimatization. Following induction of experimental
brain injury or sham procedure at P17 (30± 4 g, n=36 rats), the pups were returned to
their cages with their dams and subsequently weaned at 7d. They were housed two rats
per cage, and fed with standard lab chow and water ad libitum. Identical sham or
controlled cortical impact (CCI) surgical parameters were used for the experimental brain
injury.
Juvenile Traumatic Brain Injury Model
Controlled cortical impact (CCI) was induced in P17 old rat pups as previously
described (Ajao et al., 2012, Fukuda et al., 2012). Briefly, rat pups were anesthetized
with isoflurane (Webster Veterinary Supply, Inc., Sterling, MA) and placed into a
stereotaxic frame (David Kopf Instruments, USA). A 5 mm diameter craniotomy was
drilled over the right parietal cortex at 3 mm anterior-posterior and 4 mm medial-lateral to
bregma. CCI was induced in the jTBI group using a 2.7mm diameter rounded-tip metal
impactor fixed to an electromechanical actuator (Leica Microsystems Company,
Richmond, IL) and centered over the exposed dura at a 20° angle to the cortical surface.
The impact was delivered at a velocity of 6 m/s, with impact duration of 200 ms, and to a
depth of 1.5 mm from the cortical surface. Bleeding and convexity of the injured cortex
were recorded and showed no significant difference within the jTBI animals. The surgical
site was sutured closed. Appropriate pain management was provided through
subcutaneous administration of Buprenorphine (0.01 mg/kg; dilution: 0.01 mg/ml)
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immediately following end of suturing. The body temperature was maintained at 37°C
throughout the surgical procedure. Sham animals underwent identical procedures with
the exception of cortical impact. All rats recovered from anesthesia within 25 minutes
post-injury. No seizures resulting from experimental procedure was observed within the
2 to 3-hour observation period immediately following injury when the animals were
returned to their cages.

Tissue Processing and Immunohistochemistry
Rats were transcardially perfused with 4% PFA prepared in PBS at 1d, 3d, 7d,
and 60d with n=5 rats per group (jTBI and sham) for each time points. The brains were
removed and immersed in 30% sucrose at 4°C for 48 hours and then frozen on dry ice
and stored at -20°C pending tissue cutting. Coronal cryostat sections (Leica CM1850,
Leica Microsystems GmbH, Wetzlar, Germany) were prepared.

IgG Extravasation Staining for BBB Assessment
To evaluate the BBB disruption, IgG extravasation staining was performed as
previously described (Badaut et al., 2011). Briefly, the sections were incubated with
biotin conjugated affinity purified goat anti-rat IgG coupled with Infrared-Dye-800-nm
(1:500 dilution; Rockland, Gilbertsville, PA) in PBS containing 0.1% Triton X-100 and 1%
bovine serum albumin (BSA) for 2 hours at room temperature. After washing, sections
were dried and scanned on an infra-red scanner (Odyssey-system, LiCor, Germany) to
quantify the area of the IgG extravasation for three adjacent slices covering the lesion
with the LI-COR Odyssey system.

Double Immunohistochemical Staining:
All antibody incubations were carried out in PBS (Fisher Scientific, Pittsburgh,
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PA) containing 0.25% Triton X-100 and 0.25% BSA (both from Sigma-Aldrich Co., St.
Louis, MO). After washes in PBS, sections were blocked for 1.5 hours in PBS with 1%
BSA, and then incubated overnight at 4°C with one of the following: mouse anti-cav-1 or
-2 or -3 (each diluted 1:200; BD Biosciences, San Jose, CA), rabbit anti-cav-1 (1:200;
Abcam Inc., Cambridge, MA), mouse anti-claudin-5 (1:100; Invitrogen, Camarillo, CA),
mouse monoclonal antibodies for NeuN (1:500; Abcam Inc., Cambridge, MA), rabbit
polyclonal antibodies for IBA-1 (1:300; Wako), and chicken anti-glial fibrillary acidic
protein (GFAP, 1:1000; Millipore, Billerica, MA). After 3x10min PBS rinses, sections
were incubated for 2 hours at room temperature with a mixture of goat anti-mouse
secondary antibody coupled with Alexa-Fluor-488 and goat anti-rabbit secondary
antibody coupled with Alexa-Fluor-568 (both at 1:1000; Invitrogen, Camarillo, CA) and
subsequently rinsed again in PBS for 3x10 minutes. Sections stained with the antibodies
mentioned were all mounted on glass slides and coverslipped with anti-fading medium
vectashield containing DAPI (Vector, Vector Laboratories, Burlingame, CA).
Negative control staining where the primary antibody was omitted showed no
detectable labelling.
The area of cav-1 and cav-2 immunolabeling was quantified at 1, 3, 7, and 60d
from a series of images collected at 20X objective (422 µm X 338 µm) in perilesional
parietal cortex and ipsilateral temporal cortex using an epifluorescent microscope with
the same parameters for all animals (Olympus, BX41, Center Valley, PA). Images were
acquired from five serial coronal slices separated by 500 μm (24 images per animal).
The area of cav-1 and cav-2 staining was measured for each individual image with
MorphoPro software (Explora-Nova, La Rochelle, France) according to the following
procedure: 1) Top Hat morphologic filter to outline vascular staining from the
background, 2) user-defined thresholding value applied to each image. Final values
were represented as a percentage of the sham group.
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Cav-3 was mainly observed in astrocytes and scored in the perilesional parietal
cortex adjacent to the lesion site on 5 sections separated by 500 μm per animals.
Scoring was given a value from 0-4 with (0) no staining seen; (1) faint staining in a few
positive cells, (2) bright staining in a small area, or low intensity staining in a larger area
(more positive cells), (3) bright staining in a larger area, or (4) very intense staining over
a large area.

Western Blotting
A second set of rats was prepared with four animals per group at 1d and brains
were freshly dissected and the cortical tissue adjacent to the site of the impact was
collected. Tissues were prepared in RIPA buffer with a cocktail of protease inhibitors
(Roche, Basel, Switzerland) and sonicated for 30 s (Hirt et al., 2009). After BCA protein
assay, 10

g of protein was then subjected to SDS polyacrylamide gel electrophoresis

on a 4-12% gel (Nupage, Invitrogen, Carlsbad, CA). Proteins were then transferred to a
polyvinylidene fluoride membrane as indicated by the supplier (PerkinElmer, Germany).
The blot was incubated with a rabbit polyclonal against cav-1 (BD Biosciences, 1:2000)
and a monoclonal antibody against Tubulin (Sigma, USA, 1:10,000); a monoclonal
antibody against cav-2 or cav-3 (BD Biosciences, 1:2000) and a polyclonal antibody
against actin (Sigma, USA, 1:25,000) in Odyssey blocking buffer (LI-COR, Bioscience,
Germany) overnight at 4°C. After washing, the blot was incubated with two fluorescencecoupled secondary antibodies (1:10,000, anti-rabbit Alexa-Fluor-680nm, Molecular
Probes, Oregon and anti-mouse IR-Dye-800-nm, Roche, Germany) for 2 hours at room
temperature. After washing, the degree of fluorescence was measured using an infra-red
scanner (Odyssey, LI-COR, Germany).
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Statistical Analyses
All data are presented as mean ± SEM, statistical analyses were done using
SPSS, and graphs obtained using SigmaPlot. The IgG extravasation, cav-1, cav-2
immunolabeling, and western blot data were analyzed using student t-tests for normally
distributed data with comparison between the sham and jTBI groups for each individual
time points. Cav-3 data were analyzed using a non-parametric Mann-Whitney test with a
comparison between the sham and jTBI.

Results
Blood-Brain Barrier Disruption in Early Time Points after jTBI
IgG extravasation staining was used to evaluate BBB disruption from 1d to 7d
(Fig. 1). Increased staining of extravasated IgG was observed in the perilesion and
contralateral cortex of jTBI animals (Fig. 1) at 1d and 3d compared to the sham group.
The IgG staining decreased back to the normal (i.e. sham) level at 7d (Fig. 1A).
Quantification of the surface area of extravasated IgG showed a significant increase in
the perilesion cortex of the jTBI rats at 1d and 3d compared to sham (respectively 0.023
 0.033 mm2 vs. 0.002  0.001 mm2 and 0.035  0.042 mm2 vs. 0.002  0.001 mm2,
p<0.05, Fig. 1E). This suggests that BBB disruption is maximum at 1d and 3d postinjury, which is in agreement with our previous observations that showed vasogenic
edema formation between 1d and 3d, followed by normalization after 7d (Fukuda et al.,
2012).
In parallel with increased IgG extravasation staining, immunostaining for claudin5 showed a decrease at 1d and 3d in the cortical perilesion in the jTBI group (Fig. 1D)
compared to the sham group (Fig. 1C). At 7d, claudin-5 immunoreactivity was
comparable to the sham level (Fig. 1D), suggesting a return to normal as observed for
the IgG extravasation (Fig. 1A, B).
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Changes in Vascular Expression of Caveolin-1 and -2 after
jTBI
Caveolin-1 Expression and Distribution after jTBI
Mouse and rabbit cav-1 antibodies were used in double immunostaining to
identify the cell distribution of cav-1 after jTBI in the tissue adjacent to the lesion and
remotely. As previously described in adult brain (Nag et al., 2007), the rabbit anti-cav-1
antibody was observed in brain endothelium and also in other cell types such as
astrocytes and neurons (Fig. 2A, B, C, D). At 1d and 3d, when BBB disruption was
maximal (Fig. 1), double immunolabeling of GFAP and cav-1 showed co-localization,
suggesting the presence of cav-1 in the reactive astrocytes at the border of the lesion at
1d and 3d in jTBI (Fig. 2A, B, C). Rabbit anti-cav-1 staining also co-localized with mouse
anti-NeuN staining (Fig. 2D), suggesting an increased immunoreactivity of cav-1 in
neuronal nuclei located around the lesion site at 3d post-injury. However, cav-1 staining
did not co-localize with IBA-1 staining, a marker of microglia cells (Fig. 2E). As
previously described in literature, mouse anti-cav-1 staining showed that cav-1 is
predominantly expressed in brain endothelial cells (Fig. 2E, F) of all cerebral blood
vessels, independent of the diameter (from the pial vessels to intracerebral arterioles
and capillaries) in normal brain (not shown) and at distance from the site of the injury.
The presence of cav-1 in the endothelium was also observed with the rabbit anti-cav-1
(Fig. 2C, D).
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The regional observation of the cav-1-IR showed an increase in the staining of
brain cortical blood vessels from 1d to 60d (Fig. 3B) in the perilesion compared to the
sham groups (Fig. 3A). The quantification showed that cav-1-IR at the perilesional cortex
is significantly increased by 36% at 1d, 105% at 3d, 92% at 7d and 88% at 60d
compared to the sham groups (p<0.05, Fig. 3C). The relative change in cav-1-IR at 1d
was confirmed by western blot quantification performed on the perilesional cortical tissue
at 1d. Both monomeric (molecular weight at ~ 22 kDa) and oligomeric forms (molecular
weight at ~ 66 kDa) of cav-1 were significantly increased in jTBI compared to sham (Fig.
3D, E; p<0.05).
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Acute Change in Vascular Caveolin-2 after jTBI
Similar to cav-1-IR, cav-2-IR was observed in brain endothelial cells in brain
blood vessels of all sizes (Fig. 4A, C, D) including pial blood vessels in both shams and
jTBI group. The western blot showed a band around 20 kDa in both sham and jTBI,
without any difference between the groups (Fig. 4B). The analysis of the level of cav-2
IR was performed on the same regions of interest that was used for cav-1. There was a
slight decrease of cav-2 IR in jTBI group at 1d post-injury (Fig 4C, D; not significant).
This was followed by a significant increase in cav-2 in the jTBI animals on at 3d postinjury (p<0.05; Fig. 4, C2, D2 and E). No significant changes were seen between the
sham and jTBI animals at 7d (not shown) and 60d post-injury (Fig. 4C, D, E). This result
was confirmed by quantification of Cav-2-IR in the perilesional cortex over the timeline
(Fig. 4E) and by the western blot quantification (not shown).

Changes in Astrocytic Caveolin-3 Expression after jTBI
Cav-3 staining was observed in astrocytes located in the glia limitans, cortex,
hippocampus, white matter tract (Fig. 5A, B), and hypothalamus (data not show). Double
immunolabeling of GFAP and cav-3 confirmed the presence of cav-3 in astrocytes (Fig.
5B). Interestingly, cav-3-IR is also highly co-localized with eNOS staining in the
astrocytes at the border of the lesion cavity (Fig. 5C). Western blot of cav-3 showed a
band around 20kDa (Fig 5D) that is significantly higher in the jTBI group compared to
sham at 1d (Fig. 5D). Immunohistochemical observation showed increase of cav-3-IR in
reactive astrocytes in the vicinity of the lesion in the cortex (Fig 5A, E). In addition,
increase of cav-3 staining was also observed in the corpus callosum and in hippocampal
structures below the site of the impact, but there was no such increase in the
contralateral cortex (data not shown). These observations were confirmed by categorical
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scoring of the Cav-3 staining over several sections covering the lesion. It showed that
cav-3 staining was increased in jTBI compared to sham groups in the perilesional brain
structures at 1d (Fig. 5F1, G) and 3d (Fig.5F2, 5G) compared to the sham groups (Fig.
5E1, E2, G). After 7d and 60d, there were no longer differences between the groups
where the cav-3 staining was observed in the astrocytes in both groups (Fig. 5E3, E4,
F3, F4, G).

Discussion
The level of expression of cav-1 is increased in the endothelium and astrocytes,
cav-2 increased only in the endothelium, and cav-3 is increased in astrocytes after jTBI
during the first week post-injury, which is also known to be a period of active BBB
disruption. This increased expression level for cav-1 is still maintained even at 2 months
after injury, suggesting phenotypic changes in the endothelium after jTBI, in accordance
with our previous studies showing an increased claudin-5 and decreased PgP (Pop et
al., 2012). These observed changes in caveolin expression following jTBI, coupled with
the fact that caveolins are central to caveolae formation and function, as well as in the
regulation of several endothelial signaling pathways, indicate that cav-1, cav-2, and cav3 may be good molecular targets to mitigate the neurovascular changes at early and
later time points after jTBI. The functional roles of these proteins, however, need to be
determined in vivo in this pathological model.

Acute Increase in Endothelial Caveolins-1 and -2 Precedes
BBB Recovery
As indicated in the introduction, TBI in the juvenile population is known to be
associated with greater risks of cerebral hemodynamic dysfunction, BBB disruption, and
diffuse cerebral edema, compared to adults (Armstead, 1999, Suh et al., 2001, Campbell
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et al., 2007, Giza et al., 2007, Freeman et al., 2008). BBB disruption in clinical patients is
known to be a major cause of mortality and long-term neurological deficits in victims with
moderate to severe TBI (Shlosberg et al., 2010). There are also more recent evidence
indicating that in mild-TBI such as in blast injury, the BBB is impaired early on after the
injury (Readnower et al., 2010). Hence, there is a need to study BBB changes in jTBI at
early and long-term.
The jTBI model showed a significant increase in IgG extravasation at 1 and 3d,
paralleled with the loss of claudin-5 staining in the cortex (Fig. 1), and these indicate a
physical BBB disruption during the development of the secondary injuries. It is
interesting to note that BBB disruption parallels the peak of edema formation previously
observed on the T2-weighted MRI in a similar jTBI model (Fukuda et al., 2012). At 7d,
the extravasation of IgG as well as the claudin-5 staining returned to sham levels,
suggesting a recovery of the BBB. Similarly, BBB recovery parallels the decrease in
vasogenic edema previously observed as a return to the normal T2 values on T2weighted MRI scans at 7d in a similar injury model (Fukuda et al., 2012). Despite this
return to normal T2 values at 7d, long-term phenotypic changes at the endothelium still
occur (Pop et al., 2012).
Endothelial cav-1 and 2 could be good molecular candidates to study with regard
to changes in BBB properties because of their possible involvement in the regulation of
several intracellular signaling processes (Bucci et al., 2000, Razani et al., 2002,
Schubert et al., 2002, Minshall et al., 2003, Stamatovic et al., 2009, Gu et al., 2011).
Cav-1 was shown to be involved in the regulation of eNOS activity (Garcia-Cardena et
al., 1997, Bucci et al., 2000, Bernatchez et al., 2005), c-Jun N-terminal kinase activation
(Tourkina et al., 2008, Tourkina et al., 2010), as well as in the stabilization of tight
junction proteins such as claudin-5 within the lipid raft domain and P-gp (Jodoin et al.,
2003, McCaffrey et al., 2007, McCaffrey et al., 2012).
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In the juvenile rodent population, cav-1 and cav-2 distribution were observed in
the endothelial layer of brain blood vessels of all sizes (from capillaries to pial arteries,
Fig. 2A) in accordance with previous studies carried out in adult mammalian brains
(Cameron et al., 1997, Virgintino et al., 2002). In contrast to the distribution of cav-2,
cav-1-IR was also observed in some astrocytes and neurons in the jTBI group, which is
in accordance with previous studies (Ikezu et al., 1998, Virgintino et al., 2002, Head et
al., 2008, Head et al., 2010). The potential role of cav-1 changes in the astrocytes after
jTBI is reviewed later in the discussion. Cav-2 expression was changed significantly only
at 3d after jTBI, which was the peak of edema formation. In contrast, increased cav-1 in
the endothelial cells in the ipsilateral cortex was observed not only throughout the acute
injury phase (from 1d to 7d), but also at a later time point (2 months) after the injury.
Similar findings were reported from other adult rodent models of CNS insults with an
early increase of cav-1 in the endothelial cells preceding the decrease of claudin-5 and
occludin (Nag et al., 2007, Nag et al., 2009). From that study, the authors concluded that
the increase of cav-1 could potentially contribute to BBB disruption (Nag et al., 2007,
Nag et al., 2009).
Intriguingly, tight junction proteins, claudin-5 and occludin, have been shown to
bind to and be stabilized by cav-1 within the caveolae (McCaffrey et al., 2007). After
hypoxia-reoxygenation, levels of claudin-5 and occludin found within the caveolae were
all together reduced (McCaffrey et al., 2007, McCaffrey et al., 2009). Cav-1 was
therefore proposed to play key roles in the maintenance of these tight junction protein
subunits (McCaffrey et al., 2007, McCaffrey et al., 2009, Stamatovic et al., 2009).
Moreover, cav-1-/- mice presented higher endothelial permeability in the systemic
vasculature compared to WT (Razani et al., 2001, Schubert et al., 2002). Therefore, a
decrease in cav-1 may suggest a disruption in the BBB integrity, whereas an early
increase of cav-1, as observed in our model during the first week, may be beneficial
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toward the recovery of the BBB integrity after jTBI. In support of this hypothesis, cav-1-/mice showed a larger lesion volume compared to WT in a transient middle cerebral
artery occlusion model (Jasmin et al., 2007). That study concluded that the absence of
cav-1 is detrimental due to a decrease in angiogenesis in the cav-1-/- mice compared to
WT (Jasmin et al., 2007). Cav-1 has a CSD sequence that binds to eNOS and inhibits its
activity (Bucci et al., 2000). A decrease of NO formation following increase of Cav-1 in a
stroke model was shown to be associated with decreased activation of MMPs (Gu et al.,
2011) and consequently protected the BBB. The recent experiments with cav1-/- suggest
that early increase of cav-1 in endothelium following jTBI may be an endogenous
mechanism aimed at facilitating BBB recovery during the first week. Until now, the exact
role of cav-1 in brain injury and especially in jTBI is still unknown, and detrimental effects
of acute cav-1 increase cannot be ruled out.

Long-Term Caveolin-1 Overexpression may be Detrimental
In our model, the level of cav-1 expression was also increased in the
endothelium (Fig. 3) when claudin-5 is up-regulated at 2 months after injury (Pop et al.,
2012). Long-term changes of cav-1 expression was also reported at 14d after spinal
cord injury in adult rodent (Shin et al., 2005), when usually the tight junctions and BBB
have already recovered. This higher expression of cav-1 at 2 months after injury is
possibly a part of the endothelium phenotypic changes observed after jTBI (Pop et al.,
2012). Cav-1 could be a molecular pathway in the increase of claudin-5 as well as the
decrease of p-glycoprotein. In fact, increase of cav-1 was associated with a decrease of
the P-gp activity (McCaffrey et al., 2012). We cannot rule out the possibility that an
increase in cav-1 staining could be associated with an increase in the number of
caveolae, which in turn is responsible for increased transcytosis (Jodoin et al., 2003,
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Regina et al., 2004) and the entrance of albumin, which may contribute to the
dysfunction of the brain tissue homeostasis (Komarova and Malik, 2010).

Caveolin-1 and -3 in Astrocytes: Role in Astrogliosis?
Reactive astrocytes after jTBI showed increase in cav-1 and 3 expressions
during the first week. As described previously, the increase of cav-1 staining in the
reactive astrocytes was mostly detected with rabbit polyclonal anti-cav-1 (Virgintino et
al., 2002, Shin et al., 2005). Cav-1 and 3 are co-localized with GFAP staining, which is
consistent with previous studies in adult models (Ikezu et al., 1998, Shin et al., 2005).
Although cav-3 has been reported in smooth muscles (Ikezu et al., 1998), we did not
observe any staining in intraparenchymal cerebral blood vessels. The expression and
localization of cav-3 in the jTBI brains appears to coincide with astrogliosis, which is
similar to findings in experimental autoimmune encephalomyelitis (Shin et al., 2005). The
exact roles of these proteins in the astrocyte functions in vivo are still unknown.
Caveolins were associated with eNOS, which was previously shown in the astrocytes in
the rat brains (Colasanti et al., 1998, Wiencken and Casagrande, 1999). Excess NO
produced after brain injury can overload its inactivating enzyme, superoxide dismutase,
resulting in a cascade of events that have several cytotoxic effects on the brain tissue as
well as activation of the MMPs (Gu et al., 2011). Activated MMPs cleave key proteins
that are important for maintaining the BBB including matrix proteins in the basement
membrane and inter–endothelial junctional proteins such as the claudins and occludins
(Yang et al., 2007).
After jTBI, both cav-3 and cav-1 are present in the astrocytes and cav-3 was colocalized with eNOS. In the periphery, cav-3 was shown to interact with neuronal NOS
(nNOS), and in astrocytic culture, cav-1 was observed to function as an endogenous
inhibitor of eNOS (Colasanti et al.). Therefore, increase of Cav-1 and 3 in the astrocyte
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may be linked with the regulation of eNOS activity to prevent the release of excess NO.
Interestingly, the changes of the level of expression of cav-1 in astrocyte cultures were
associated with the glutamate transporter, GLT1 (Zschocke et al., 2005, Gonzalez et al.,
2007). The application of transforming growth factor-alpha (TGF-α) induced a decrease
of cav-1 and an increase of GLT1 (Zschocke et al., 2005, Gonzalez et al., 2007).
Increase of cav-1 in the astrocytes may, therefore, induce a decrease of GLT1 in the
astroglia. This decrease will have a consequence on the glutamate uptake and the
excitotoxicity after jTBI.

Conclusion
Cav-1 and cav-3 showed immunoreactivity changes in the astrocytes and
endothelial cells after jTBI at early time point as well as long-term. These proteins have
several physiological roles within the cells and in the neurovascular unit. This study
shows for the first time changes in the expression of these molecules in a model of jTBI.
Further studies will be needed to characterize the role of each caveolin in each cell type
after jTBI.
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PROLOGUE TO CHAPTER 4
CAVTRATIN AMELIORATES EDEMA AND REDUCES BRAIN
LESION VOLUME AT ACUTE TIME POINTS AFTER JUVENILE
TRAUMATIC BRAIN INJURY
In chapter 3, we described acute and long-term changes in the immunoreactivity
and protein expression levels of caveolin-1, -2, and -3 in rat brains following juvenile TBI,
and highlighted the potential beneficial role of caveolin-scaffolding domain in the
recovery of brain endothelial tight junctions and regulation of BBB permeability following
injury. Chapter 4 now focuses on the therapeutic potential of cavtratin – an injectable
peptide mimetic of the caveolin scaffolding domain – with respect to repair of BBB tight
junctions, reduction of cerebral edema, and improvement in functional outcomes during
the peak of edema (See Figure A below for a diagrammatic illustration of the proposed
intervention strategy with cavtratin). The question of long-term impact of cavtratin
treatment on the histopathology and functional outcome of juvenile TBI is not addressed
in this project, and will be a subject of future studies.
The aim of this chapter is therefore to examine the effects of cavtratin treatment
on tight junction disruption and associated vasogenic edema, and on functional (mainly
neurological and sensorimotor) outcomes following juvenile TBI at acute time point. The
hypothesis is that acute treatment with cavtratin (dose = 2.5 mg/kg; injected at 3 hours, 1
day, 2 day, and 3 day post-injury time points) following juvenile TBI will reverse the
damage to brain endothelial tight junction proteins and restore its function, thereby
reducing cerebral edema and consequently leading to improved functional outcomes.
The rationale for the technique and drug dosage used is explained in the section.
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The chapter follows the blueprint of a scientific manuscript with detailed figures
and figure legends. The data contained in this chapter are yet to be submitted for journal
publication.
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CHAPTER 4
CAVTRATIN AMELIORATES EDEMA AND REDUCES BRAIN
LESION VOLUME AT ACUTE TIME POINTS AFTER JUVENILE
TRAUMATIC BRAIN INJURY
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Abstract
Blood-brain barrier (BBB) breakdown and the resultant edema formation are
emergent therapeutic targets for addressing traumatic brain injury (TBI) in the juvenile
brain, which is known to be vulnerable to these two secondary pathophysiological
processes of brain trauma. Caveolin-1 has also emerged as an important protein that
modulates brain endothelial permeability. We investigate the therapeutic potential of
cavtratin – a caveolin mimetic peptide injected systemically – on the brain, following
juvenile TBI (jTBI) in P17 rats. We show that intraperitoneal administration of cavtratin at
3 hours post-jTBI results in reduction of brain lesion volume in treated rats at 1d (by
47.9%) and 3d (by 65.8% ) post-injury. In addition, edema formation in the lesion ROI –
measured with T2-weighted MRI – undergoes significant reduction with cavtratin
treatment at both acute time points (1d and 3d). There is however no rapid recovery of
neurological functions (tested with foot-faults, beam balance, and rotarod) observable in
cavtratin-treated rats compared to saline-controls at 1d and 3d. We therefore conclude
that systemic, acute treatment with cavtratin following jTBI protects against enlargement
of brain lesion and edema formation, and this suggests future potential development of
cavtratin as a therapeutic tool.
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Introduction
Two of the secondary pathophysiological processes most commonly associated
with traumatic brain injury (TBI) are blood-brain barrier (BBB) disruption and concomitant
edema formation (Werner and Engelhard, 2007, Shlosberg et al., 2010). These
processes are especially common in juvenile cases of TBI (jTBI) and are a deadly duo
responsible for deaths, disability and enormous economic burden (Yeates et al., 2002,
Schneier et al., 2006, Coronado et al., 2011) . The juvenile brain is susceptible to
disruption of its BBB and to diffuse edema formation owing to some unique
developmental features which include weak ligamentous protection, less myelination of
white mater fibers, and higher brain water content (Battin, 2001, Campbell et al., 2007,
Giza et al., 2007, Freeman et al., 2008). Subtle forms of BBB disruption have been
observed for months to years following initial TBI assault on young brains (Tomkins et
al., 2001, Tomkins et al., 2011). In addition, the juvenile brain has a greater risk for
hemodynamic dysfunction (Armstead, 1999, Udomphorn et al., 2008), and together,
these unresolved pathological processes translate into long-term functional deficits
(Thomsen, 1992, Sbordone et al., 1995, Giza, 2006). These and many more studies
highlight post-TBI BBB disruption and edema as bona fide therapeutic targets that
require further investigation (Aldrich et al., 1992, Adelson et al., 1997, Shlosberg et al.,
2010).
Caveolin-1 – the first member of the caveolin family to be discovered (Rothberg
et al., 1992) – is abundant within lipid rafts of brain endothelial cells (Cameron et al.,
1997, Virgintino et al., 2002). Together with caveolin-2, caveolin-1 forms the
fundamental structural framework of the caveolae (Sargiacomo et al., 1995, Predescu et
al., 2007), and is very crucial in mediating transcellular transport through the
endothelium into brain parenchyma via transcytosis (Schubert et al., 2002, Predescu et
al., 2007, Frank et al., 2009). The rate of transcytosis is, however, very low, and the
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process is tightly regulated across the BBB (Wolburg and Lippoldt, 2002). In addition to
its role in transcytosis, caveolin-1 has the capacity to scaffold several signaling proteins,
some of which are crucial to regulating BBB permeability (Razani et al., 2002,
Bernatchez et al., 2005). It performs this role through its caveolin scaffolding domain
(CSD) which recognizes specific caveolin binding motifs (CBM) on signaling proteins,
ligands and receptors (Razani et al., 2002). A classic example of this CSD-CBM binding
and functional interaction is found in the negative regulation of endothelial nitric oxide
synthase (eNOS) by caveolin-1, with the resultant reduction in production of nitric oxide
(NO) – a highly potent endogenous vasodilator and inducer of BBB permeability (GarciaCardena et al., 1997, Bucci et al., 2000). In order to investigate the mechanism and
therapeutic potential of endogenous CSD, a synthetic cell-permeable peptide which
mimics the scaffolding domain of caveolin – termed CSD peptide or cavtratin (CSD
peptide sequence fused with the cell-permeable antennapedia internalization sequence)
– has been developed and used extensively (Bucci et al., 2000, Bernatchez et al., 2005,
Argaw et al., 2012).
In the search for therapeutic agents to combat post-traumatic BBB disruption in
the juvenile setting, CSD mimetic peptide cavtratin is a potentially strong candidate
based on multiple literature evidence. Caveolin-1 knockout mice are known to display
microvascular hyperpermeability among other phenotypic defects (Razani et al., 2001,
Schubert et al., 2002). Using caveolin-1 knockout mice and silencing RNA against
caveolin-1 (siCav-1), it was shown that caveolin-1 protects against BBB
hyperpermeability after focal cerebral ischemia and reperfusion injury through a negative
regulation of nitric oxide (NO)-mediated matrix metalloproteinases (MMPs) activity in the
brain (Gu et al., 2011). Using cavtratin as a selective inhibitor of eNOS, improvement in
BBB dysfunction and associated reduction in neurologic deficits were observed in a
model of multiple sclerosis (MS) (Argaw et al., 2012). Moreover, cavtratin protects
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against chemokine-induced breakdown of brain endothelial junctional proteins including
occludin and ZO-1 in an in vitro model of brain microvascular endothelial cells (BMECs)
(Song et al., 2007).
We therefore propose the use of intraperitoneal injection of cavtratin following
juvenile TBI in P17 rats to investigate the drug’s potential therapeutic benefits. Our
objective was to determine whether cavtratin, which mimics some activities of
endogenous caveolin-1, is effective in improving BBB integrity and behavioral outcomes
post-jTBI. We showed that cavtratin protects against TBI-induced edema formation and
remarkably reduced the size of ensuing brain lesion. Our findings showed, however, that
there are no appreciable sensorimotor improvements associated with cavtratin
administration at least at the acute time points.

Materials and Methods
Subjects
This experiment generally follows previously described animal and experimental
protocols in chapters 2, 3 and 4 of this dissertation. Briefly, 12 ten-day old (P10) male
Sprague-Dawley rats were ordered from Harlan Laboratories (Harlan, Indianapolis, IN).
Upon delivery, they were housed with their dam on a 12-hour light-dark cycle at constant
temperature and humidity, in accordance with standard guidelines. The rats were
allowed to acclimatize for 7 days prior to induction of controlled cortical injury (CCI) – the
key experimental surgical procedure – carried out on the pups at P17. The pups were
fed with standard lab chow and water ad libitum. All groups of animals used in the study
(total n = 12, comprising of 2 different cohorts) had identical CCI surgical parameters,
and were randomly divided into saline-injected control and cavtratin-treated groups. The
first cohort is comprised of 8 randomly selected rat pups (4 cavtratin-treated and 4
saline-controls) which were all subjected to both MRI and neurological tests at 1dpi and
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3dpi before being euthanized. The second cohort comprising of 4 rat pups (2 cavtratintreated and 2 saline-controls) underwent only neurological testing but no MRI.
Euthanization and brain collection were carried out at 3dpi. All protocols and procedures
used in this study were approved by the Institutional Animal Care and Use Committee of
Loma Linda University and are in compliance with the U.S. Department of Health and
Human Services Guide.

Juvenile Traumatic Brain Injury Procedure
The procedure was carried out as we have previously described in literature
(Ajao et al., 2012) and as earlier described in this dissertation (see chapters 2, 3 and 4).
The same CCI surgery method and parameters were used. Briefly, each rat was
subjected to light anesthesia with isofluorane (Webster Veterinary Supply, Inc., Sterling,
MA) and placed in a mouse stereotaxic frame (David Kopf Instruments, USA). Following
a midline incision on the scalp, a 5-mm craniotomy was bored over the right frontoparietal cortex at the following coordinate: 3 mm anterior-posterior and 4 mm mediallateral relative to Bregma. The brain was then impacted by an electromagnetic impactor
(impactor tip diameter = 2.7mm) (Leica Microsystems Company, Richmond, IL) to a
depth of 1.5 mm from cortical surface, at a 200 angle to dura surface, at a velocity of
6m/s and with impact duration of 200ms. Morphological aberrations to the cortex such as
hemorrhage and herniation were recorded. The surgical site was then sutured close
followed by subcutaneous administration of an analgesic drug – Buprenorphine (0.01
mg/kg; dilution: 0.01 mg/ml).

Systemic Administration of Cavtratin
The cavtratin dose used in this study is 2.5mg/kg. This dose was effective for
selective eNOS inhibition in previously reported in vivo studies (Gratton et al., 2003,
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Hagendoorn et al., 2004, Bernatchez et al., 2005). The peptide was dissolved in 1%
DMSO and diluted 1000-fold in saline to a desired volume before intraperitoneal injection
(Gratton et al., 2003). The peptide was injected first at 3 hours post-TBI, and then at
1dpi, 2dpi and 3dpi (between 7am and 9am). Control animals received equivalent
volume of 0.9% saline. The rats were returned to their dam after treatment.

Magnetic Resonance Imaging (MRI): Acquisition and Analyses
Image Acquisition
In vivo MRI was performed at 1 and 3 dpi for a subset of the animals (n = 8).
Rats were prepared for in vivo MRI as previously described (Ajao et al., 2012). Briefly,
following induction of anesthesia (with 1-2% isofluorane), each rat was placed in a
temperature controlled cradle containing a volume radiofrequency (RF) coil and imaged
mostly on a 11.7T MRI (8.9 cm bore) at 1d and 3d. Some animals were scanned on a
larger bore (40 cm) 4.7T MRI (Bruker Biospin, Billerca, MA) at 3d. T2 weighted imaging
(T2WI) was acquired in vivo with the following parameters: repetition time/echo time
(TR/TE) = 2357.9/10.2 ms; 128 X 128 matrix; 1 mm slice thickness; 1 mm interleaved;
average of 4 acquisitions; number of slices = 20; and field of view (FOV) = 2.0 cm for a
total imaging time of 20 min on 11.7T MRI; and repetition time/echo time (TR/TE) =
3563.4/20 ms; 128 X 128 matrix; 1 mm slice thickness; 1 mm interleaved; average of 2
acquisitions; number of slices = 20; field of view (FOV) = 2.0 cm for a total imaging time
of 15 min on the 4.7T MRI. As previously reported, the use of two different field
strengths for in vivo MRI did not alter our relative measurements (Obenaus and Hayes,
2011, Ajao et al., 2012).

Lesion Volume Analysis
As previously described (Ajao et al., 2012), volumetric analyses of brain and
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lesion volumes were performed using the T2WI in Cheshire software (Hayden Image
Processing Group, Waltham, MA). Lesion volumes were defined as the cortical brain
regions containing abnormal hypo- and/or hyperintense signals compared to normalappearing cortical brain matter on the contralateral hemisphere (Fig. 1A). Total brain
volume encompasses both normal-appearing and abnormal brain tissues, while
herniated tissue, if present, was excluded. In some animals, subcortical and extracortical
abnormalities were present but were not included in the lesion. In order to correct for
individual brain size differences in the animals and age-related brain growth, the injury
volumes were normalized to the brain volumes. Hemispheric volumes were also
analyzed using the same inclusion and exclusion criteria.

T2 Analysis
For each T2WI scan, a region of Interest (ROI) was drawn on the slice with the
largest lesion area for each of the following areas: lesion, perilesion, striatum and
hippocampus on both ipsilateral and contralateral hemispheres. The lesion and
perilesion ROIs encompass both hypointense (which may indicate hemorrhage) and
hyperintense pixels [which may indicate edema (Gomori et al., 1985, Kato et al., 1986)]
within the brain parenchyma (Fig. 2A). ROIs for the hippocampus encompass all visible
hippocampal regions along the anterior-posterior axis. All the aforementioned ROIs were
later posted on co-registered T2 maps corresponding to each chosen brain slice for
acquisition of T2 values. T2 value was extracted for each of the ROIs using Cheshire
software.

Neurological Tests
Each behavioral test used in this report has been previously detailed (Ajao et al.,
2012). All tests on both saline-controls and cavtratin-treated animals were carried out
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within a 3-hour time-block between 8am and 11am, and the animals from both groups
were interleaved. The tests were carried out in the sequence in which they are listed
below.

Foot-fault
This was performed using an elevated wire mesh (2.5 cm X 30 cm rectangular
holes/grid spacing) raised 76 cm above the floor. Movements of each rat placed in the
middle of the mesh were video-recorded for 60 sec in two separate trials at 1 and 3dpi. A
foot-fault was counted when a rodent’s paw slipped completely through the wire mesh.
The number of foot-fault for both groups were compared.

Beam Balance
Juvenile animals were tested on a 0.65 cm wide plexiglass beam which is
commensurate to their size at 1 and 3dpi. Each animal walked unrestricted for 60 sec for
each of two trials 20 min apart, and the distance covered was recorded and compared
between saline-controls and cavtratin group.

Rotarod
A constant velocity rotarod paradigm consisting of 2 trials at a slow speed
(10rpm) and 2 trials at a faster speed (20rpm) is used at 1 and 3dpi. The rotarod
(Rotamex-5, Columbus Instruments, Columbus, OH) operates until each animals falls
off. Latency to fall was recorded as a measure of motor coordination and balance and
compared between the two groups.
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Statistical Analyses
All data are presented as mean ± SEM. Statistical analyses were done using
SPSS, and graphs were obtained using Sigmaplot (SPSS Inc.). All the data were
analyzed using student t-tests for normally distributed data with comparison between the
cavtratin and control groups for each of the time points. Repeated measures ANOVAs
(rm ANOVAs) were used for serial data collected on the same groups.

Results
Cavtratin Reduces Cortical Lesion Volume and Ameliorates
Some Morphological Alterations
To investigate the potential therapeutic effect of caveolin in brain injuries,
cavtratin was injected intraperitoneally at 3 hours following jTBI in P17 rats. Following
previously established protocol (Ajao et al., 2012), T2-weighted MRI (T2WI) was utilized
to outline and quantify cortical lesion volumes in the brains of both saline-controls and
cavtratin-treated animals (Fig. 1A, red outlines). The lesion encompassed both visible
hyperintense and hypointense pixels (Fig. 1A). We found that systemic administration of
cavtratin results in significant reductions of brain lesion volume in treated rats at 1d (47.9
+/- 13.7% reduction) and 3d (65.8 +/- 3.1% reduction; **p < 0.001, rm ANOVA) postinjury compared to controls (Fig. 1B). Another key difference between the two groups is
increase in lesion volume in TBI-saline group between 1d and 3d, not seen in the
cavtratin-treated group (Fig. 1B).
There are intragroup differences in hemispheric volumes (Fig. 1C, D). In the SAL
group, the ipsilateral hemisphere volumes are significantly increased compared to the
contralateral hemisphere at 1d (*p < 0.03, t-test), but these differences have been
neutralized by 3d (p < 0.23, t-test) (Fig. 1C). Similarly, in the treated group, the ipsilateral
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hemisphere volumes are significantly increased at 1d (*p < 0.04, t-test) but not at 3d (*p
< 0.06, t-test) (Fig. 1D).
Moreover, there were no prominent midline shifts observed in brains of both
saline and cavtratin-treated subjects. There were also no significant weight differences
between the two groups over the experimental period.
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Cavtratin Reduces Edema in the Lesion Region Following
Brain Injury
We used serially acquired T2WI on the animal subjects to profile T2 changes
over the acute time points (Fig. 2A). Shown in Fig. 2A are representative T2WI from
saline and cavtratin groups at 1d and 3d, with boxed regions enlarged in the lower
panes, and with some major brain structures and ROIs labeled (HPC = Hippocampus;
Cx = Cortex; Str = Striatum; CC = Corpus Callosum; L = Lesion; PL = Perilesion).
Interestingly, there was a statistically significant decrease in T2 values acquired from
lesion ROI (Fig. 2A, red outlines with red letter “L”) in the cavtratin-treated animals
compared to saline controls at both 1dpi and 3dpi (**p < 0.007, rm ANOVA) following
jTBI (Fig. 2A, B), suggesting that cavtratin treatment attenuates edema formation
acutely. Not surprisingly, there are no significant intragroup changes in T2 values at the
lesion ROI between 1d and 3d (Fig. 2B; p < 0.635, rm ANOVA). In the brains of saline
control rats, T2 values in the perilesion ROIs (Fig. 2A, yellow outlines with yellow letter
“PL”) at 1d and 3d were significantly lower compared to corresponding T2 values in
lesion ROIs (Fig. 2A, red outlines with red letter “L”) (** p˂0.001, Student’s t-test). This
distinction is, however, not seen in brains from cavtratin-treated rats which had similar
T2 values from both lesion and perilesion ROIs over the acute time points (Fig. 2B, C)
(p˂0.748, Student’s t-test). Unlike T2 values in lesion ROI, there are no intergroup
differences in T2 values in the perilesion ROI at both 1d and 3d (Fig. 2C; p˂0.703, rm
ANOVA). Other regions of the brain besides lesion and perilesion (e.g. contralateral Cx,
HPC, and Str, and ipsilateral HPC and Str) show no significant changes in T2 values
between the two groups at both time points (data not shown).
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Cavtratin Does Not Improve Sensorimotor Functions at Acute
Time Point
Because the injury is centered on the somatosensory cortex, it was important to
test for the functional impact of the treatment during the peak of edema. To this end, a
previously validated set of neurological and behavioral tests were carried out to
investigate the impairment and/or recovery of sensorimotor functions which include footfault, beam balance and rotarod tests at 1d and 3d post-treatment (Fig. 3) (Ajao et al.,
2012). There were no significant differences in the number of foot-faults between the two
groups at 1dpi and 3dpi (Fig. 3A; p<0.35, rm ANOVA). Likewise, beam balance test
showed no differences between the two groups at both time points (Fig. 3B; p˂0.33, rm
ANOVA). Consistent with the two previous tests above, rotarod tests showed no
intergroup differences either in the 10RPM (p˂0.79, rm ANOVA) or 20RPM (p˂0.48, rm
ANOVA) constant speed paradigm at 1d and 3d (Fig. 3D). Overall, these neurological
test results suffer from low statistical power. With increased group sizes, sensitivity may
be enhanced for detecting fine motor improvements in between the groups for some of
the tests.

Discussion
Multiple reports in scientific literature have highlighted some beneficial effects of
the synthetic caveolin-1 scaffolding domain (CSD) peptide, cavtratin, in various
experimental models, but not yet in juvenile TBI models. These include studies that
utilized in vitro (Song et al., 2007, Schmitz et al., 2011) and in vivo (Bucci et al., 2000,
Gratton et al., 2003, Jasmin et al., 2006, Desjardins et al., 2008) models of disease and
system. Caveolin-1 plays a role in regulating endothelial hyperpermeability as
demonstrated by the microvascular hyperpermeability of caveolin-1 knockout (-/-) mice
(Razani et al., 2001, Schubert et al., 2002). In addition, Song and colleagues (2007)
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showed in vitro that cavtratin is effective in inhibiting microvascular hyperpermeability in
chemokine-stimulated brain microvascular endothelial cells (BMECs) which models BBB
in vitro. They also found that treatment of BMECs with silencing RNA against caveolin-1
not only reduced caveolin-1 expression, but also reduced expression of key tight junction
proteins (Song et al., 2007). More studies are providing further evidence of strong link
between endothelial caveolins and TJ proteins. Claudins and occludins are found in
isolated caveolae, putatively interacting with caveolins (Nusrat et al., 2000, McCaffrey et
al., 2007, Song et al., 2007, Stamatovic et al., 2009). The level of oligomeric claudin-5
and occludin seen in normal brain endothelial caveolae is reduced during pathological
conditions such as hypoxia-reoxygenation (McCaffrey et al., 2009). Such reduction
engenders TJ and BBB disruption (McCaffrey et al., 2008). Gu and colleagues (2011)
recently showed that caveolin-1 protects the BBB against hyperpermeability following
focal cerebral ischemia and reperfusion injury through its negative regulation of nitric
oxide (NO)-mediated matrix metalloproteinases (MMPs) activity in the brain. These
studies above and many more (Miyawaki-Shimizu et al., 2006, Siddiqui et al., 2011)
suggest that caveolin-1 is functionally associated with brain endothelial junctional
integrity.
Interestingly, recent studies have suggested that caveolin-1 plays crucial roles in
regulating efflux transporters in the BBB (Barakat et al., 2007, McCaffrey et al., 2012).
McCaffrey and colleagues (2012), for instance, showed that in λ-carrageenan-induced
paw edema model (a peripheral inflammatory model in rats), P-glycoprotein (P-gp) – a
key efflux transporter at the BBB – was rapidly trafficked to the membrane lipid raft
domain, where it colocalized with phosphorylated caveolin-1. This colocalization
promoted the redistribution of P-gp at the microvascular endothelial luminal membrane
with increased ATPase activity, which suggests functionally active P-gp. Using a rat
brain endothelial cell line, Barakat et al (2007) previously suggested that phosphorylated
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caveolin-1 may impact the transport property of P-gp. Hence, caveolin-1 is implicated in
the maintenance of both molecular TJ proteins as well as transport barriers at the BBB.
A crucial secondary pathophysiological phenomenon commonly observed in
juvenile brain trauma that needs to be addressed therapeutically is BBB disruption –
which has been shown to last for months and in some cases years after primary injury
(Seiffert et al., 2004, Tomkins et al., 2011) – with resultant edema formation (Bolton and
Perry, 1998, Schutzman and Greenes, 2001, Stock, 2011). Given literature evidence
stated above linking caveolin-1 to regulation of endothelial permeability, we set out to
study the effect of systemic administration of caveolin-1 mimetic peptide, cavtratin, on
brain lesion, edema formation and, by extension, on neurological function at acute time
points following juvenile TBI in P17 rats.

Reduction of Lesion Volume and Amelioration of
Morphological Alterations by Cavtratin
We found that cavtratin treatment results in significantly lower lesion volumes in
the brains of treated rats compared to saline controls at both 1dpi and 3dpi (Figs. 1A, B).
Analyzed along hemispheric lines (Fig. 1C - F), the ipsilateral hemispheres of both
control (Fig. 1E) and cavtratin brains (Fig. 1F) had higher volumes compared to their
contralateral hemispheres, suggesting a uniformity in injury profile for both groups. The
lowered lesion volume in cavtratin group (Figs. 1A, B) however suggests that cavtratin is
functionally limiting the extent of the injury. This set of results is important for potential
therapeutic application of cavtratin as a caveolin-mimicking pharmacological agent
(Desjardins et al., 2008) in jTBI.
There are a few studies in other models of brain injuries that support these
findings. In an ischemic stroke (MCAO) study in mice, Jasmin and colleagues (2007)
reported that caveolin-1 knockouts (KOs) have a generally worse outcome than the wild-
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type (WT), with increased cerebral volume of infarction coupled with impaired
angiogenesis and increased apoptotic cell death. Acute and sometimes sustained
increase in caveolin-1 expression has been reported following various forms of CNS
injuries (Shin et al., 2005, Nag et al., 2007, Shin, 2007, Nag et al., 2009), but opinions
are divided on whether this is beneficial or detrimental to the structural and functional
recovery of the BBB and brain tissues (Nag et al., 2007, Song et al., 2007). Based on
findings in this study, endogenous increase in caveolin-1 could be a form of innate
protective mechanism that the brain deploys during active evolution of injury to minimize
damage. In further support of this hypothesis, down-regulation of caveolin-1 expression
in ischemic-reperfusion stroke model in rodents is concomitant with increased infarction
volume, neurological deficit and BBB disruption (Ding-Zhou et al., 2002, Shen et al.,
2006, Gu et al., 2011).

Reduction of Acute Edema Formation at Lesioned Brain
Region by Cavtratin
Our findings on reduced edema formation (indexed by reduced T2 values) in the
lesion ROIs of brains of cavtratin-treated animals (Fig. 2A, B) constitute a strong support
for the theory that this CSD mimetic peptide helps in maintaining and protecting the
BBB. This effect however was not found in the outlying perilesion ROI (Fig. 2C),
suggesting that the drug’s therapeutic effect is focused more on clearly lesioned brain
regions. In a study that utilized an in vivo model of multiple sclerosis (MS) in mice,
researchers confirmed that systemic administration of cavtratin reduced eNOSassociated BBB disruption and its resultant edema (Argaw et al., 2012). Argaw and
colleagues (2012) further showed that cavtratin increases the expression of TJ proteins
claudin-5 and occludin both in vitro in human brain microvascular endothelial cells and in
vivo in VEGF-A null mice model of MS. These findings support a tight junction protein-
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maintaining role for caveolin-1 and provide solid support for its role in preventing BBB
permeability and edema formation.

Absence of Improvement in Neurological Function
There was a general lack of functional improvements at acute time points (1d
and 3d) following cavtratin treatment (Fig. 3), which could be explained in two possible
ways. A possible drawback is the shortness of testing period (within 3 days following
jTBI) which coincides with period of maximum edema formation (Fukuda et al., 2012).
We have previously shown that in this brain injury model, there were no clear increases
in the number of foot-faults in jTBI animals compared to shams until 7d post-injury (Ajao
et al., 2012). Hence, testing both sensorimotor and cognitive functions at later time
points (7d, 30d and 60d) could provide an extended opportunity for picking up subtle
functional differences that might have been masked by the evolution of the injury at
earlier time points. Later time point testing also affords cavtratin the opportunity to act for
a longer time. Given the effects of cavtratin on lesion volume and edema, it is plausible
that there would be beneficial functional effects that could be picked out by the right tests
at the right time points. Secondly, drugs may confer other functional benefits that may
not be reflected in neurological and cognitive tests. For instance, electrophysiological
recordings of neuronal firing (such as the measurement of compound action potential –
CAP) may be helpful in picking out more subtle functional changes like we demonstrated
in a previous report using this jTBI model (Ajao et al., 2012). Given the effects of
cavtratin stated above, there is a need for investigating the mechanism(s) of action of
this drug.
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A Potential Mechanism of Action for Cavtratin – Blood-Brain
Barrier Protection
One of the mechanistic possibilities for cavtratin action is through BBB protection.
Caveolins are highly enriched in brain microvasculature, although they are found, albeit
in smaller amounts, in other cells in the brain such as neurons and vascular astrocytes
(Cameron et al., 1997, Virgintino et al., 2002, Head et al., 2010). Caveolins act as
scaffolding proteins which bind and modulate the activities of a wide variety of signaling
molecules that are segregated within the caveolae compartments not only in brain
endothelial cells but also in the periphery (Palade, 1953, Sargiacomo et al., 1995,
Cameron et al., 1997, Razani et al., 2002, Lajoie et al., 2009, Lajoie and Nabi, 2010).
Tight junction proteins have been shown to actively bind to and be regulated by
caveolins (McCaffrey et al., 2007, Stamatovic et al., 2009). Hence, a logical mechanism
for the neuroprotective effect of cavtratin seen through reduced lesion volume is the
protection against uncontrolled and prolonged BBB breakdown through decreased tight
junction protein expression (Song et al., 2007, Gu et al., 2011). This BBB-focused
mechanism is evidenced by reduction in edema formation (Fig. 2A, B) – which often
results from disrupted BBB – seen in cavtratin-treated subjects and discussed in the next
section below. Furthermore, caveolin-1 is known to negatively regulate eNOS which
produces NO which in turn activates tight junction proteins-degrading MMPs in the brain
(Gu et al., 2011).
There is also a strong positive correlation reported in TBI literature between
extent or size of post-TBI brain lesion and BBB disruption (Tomkins et al., 2011).
Tomkins and colleagues (2011) noted in their study that the set of patients with larger
volume of BBB disruption (measured with T1-weighted MRI and the contrast agent
gadolinium/Gd-DTPA) also had significantly larger volume of lesioned and dysfunctional
cortex (measured with standardized low-resolution brain electromagnetic tomography
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[sLORETA]). Subtle BBB disruption with concomitant functional cortical dysfunction was
found in up to four TBI patients in the study (Tomkins et al., 2011). These reports
support the theory that cavtratin may be acting mechanistically through protection of TJ
proteins and BBB. Increased endogenous caveolin post-TBI may also constitute a
compensatory mechanism aimed at limiting BBB damage. These proposed mechanisms
need to be investigated by further studies.
Meanwhile, increased immunoreactivity of claudin-5 and decreased
immunoreactivity of the efflux transporter p-gp at the BBB have been reported at 2
months following the juvenile TBI model used in this study (Pop et al., 2012). Since
caveolin-1 have been implicated in the regulation of both claudin-5 (Liu et al., 2012) and
p-gp (Barakat et al., 2007, McCaffrey et al., 2012), it is possible that cavtratin may
modulate beneficial changes in these BBB components at long-term following juvenile
TBI. This hypothesis needs to be investigated in the future.

Conclusion
We have shown in this study that systemic administration of cavtratin at 3 hours
after juvenile TBI is effective in reducing lesion volume and edema formation. We further
proposed that these protective effects might be modulated by cavtratin’s beneficial
activities on the tight junction proteins that make up the BBB. More elaborate studies are
highly encouraged to investigate mechanistic details of cavtratin with respect to BBB
maintenance, as well as test for functional improvements in cavtratin-treated animals.
Such studies may shed further light on the caveolins as potential therapeutic targets in
combating BBB disruption following juvenile TBI.
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PROLOGUE TO CHAPTER 5
ACUTE ADMINISTRATION OF DJNKI-1 FOLLOWING JUVENILE
TBI IN RATS IMPROVES NEUROIMAGING, HISTOLOGICAL AND
FUNCTIONAL OUTCOMES
Having dealt with the caveolins and cavtratin in chapters 3 and 4 respectively,
the second set of molecules that are of interest for early intervention in juvenile TBI
(jTBI) are c-Jun N-terminal kinases (JNKs). DJNKI-1 is used as a competitive inhibitor of
JNK pathway. See Fig. 1 below for a diagrammatic representation of the proposed
intervention strategy for juvenile TBI using DJNKI-1.
The aim of this chapter is to examine the effect of acute DJNKI-1 treatment on
BBB disruption, edema formation, and neurological and behavioral outcomes following
juvenile TBI. The underlying hypothesis is that acute inhibition of the JNK pathway
through the administration of DJNKI-1 will limit the extent of BBB disruption and
vasogenic edema, with concomitant improvements in histological and functional
outcomes both short-term and long-term.
Results in this section show that intraperitoneal administration of DJNKI-1 at 3
hours post-jTBI produces a reduction of brain lesion volume in DJNKI-1 treated rats at
both acute and chronic time points. Furthermore, there is concomitant reduction in
edema formation at acute time point in lesioned cortical region with DJNKI-1 treatment.
Immunohistochemical staining showed lower Immunoglobulin G (IgG) extravasation in
the brains of treated subjects. There is also a significant recovery of neurological
functions in the DJNKI-1 treated rats compared with controls as examined by a battery of
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tests which include: foot-fault, rotarod, zero maze, and Morris Water Maze (MWM) tests.
These results suggest beneficial effects of early DJNKI-1 intervention in jTBI.
The chapter follows the blueprint of a scientific manuscript with abstract,
introduction, methods, results and discussion sections. It is also replete with detailed
figures and legends, and a table.
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ACUTE ADMINISTRATION OF DJNKI-1 FOLLOWING JUVENILE
TBI IN RATS IMPROVES NEUROIMAGING, HISTOLOGICAL AND
FUNCTIONAL OUTCOMES
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Abstract
The juvenile brain is known to be susceptible to Blood-Brain Barrier (BBB)
damaging secondary processes which occur for days to weeks following brain trauma. In
this study, we investigate the therapeutic potential of competitively inhibiting the
activation of c-Jun N-terminal kinases (JNKs) acutely in the brain following an
experimental model of juvenile TBI (jTBI) in P17 rats. We show that intraperitoneal
administration of DJNKI-1 – a competitive inhibitor of JNK pathway – at 3 hours postjTBI results in reduction of brain lesion volume in DJNKI-1 treated rats at 1d (by 47.3%),
3d (by 37.2%), 7d (by 51.7%), 30d (by 38.1%), and 60d (by 45.8%) post-injury.
Furthermore, edema in the cortical lesion – measured with T2-weighted magnetic
resonance imaging (MRI) – is reduced significantly at acute time points (e.g. 3d by
26.4% and 7d by 26.9%) with DJNKI-1 treatment. Immunohistochemical staining for IgG
showed lower IgG extravasation in DJNKI-1 treated subjects. In addition, there is
significant recovery of neurological functions in the DJNKI-1 treated rats compared with
controls as examined by foot-fault (**p<0.0001, rm ANOVA at 1d – 60d), rotarod (at 3d,
*p<0.02 and at 7d, **p<0.002, t-test), zero maze (at 60d, *p<0.04, t-test), and Morris
Water Maze tests (e.g. 30d West spatial, **p<0.008, rm ANOVA). We conclude that
acute inhibition of JNK pathway following jTBI protects against prolonged BBB disruption
and edema formation, and aids in the recovery of some sensorimotor and neurocognitive
functions at both acute and later time points.
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Introduction
The mechanical impact that initiates traumatic brain injury (TBI) is known to
induce secondary pathophysiological and biochemical processes, which progressively
determine the consequent outcomes of the injury (Adelson and Kochanek, 1998, Park et
al., 2008). Among these secondary processes are: blood-brain barrier disruption, edema
formation, impaired metabolism, alteration in cerebral blood flow (CBF) and
hemodynamic regulation, hypotension, hypoxia, free radical formation,
neuroinflammation, and excitotoxicity (Werner and Engelhard, 2007, Shlosberg et al.,
2010). TBI in the juvenile population (jTBI) is particularly associated with greater risks of
cerebral hemodynamic dysfunction (Armstead, 1999, 2005, Freeman et al., 2008,
Udomphorn et al., 2008, Chaiwat et al., 2009, Armstead et al., 2011), hypoxic-ischemic
injury (Armstead, 2005), and diffuse cerebral edema (Suh et al., 2001, Giza et al., 2007),
with resultant long-term functional deficits (Giza, 2006). The susceptibility of juvenile
brain to tight junction (TJ) protein breakdown, edema, and dysfunction of cerebral
hemodynamics are bona fide therapeutic targets that require further investigation
(Aldrich et al., 1992, Adelson and Kochanek, 1998, Huh and Raghupathi, 2009, Fukuda
et al., 2012).
The c-Jun N-terminal kinases (JNKs) constitute a subfamily of mitogen-activated
protein kinases (MAPKs) which respond to various forms of internal and external stress
stimuli such as: UV light, inflammatory cytokines, reactive oxygen species (ROS), growth
factors, as well as physical and biomechanical perturbations (Hibi et al., 1993, Derijard
et al., 1994). All 3 isoforms of JNKs are highly conserved across various species ranging
from yeast to mammals (Goberdhan and Wilson, 1998, Kirkham et al., 2008), and are
found in various cell types in the brain, including neurons (Lannuzel et al., 1997,
Herdegen et al., 1998), endothelial cells (Etienne et al., 1998, Waetzig et al., 2006), and
astrocytes (Migheli et al., 1997, Xie et al., 2004). Basal JNK activity level in the brain is
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15 to 30-fold higher than in other tissues under physiological conditions (Xu et al., 1997,
Coffey et al., 2000). JNKs in the brain are activated even further following external
stimuli and pathological events (Borsello and Bonny, 2004). Most studies on JNK
pathway in the brain have focused predominantly on neuronal activation triggered by
excitotoxic events in adult rodents (Borsello et al., 2003, Cui et al., 2007, Haeusgen et
al., 2009) or human (Ortolano et al., 2009). There is however increasing evidence that
JNK is also activated in glial cells (Xie et al., 2004, Cui et al., 2007) and brain endothelial
cells (Lennmyr et al., 2002, Lo et al., 2005, Kacimi et al., 2011, Tu et al., 2011), and that
such activation in non-neuronal cells negatively impacts neuronal function and cell death
(Xie et al., 2004, Kaminska et al., 2009).
Hyperactivation of JNKs is a phenomenon that could mediate the secondary
events of TJ protein breakdown and the formation of edema, which can lead to
functional and behavioral consequences. JNK hyperactivation has been documented
both clinically (Ortolano et al., 2009) and experimentally (Otani et al., 2002a, Otani et al.,
2002b, Raghupathi et al., 2003, Tran et al., 2012) post-TBI, in parallel with secondary
injuries. It has also been shown in models of stroke (Borsello et al., 2003, MichelMonigadon et al., 2010, Nijboer et al., 2010), Parkinson’s disease (Peng and Andersen,
2003, Kuan and Burke, 2005), and Alzheimer’s disease (Okazawa and Estus, 2002, Wei
et al., 2002).
Hyperactivation of JNKs has been shown to result in downregulation of TJ
proteins in both in vitro brain endothelial cell cultures (Tai et al., 2010) and in vivo in the
periphery (Kojima et al., 2010, Samak et al., 2010), consequently affecting the BBB
integrity (Tai et al., 2010, Tu et al., 2011). Interestingly, JNK inhibition with SP600125
was shown to reverse decrease in TJ proteins such as claudin-5 in the periphery
(Carrozzino et al., 2009). In an experimental model of pancreatitis, JNK inhibition with
CEP-1347 was found to reduce edema formation in rat pancreas (Wagner et al., 2000).
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Inhibition of JNK with SP600125 was also found to reduce brain swelling in experimental
subarachnoid hemorrhage (SAH) model (Yatsushige et al., 2007). SAH induces JNK
activation in rat cerebral arteries by 24 hours which is concomitant with increased BBB
permeability and brain edema (Kusaka et al., 2004). Furthermore, JNK hyperactivation
was found to play a role in experimental jTBI-induced cerebrovascular dysregulation in
piglets (Armstead et al., 2011). Successful reversal of pial arterial vasoconstriction that
occurs following TBI induction was achieved with the use of JNK inhibitors, SP600125
and DJNKI-1 (Armstead et al., 2011). JNK antagonist SP600125 has also been used in
combination with glucagon to achieve full reversal of cerebral vasoconstriction in jTBI
model in piglets (Armstead et al., 2012). These studies provide evidence that the
hyperactivation of JNK pathway may be involved in jTBI-induced disruption of tight
junction and cerebrovascular regulation.
Investigators have up to date experimented with three main types of JNK
inhibitors with varying efficacies (Cui et al., 2007). The first group comprises of ATPcompetitive inhibitors of JNK, such as SP600125 and CEP-1347, which are small
organic compounds that occupy the ATP-binding site of the protein kinase (Herdegen et
al., 1998, Haeusgen et al., 2009). However, the disadvantage of this set of inhibitors is
that their efficacy is reduced by the high endogenous levels of ATP (Cui et al., 2007).
SP600125 has been used in some experimental TBI (Hong et al., 2012), stroke (Gao et
al., 2005, Guan et al., 2006) and Parkinson’s disease (Kuan and Burke, 2005) studies.
The second and third groups of inhibitors target the substrate-binding sites and the
allosteric regulatory sites of JNK respectively with non-phosphorylatable analogues (Cui
et al., 2007, Comess et al., 2011). Peptide inhibitors are examples of these second and
third groups, and these provide a more specific inhibition mechanism than ATPcompetitive inhibitors (Haeusgen et al., 2009). Peptide inhibitors which competitively
bind to JNK-interacting peptide-1 (JIP-1) – a scaffolding protein that act upstream of the
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3 isoforms of JNK – have been used extensively in experimental brain research
(Bogoyevitch and Arthur, 2008). JIP-1 scaffolding protein structurally organizes the MAP
kinase signaling module by linking MLK-3 and MKK-4/7 (upstream kinases that
phosphorylate JNK) with JNK and thereby providing a spatial and temporal platform for
regulating the JNK pathway (Borsello and Bonny, 2004, Bogoyevitch and Arthur, 2008)
(See Fig. 2). L-DJNK-1 and D-JNK-1 are examples of these peptides (Bogoyevitch and
Arthur, 2008).
D-JNKI-1 is a synthetic, protease-resistant and cell-penetrating peptide made by
linking HIV-TAT transporter peptide sequence to the 20-amino acid JNK-binding motif of
JIP-1 (Borsello et al., 2003). The D-retro-inverso synthesis (i.e. made with D-amino
acids) of D-JNKI-1 gives it strong resistance against proteolytic degradation and
increases its stability in the body (Borsello et al., 2003, Borsello and Bonny, 2004). DJNKI-1 functions through competitive inhibition of all JNK isoforms (Fig. 2). D-JNKI-1
selectively blocks access of JNK to c-Jun and other downstream substrates such as
JunB, JunD, and c-myc by competing for the JNK-binding site of JIP-1(Borsello et al.,
2003, Borsello and Forloni, 2007) (See Fig. 2 below). The therapeutic effectiveness of
D-JNKI-1 is pegged on its potential to modulate upstream and downstream arms of the
secondary injury cascade following jTBI, including excitotoxicity, hypoxia-ischemia,
edema, neuroinflammation and apoptosis (Yang et al., 1997, Kuan et al., 2003, Tu et al.,
2011).
Meanwhile, long-term functional deficits of sensorimotor, cognitive, and
neuropsychiatric nature which could last for years have been reported in patients with
incidence of jTBI (Chadwick et al., 1981, Yeates et al., 2002, Jonsson et al., 2013). Most
experimental studies of jTBI in animals have, however, focused on acute time-points
following trauma (Saatman et al., 2008), making them inapplicable and nongeneralizable
to clinically observed long-term sequelae of TBI (Doppenberg et al., 2004, Saatman et
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al., 2008). This justifies the establishment of models for long-term profiling of functional
and behavioral parameters following experimental jTBI as have been reported (Giza et
al., 2005, Ajao et al., 2012). Such models that assess both sensorimotor (e.g. through
the use of foot-fault, beam balance, and rotarod tests) and cognitive (e.g. through the
use of Morris Water Maze [MWM] test) parameters can be used to determine the longterm efficacy of potential therapeutic agents such as D-JNKI-1. D-JNKI-1 has been
shown to ameliorate behavioral deficits in experimental models of stroke (Esneault et al.,
2008), neuroinflammation (Palin et al., 2008), and spinal cord injury (Repici et al., 2012)
in adult rodents. D-JNKI-1 was also successfully used to arrest the progression of
hearing loss in a model of cochlear implantation trauma (Eshraghi et al., 2006).
To date, there have been no reports on the potential link between juvenile TBIinduced JNK activation and post-injury BBB disruption and edema. Neither have there
been studies on the therapeutic potential of DJNKI-1 in this model. The working
hypothesis for this study is that acute competitive inhibition of JNK in the brain will
mediate rapid recovery at BBB level, and lead to reduced edema formation and lesion
volume, reflected in improved motor and behavioral outcomes at both acute and delayed
time points following jTBI. We report that acute treatment with DJNKI-1 following jTBI in
P17 rats results in remarkable reduction in edema, lesion volume and neurological
deficit, alongside with reduced BBB disruption.
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Materials and Methods
Subjects
Juvenile (P10) male Sprague-Dawley rats were ordered from Harlan Laboratories
(Harlan, Indianapolis, IN). They were housed with their dams upon delivery on a 12-hour
light-dark cycle at constant temperature and humidity, in accordance with standard
guidelines, and allowed to acclimatize for 7 days. Key surgical procedures were carried
out on the pups at P17. Subsequently, the pups were weaned at P24, housed 2 rats per
cage, and fed with standard lab chow and water ad libitum. All groups of animals used in
the study (total n = 28, comprising of 3 different cohorts) had identical CCI surgical
parameters, and were randomly divided into saline-injected control and DJNKI-1 treated
groups. The first cohort of subjects (n = 5 SAL, n = 5 DJNKI-1) was studied acutely with
MRI and behavioral tests (i.e. at 1 and 3dpi), and then euthanized, followed by brain
collection at 3dpi. The second cohort (n = 5 SAL, n = 5 DJNKI-1) was studied
longitudinally for MRI (at 1, 3, 7, 30 and 60 dpi) and all behavioral tests (at 1, 3, 7, 30
and 60 dpi) over a 2-month period. The third cohort (n = 4 SAL, n = 4 DJNKI-1) was
identical to the second cohort with the exception of MRI scans. Euthanization and brain
collection for the second and third cohorts occurred at 60dpi, and the brains were
prepared for immuhistochemistry. All protocols and procedures used in this study were
approved by the Institutional Animal Care and Use Committee of Loma Linda University
and are in compliance with the U.S. Department of Health and Human Services Guide.

Juvenile Traumatic Brain Injury Procedure
TBI was induced in juvenile rats at P17 through a controlled cortical impact (CCI)
as previously described (Ajao et al., 2012). Briefly, the rats were anesthetized with
isofluorane (Webster Veterinary Supply, Inc., Sterling, MA) and afterwards placed into a
mouse stereotaxic frame (David Kopf Instruments, USA). A midline scalp incision
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followed by a 5 mm craniotomy was performed unilaterally over the right fronto-parietal
cortex (Bregma: 3 mm anterior-posterior and 4 mm medial-lateral). A controlled impact
on the brain was delivered using a 3 mm rounded-tip metal impactor fixed to an
electromechanical actuator and centered over the exposed dura at a 20° angle to be
parallel to the cortical surface (Leica Microsystems Company, Richmond, IL). The impact
was delivered at a 1.5 mm depth from the cortical surface, with impact duration of 200
ms, and at a velocity of 6 m/s. Aberrations to the cortical tissue, such as bleeding and
protrusion of cortical tissue through the craniotomy, were duly recorded. Thereafter, the
surgical site was sutured closed. Subject’s body temperature was maintained throughout
the surgery at 37°C. For pain relief, Buprenorphine (0.01 mg/kg; dilution: 0.01 mg/ml)
was injected subcutaneously into the subjects before they were returned to their dams.
The time between the end of surgery and when subjects wake up were also recorded.
There was close daily monitoring of the subjects for at least 7 days post injury, followed
by more spaced out examinations afterwards.

DJNKI-1 Treatment
D-JNKI-1 (11mg/kg) or normal saline was intraperitoneally administered to each
subject at 3 hours post-injury. This dosage was based on previously reported efficacy of
DJNKI-1 in middle cerebral artery occlusion (MCAO) model in male P14 Wistar rats
(Repici et al., 2007) where the drug was injected intraperitoneally. The same dosage has
also been used effectively in spinal cord injury model in adult mice (Repici et al., 2012).
The rats were returned to their dams right after injection.
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Magnetic Resonance Imaging (MRI): Acquisition and Analyses
Image Acquisition
In vivo MRI was performed at 1 and 3 dpi for all animals, while a subset of the
animals was also scanned at 7 and 30 dpi, followed by high resolution ex vivo imaging at
60 dpi. Rats were prepared for in vivo MRI as previously described (Ajao et al., 2012).
Briefly, following induction of anesthesia (with 1-2% isofluorane), each rat was placed in
a temperature controlled cradle containing a volume radio frequency (RF) coil and
imaged on a 11.7T MRI (8.9 cm bore) at 1d and 3d, and on a larger bore (40 cm) 4.7T
MRI (Bruker Biospin, Billerca, MA) at 7d and 30d. Ex vivo imaging at 60d was carried out
in the 11.7T magnet.
T2 weighted imaging (T2WI) was acquired in vivo with the following parameters:
repetition time/echo time (TR/TE) = 2357.9/10.2 ms; 128 X 128 matrix; 1 mm slice
thickness; 1 mm interleaved; average of 4 acquisitions; number of slices = 20; and field
of view (FOV) = 2.0 cm for a total imaging time of 20 min on 11.7T MRI; and repetition
time/echo time (TR/TE) = 3563.4/20 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm
interleaved; average of 2 acquisitions; number of slices = 25; field of view (FOV) = 3.0
cm for a total imaging time of 30 min on the 4.7T MRI. Diffusion-weighted imaging (DWI)
was acquired using a repetition time/echo time (TR/TE) = 1096.5/50 ms; 128 X 128
matrix; 1 mm slice thickness; 1 mm interleaved; average of 2 acquisitions; number of
slices = 20; field of view (FOV) = 2.0 cm; and b values = 116.96 s/mm2, 1044.422 s/mm2
for a total imaging time of 17 min on 11.7T MRI; and a repetition time/echo time (TR/TE)
= 3000/50 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm interleaved; average of 2
acquisitions; number of slices = 25; field of view (FOV) = 3.0 cm; and b values = 43.05
s/mm2, 441.991 s/mm2 for a total imaging time of 51 min on 4.7T MRI.
At 60 dpi, perfusion-fixed brains were prepared as previously described (Ajao et
al., 2012) before undergoing ex vivo scanning using the 11.7T magnet. T2WI were
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acquired using: a repetition time/echo time (TR/TE) = 1769.9/10.2 ms; 256 X 256 matrix;
1 mm slice thickness; 1 mm interleaved; average of 4 acquisitions; number of slices =
15; and a field of view (FOV) = 2.0 cm for a total imaging time of 30 min on 11.7T MRI.
DWI was carried on the same scanner and with the same parameters as the T2WI, with
the exception of TR/TE (552.5/15.1 ms), acquisition time (70 min), and b values (116.96
s/mm2; 1044.422 s/mm2). Apparent Diffusion Coefficient (ADC) was calculated from six
gradient vectors. As previously reported, the use of two different field strengths and the
use of both in vivo and ex vivo MRI did not alter our relative measurements (Obenaus et
al., 2011, Obenaus and Hayes, 2011, Ajao et al., 2012). Acquisition of both T2WI and
DWI was done in sequence without any apparent change in the positioning of the
animals.

Lesion Volume Analysis
As previously described (Ajao et al., 2012), volumetric analyses of brain and
lesion volumes were performed using the T2WI in either Cheshire (Hayden Image
Processing Group, Waltham, MA) or Amira (Mercury Computer Systems, Visage
Imaging, Inc., San Diego, CA, USA) software. Lesion volumes were defined as the
cortical brain regions containing abnormal hypo- and/or hyperintense signals compared
to normal-appearing cortical brain matter on the contralateral hemisphere (Fig. 1C).
Total brain volume encompassed both normal-appearing and abnormal brain tissues,
while herniated tissue, if present, was excluded. In some animals, subcortical and
extracortical abnormalities were present but were not included in the lesion. These
abnormalities were recorded as injury-related morphological alterations (Table 1), and
included: ventricular hypertrophy, hemorrhage, shrunken hippocampus, disrupted corpus
callosum (and other affected white mater structures), and cortical herniation. In order to
correct for individual brain size differences among the animals and age-related brain
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growth, the injury volumes were normalized to the brain volumes. Hemispheric volumes
were also analyzed using the same inclusion and exclusion criteria.

T2 Analysis
For each T2WI scan, a region of Interest (ROI) was drawn on the slice with the
largest lesion area for each of the following areas: lesion, perilesion, striatum and
hippocampus on both ipsilateral and contralateral hemispheres. The lesion and
perilesion ROIs encompass both hypointense (which may indicate hemorrhage) and
hyperintense pixels (which may indicate edema) within the brain parenchyma (Fig. 3A,
D). A rectangular box measuring 6-by-8 pixels constitutes the ROI for both ipsilateral and
contralateral striatum. ROIs for the hippocampus encompass all visible hippocampal
regions along the anterior-posterior axis. All these aforementioned ROIs were
subsequently posted on co-registered T2 maps corresponding to each chosen brain
slice for acquisition of T2 values. T2 values were compared between DJNKI-1 group and
saline-control group.

Apparent Diffusion Coefficient (ADC) Analysis
The ROIs drawn for T2WI scans were copied to co-registered diffusion-weighted
MRI-derived ADC maps on the slice with the largest lesion for each subject. Extraction
of ADC values from these ROIs on the maps followed. There were no overt differences
in ADC values resulting from the use of in vivo versus ex vivo MRIs in all ROIs.

Area Measurements of the Corpus Callosum
Thickness
A ROI was drawn around the portion of visible corpus callosum in each
hemisphere from a selected T2-weighted MR image at bregma level +1mm, anterior to
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the lesion in each animal. The chosen coronal slice often corresponds to the slice that is
directly anterior to the visible lesion. Equivalent anatomical landmarks were used for
selection of the slice chosen for analysis for all animals. The corpus callosal areas for
each image were extracted with Cheshire software.

Neurological and Behavioral Tests
Detailed procedure for each behavioral test used in this study has been
previously described (Ajao et al., 2012). All tests on both saline and DJNKI-treated
animals were carried out within a 3-hour time-block between 8am and 11am, and the
animals from both groups were interleaved. The tests were carried out in the sequence
in which they are listed below.

Foot-fault
This was performed using an elevated wire mesh (2.5 cm X 30 cm rectangular
holes/grid spacing) raised 76 cm above the floor. Movements of each rat placed in the
middle of the mesh were video-recorded for 60 sec in two separate trials. A foot-fault
was counted when a rodent’s paw slipped completely through the wire mesh. The
number of foot-fault for both groups were compared.

Beam Balance
Juvenile animals were tested on a 0.65 cm wide plexiglass beam at 1, 3, and 7
dpi. Adult animals were tested on a 2.5 cm wide beam at 30 and 60 dpi commensurate
to their size increase. Each animal walked unrestricted for 60 sec for each of two trials
20 min apart, and the distance covered was recorded and compared between salinecontrols and DJNKI-1 group.
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Rotarod
Two different rotarod paradigms were used: constant velocity (at 1, 3, 7, 30 and
60dpi), and constant acceleration (2rpm/5s and 5rpm/5s at 30 and 60 dpi). The rotarod
(Rotamex-5, Columbus Instruments, Columbus, OH) operates until each animals falls
off. Latency to fall was recorded as a measure of motor coordination and balance.

Open-field
General activity level and exploratory behavior of the animals were assessed
with open-field test at 30 and 60 dpi. Each subject was video-recorded for 30 min
(Noldus Ethovision, Noldus Information Technology, Inc., Leesburg, VA) inside an empty
plastic bin. Total distance traveled was recorded as a measure of overall activity levels
and compared between groups.

Zero Maze
This test was carried out on an elevated circular apparatus fitted with a brightly
lit, open half, and also with an enclosed half. A 5-min trial was conducted at 30 and 60
dpi, and the percentage of time spent in the enclosed half was recorded. Increased
percentage of time spent in the dark quadrants of the track is associated with increased
anxiety-like behaviors as previously shown (Ajao et al., 2012).

Morris Water Maze (MWM)
A 3-day assessment of subject performance in cued and spatial water maze
paradigms was used as a measure of learning and spatial memory functions at 30 and
60 dpi. The water maze metal tank was filled with opaque water. An escape platform (11
cm diameter) was adjusted so that its surface was 2 cm above the water surface for
cued testing, and submerged 1 cm below the water surface for the spatial learning and
memory tasks. Rodent’s swim paths were recorded with a computerized tracking device
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(Noldus Information Technology, Inc., Leesburg, VA) (Hartman et al., 2005, Ajao et al.,
2012). In the cued task, platform location was changed for each of 5 trial blocks – each
block consisting of 2 consecutive trials (60 sec maximum for each) with a 5 sec inter-trial
interval. For the spatial testing, platform location was kept constant for all 10 trials, and
there were four release points. 1.5 hrs following the spatial trials, a 60 sec probe trial
was performed, in which the platform was removed from the tank and the rats were
allowed to swim in search of it. Outcomes for the MWM include: distance traveled to
reach the platform, number of entries into the target quadrant, percentage of time spent
in the target quadrant, and swim speed.

Tissue Processing and Immunohistochemistry
A cohort of rats were transcardially perfused with 4% PFA prepared in PBS at 3d
and 60d post-jTBI. The brains, upon removal, were immersed in 30% sucrose solution at
4°C for 48 hours, until they sink to the bottom. They were then frozen on dry ice and
stored at -20°C pending cryosectioning. Coronal cryostat sections were pre-mounted on
glass slides (thickness = 20µm) (Leica CM1850, Leica Microsystems GmbH, Wetzlar,
Germany). The sections were stored at -20°C until used.

Extravasated Serum Immunoglobulin G (IgG)
Staining and Analysis
To evaluate disruption at the BBB, staining for extravasated IgG was performed
as previously described (Badaut et al., 2011). Briefly, pre-mounted sections were twice
washed (10min each) in PBS and then blocked with 1% BSA in PBS for 1.5 hrs. The
sections were then incubated for 2 hrs at RT with biotinylated, affinity-purified goat antirat IgG, coupled with an 800nm wavelength infrared dye (1:500 dilution; Rockland,
Gilbertsville, PA), in a PBS-based antibody incubation buffer containing 0.1% Triton X100 and 1% BSA. The sections were washed in PBS and dried. The sections were then
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scanned on an infra-red scanner (Odyssey-system, LiCor, Germany) to quantify the area
of IgG extravasation on 3 to 5 adjacent slices covering the lesion. ROIs were drawn with
LI-COR Odyssey system around the regions where extravasated IgG is observed in
each section. The areas of these regions were then extracted for each section,
summated for each brain, and averaged for each group.

Statistical Analyses
All data are presented as mean ± SEM. Statistical analyses were done using
SPSS, and graphs were obtained using Sigmaplot (SPSS Inc.). All the data were
analyzed using student t-tests for normally distributed data with comparison between the
DJNKI-1 and control groups for each of the time points. Repeated measures ANOVAs
were used in cases where longitudinal data were collected on the same groups.

Results
DJNKI-1 Reduces Lesion Volume and Ameliorates
Morphological Alterations
Data gathered from non-invasive MRI was used to quantify lesion volume at 1d,
3d, 7d, and 30d. It was also used for lesion volume measurements following removal of
brains from euthanized rat subjects at the 60d time points. 3D reconstructions of
representative saline and DJNKI brains along the rostral-caudal axis show that the
lesions (red) constitute 1.9% and 2.2% of DJNKI brains compared to 3.5% and 3.9% of
saline brains respectively at 3d and 60d (Fig. 3B). The lesion is located on frontoparietal
cortex that encompasses the motor and somatosensory cortices. Intraperitoneal
administration of DJNKI-1 at 3 hours post-jTBI (Fig. 3A) results in significant reductions
of brain lesion volume in DJNKI-1 treated rats at 1d (by 47.3 +/- 11.1 %), 3d (by 37.2 +/17.5 %), 7d (by 51.7 +/- 12.7 %), 30d (by 38.1 +/- 19.9 %), and 60d (by 45.8 +/- 11.3 %)
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post-injury (Fig. 3D). Repeated measures ANOVA confirms a reduction in lesion volume
in DJNKI-treated rat brains across all time points compared to brains of saline control
rats (**p < 0.001; Fig. 3D). Fig. 3D shows lesion volumes as percentages of total brain
volumes for both saline and DJNKI-1 groups. In addition, pairwise comparisons (with rm
ANOVA) reveal intragroup variations in lesion volume as a percentage of brain volume in
the saline group but not in the DJNKI-1 group (Fig. 3D). Compared to 1d value, lesion
volume (in the saline group) is significantly lower at 7d (*p < 0.02) and 30d (**p < 0.005).
Juxtaposed brain sections (consisting of the brain slice that is most central to the lesion
and that has the largest lesion volume, for each time point) and lesion ROIs demarcated
in red are shown in saline and DJNKI-1 brains for each time point in Fig. 3C. Visual
comparison reveals that DJNKI-1 brain sections have smaller lesion volume across all
time points compared to saline brains (Fig. 3C).
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Table 1: Morphological Observations of Tissue Alterations
Morphological
Observation
Ventricular
Hypertrophy
(Ipsil. Cortex)

Experimental
Group
SAL

1d

3d

7d

30d

60d

70%*

90%

100%

100%

100%

DJNKI

20%

40%

40%

100%

80%

Ventricular
Hypertrophy
(Contra. Cortex)

SAL

60%

30%

80%

75%

100%

DJNKI

10%

20%

60%

40%

40%

SAL

50%

90%

80%

100%

100%

DJNKI

0%

0%

60%

100%

80%

SAL

90%

90%

100%

100%

100%

DJNKI

0%

0%

60%

20%

60%

SAL

0%

0%

10%

0%

0%

DJNKI

0%

0%

0%

0%

0%

SAL

90%

100%

100%

50%

0%

DJNKI

90%

80%

80%

40%

0%

SAL

50%

80%

100%

100%

50%

DJNKI

40%

50%

80%

100%

40%

SAL

0%

10%

60%

100%

100%

DJNKI

0%

10%

0%

80%

20%

SAL

70%

80%

60%

100%

100%

DJNKI

0%

20%

60%

80%

100%

Total n (SAL)

10

10

5

4

4

Total n (DJNKI)

10

10

5

5

5

Cortical
Thinning (Ipsil.
Cortex)
Damaged HPC
(Ipsil. Cortex)

Damaged HPC
(Contra. Cortex)

Hemorrhage
(Ipsil. Cortex)

Herniation
(Ipsil. Cortex)

Cyst
(Ipsil. Cortex)

Disrupted
Corpus Cal.
(Ipsil.
Hemisphere)

* Percentage of animals in the group with the observed morphological alteration
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Comparison of the two hemispheric volumes in saline group shows increased
contralateral hemisphere volume at 3, 7 and 30dpi (*p = 0.03, **p = 0.003, and **p =
0.01 respectively; t-test) (Fig. 4A). In the DJNKI-1 group, there is increased contralateral
volume at 7 and 60dpi (**p = 0.002, and *p = 0.02 respectively; t-test) (Fig. 4B). As
expected, the raw volumes of both hemispheres in saline and DJNKI-1 brains are
significantly increased at 30d and 60d compared to the volumes at earlier time points
(**p < 0.001 for each comparison), reflecting brain growth with increasing age (Figs. 4A
and B). When compared, ipsilateral hemispheres volumes for the saline group is higher
than that of the DJNKI-1 group only at the 60d time point (**p < 0.01) (Fig. 4C). There
are no differences at other time points. The contralateral hemisphere volumes are
however similar for both groups at all time-points (Fig. 4D).
Some alterations in brain morphology were observed at varying frequencies in
the T2WI of the two groups (see Table 1). Of particular note are: ventricular hypertrophy
(enlargement of the ventricles) which was less frequent in DJNKI animals at 1, 3, and
7dpi on both ipsilateral (70% [saline] vs. 20% [DJNKI], 90% vs. 40%, and 100% vs. 40%
respectively at 1, 3 and 7dpi) and contralateral cortices (60% vs. 10%, 30% vs. 20%,
and 80% vs. 60% respectively) (Table 1); cortical thinning (reduction in cortical
thickness) which was less frequent in DJNKI animals at 1, 3, and 7dpi on ipsilateral
cortex (50% vs. 0%, 90% vs. 0%, and 80% vs. 60% respectively at 1, 3 and 7dpi), and
damaged hippocampus on ipsilateral cortex (90% vs. 0%, 90% vs. 0%, and 100% vs.
60%, 100% vs. 20%, and 100% vs. 60% respectively at 1, 3, 7, 30 and 60dpi). Other
morphological changes include hemorrhage/hematoma which was less frequent on
DJNKI brain at 3 (100% vs. 80%) and 7dpi (100% vs. 80%) on ipsilateral cortex,
herniation (displacement and protrusion of brain tissue) which was less common in
DJNKI brains at 1 (50% vs. 40%), 3 (80% vs. 50%), and 7dpi (100% vs. 80%) on the
ipsilateral cortex, formation of cyst (enclosed sphere separated from the brain that is
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made up of a mixture of fluid and abnormal brain mater) which was less frequent on
DJNKI brain at 7 (60% vs. 0%) and 60dpi (100% vs. 20%) on ipsilateral cortex, and
disrupted corpus callosum which was less frequent on DJNKI brain at 1 (70% vs. 0%)
and 3dpi (80% vs. 20%) on the ipsilateral cortex (Table 1). Representative samples of
these morphological changes are presented in Fig. 4E with abnormalities demarcated in
red. The reduced frequencies of these alterations in brain morphology in DJNKI-treated
animals’ brains suggest that the DJNKI-1 treatment is protective at various levels in the
brain. No prominent midline shifts were observed in both saline and DJNKI-treated
brains. There were also no significant weight differences between the two groups over
the experimental period.
To investigate possible effect of acute DJNKI-1 treatment on white matter
structure, we quantified the surface area of regional corpus callosum (CC) from T2weighted images (T2WI) at the level of +1mm from bregma (just anterior to the lesion) at
each of the time points in each group. Overall increase in total CC surface areas was
observed for DJNKI-1 animals across all time points compared to saline-controls (**p <
0.001, repeated measures ANOVA; Fig. 5A, B). Individual t-test for total CC showed that
the increased CC size was more evident at later time points, especially at 7d (p = 0.021),
30d (p = 0.005), and 60d (p = 0.005) time points in the DJNKI-1 animals, although CC
size at 1d is also higher for DJNKI-1 animals (p = 0.012) (Fig. 5B, C). Comparison of CC
size along hemispheric lines further shows overall increase for the DJNKI-1 group
across all time points (for ipsilateral CC, **p < 0.009; for contralateral CC, **p < 0.003)
(Fig. 5D, E). These results are suggestive of beneficial role for DJNKI-1 in maintaining
white matter structural integrity, especially at later time points.
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DJNKI-1 Reduces Edema and Improves Water Diffusion after
Juvenile TBI
Hyperintensity on T2-weighted MRI (T2WI) has long been used as an index of
water accumulation possibly related to edema formation (Gomori et al., 1985, Kato et al.,
1986) as shown in Fig. 6A (SAL, white box). In this study, we serially acquired T2WI on
the subjects to profile T2 changes over the experimental timeline (Figs. 3A, 6B & C).
Shown in Fig. 6A are representative T2WI of saline and DJNKI brains at 3d, with the
boxed region enlarged in the lower pane and the important regions labeled (L = Lesion;
PL = Perilesion; CC = Corpus Callosum; HPC = Hippocampus; Cx = Cortex; and Str =
Striatum).
The overall T2 profile in lesion ROI shows increase in T2 values at the acute
injury phase (1d and 3d), followed by a decrease back to normal values by 7d, and
another rise in T2 values by 30d, followed by decrease by 60d (Fig. 6B). This intragroup
variation in T2 value over time is statistically significant (**p < 0.001, rm ANOVA, Fig.
6B). Pairwise comparisons show that the T2 values from the lesion ROI at 7d and 60d
are significantly lower than the T2 values at the same ROI at 1d (**p < 0.001) and 3d
(**p < 0.001) (Fig. 6B). Overall, T2 values are higher in the lesion (Fig. 6B) than in the
perilesion (Fig. 6C). Inter-group differences are also observed. T2 values acquired from
lesion ROI in the DJNKI-treated animals are significantly decreased compared to
controls at both acute (3dpi [**p < 0.003] and 7dpi [*p < 0.04], t-tests) and later (30dpi [*p
< 0.03] and 60dpi [*p < 0.04], t-tests) time points following jTBI (Fig. 6B), suggesting that
DJNKI treatment ameliorates edema formation acutely. The treatment may also reduce
continued cell death and water accumulation in the lesion cavity at later time points (Fig.
6B). Repeated measures ANOVA confirms the reduced T2 in DJNKI-treated group over
all time points (**p < 0.002). The use of ex vivo MRI modality at 60d does not
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significantly affect value comparison with in vivo MRI scans at earlier time points as
earlier reported (Obenaus et al., 2011, Ajao et al., 2012).
Significant intergroup difference in perilesion T2 is found only at 30dpi with
reduced T2 in DJNKI-1 brains (*p < 0.05, Fig. 6C). Intragroup variation in perilesion T2
value over time is statistically significant (**p < 0.001, rm ANOVA, Fig. 6C). Pairwise
comparisons show that the T2 values from the perilesion ROI at 7d and 60d are
significantly lower than the T2 values at the same ROI at 1d (**p < 0.001) and 3d (**p <
0.001) (Fig. 6C). Other brain regions besides lesion and perilesion show the same
pattern of stepwise T2 decrease from 1d to 60d without the transitory, upsurge in T2
values at 30d (data not shown).
Apparent diffusion coefficient (ADC), which is a quantitative parameter of
diffusion-weighted MRI (DWI), is often used as a measure of water mobility in the brain
(Le Bihan, 2007, Badaut et al., 2011). Shown in Fig. 6D are representative DWI of saline
and DJNKI brains at 7d, with the boxed region enlarged in the lower pane and the
important regions labeled as in Fig. 6A. There were no detectable intergroup differences
in the ADC values in the lesion ROI across the experimental timeline (Fig. 6E). Whereas
ADC values in the lesion ROI were fairly at the same levels at 1, 3, 7, and 60dpi, there
was a significant spike at 30dpi in both groups (Fig. 6E; **p < 0.008).
There is significant variation in ADC values in the perilesion ROI over the course
of the experiment (**p < 0.01). ADC profile of the perilesion ROI is strikingly similar to
that of the lesion ROI over the experimental timeline (Fig. 6F) with the exception of a
significant increase in ADC in DJNKI-1 group compared to saline group at 7dpi (p <
0.05) (Fig. 6F). The similarity in the profiles of ADC changes in both lesion and perilesion
ROIs suggests intragroup uniformity with respect to jTBI model and effect of DJNKI-1
treatment.
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DJNKI-1 Improves Neurological Functions at Acute Time
Points and Cognitive Functions at Chronic Time Points.
To test the efficacy of DJNKI-1 to reverse functional deficits such as motor
coordination impairment, the rats were subjected to foot-fault, beam balance and rotarod
tests over the experimental timeline (Fig. 7A). Significant reduction in the number of footfaults was found in DJNKI-treated rats at 3, 7, 30 and 60 dpi (**p < 0.01) compared to
control rats (Fig. 7A), suggesting that DJNKI improves motor function not just acutely but
also chronically. A repeated-measures ANOVA confirms significant intergroup
differences in number of foot-faults over time (**p < 0.001; Fig. 7A). There was a
progressive, stepwise decrease in the number of foot-faults registered by all subjects
over time regardless of group (Fig. 7A; **p < 0.001, rm ANOVA). The beam balance test,
however, does not show any significant intergroup differences in mean distance travelled
across all time points (Fig. 7B; p < 0.67, rm ANOVA). Nonetheless, profile of distance
travelled over the experimental timeline shows a stepwise decrease in value that is
similar (although less steep) to the foot-fault graph (Fig. 7B; **p < 0.001, rm ANOVA).
Two different rotarod paradigms (with 2 velocity/acceleration settings on each)
were used to further test motor balance, coordination and endurance (Figs. 7C, D, and
E). Constant speed paradigms (consisting of 10RPM and 20RPM trials) were used at all
experimental time points, while constant acceleration paradigms (consisting of 2RPM/5s
and 5RPM/5s) were employed only at 30dpi and 60dpi. DJNKI-treated animals
performed better in the 10RPM rotarod with higher latencies at 3dpi (*p < 0.02, t-test)
and 7dpi (**p < 0.002, t-test) (Fig. 7C), and at 7dpi (**p < 0.001, t-test) in the 20RPM
rotarod (Fig. 7D). Constant acceleration rotarod paradigms (2RPM/5s and 5RPM/5s)
showed no differences in latency to fall between the 2 groups at 30d and 60d (Fig. 7E).
Taken together, results from foot-fault and rotarod (constant speed paradigm) tests
suggest that acute DJNKI-1administration ameliorates motor deficits following jTBI.
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The open field (OF) test consists of 10 3-mins continuous recording period, with
each 3 mins constituting a trial block. There are no significant intergroup changes in
distance travelled across the 10 blocks either at 30d (Fig. 8A) or 60d (Fig. 8B). The OF
profiles follow a pattern of progressive decrease in distance moved from one block to the
next resulting in overall variation in distance traveled across the 10 blocks for both
groups (**p < 0.001, rm ANOVA; Figs. 8A & B). The cumulative distance graph shows a
significant increase in total distance traveled by saline animals compared to their DJNKItreated counterparts at 60 dpi (*p < 0.05) (Fig. 8D), suggesting an overall decrease of
activity in DJNKI-1 treated rats. Distance traveled during the first 3 mins of the 10-block
test – used as a measure of exploratory behavior – showed no inter-group differences at
30dpi and 60dpi (Fig. 8C). In addition, to evaluate anxiety behavior, the rats were
subjected to Zero Maze test, which showed significantly reduced percentage of time
spent in the dark arm by DJNKI animals compared to saline (42.7% vs. 73%; *p < 0.04)
at 60dpi (Fig. 8E).
Cognitive outcomes were assessed by a combination of MWM trials, which
includes cued, spatial and probe trials (Figs. 9A-E). Cued MWM test was carried out at
30 and 60dpi to test for equivalence in visual, swimming and motor abilities between the
2 groups. There were no intergroup differences at 30dpi (Fig. 9A; *p = 0.72, rm ANOVA).
At 60dpi however, rm ANOVA ran on cued MWM indicates significantly lower distance
covered by DJNKI animals to reach submerged platforms across the 5 trial blocks (Fig.
9B; *p < 0.03, rm ANOVA). This suggests that the DJNKI-1 animals had either higher
motor and swimming or visual ability compared to the controls at 60d. The distance
traveled to reach submerged platforms in MWM spatial trials are indicators of spatial
learning and working memory. Spatial MWM was carried out with a western (W) start
location. In spatial MWM, cumulative distance covered by DJNKI-treated rats at 30dpi
was significantly lower compared to controls across the blocks (Fig. 9C; **p < 0.008, rm
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ANOVA). There was, however, no significant between-group difference in MWM spatial
test at 60d (W) across the trial blocks, although there was a group-distance interaction
(*p < 0.04). Meanwhile, in the probe trials, the number of entries to platform location,
which is an index of spatial memory, was significantly higher in DJNKI-treated rats
compared to controls at 60dpi (Fig. 9E; *p < 0.02, t-test), but not at 30dpi. Taken
together, these MWM results indicate that the effect of acute DJNKI-1 treatment on
cognitive deficits at long-term following jTBI may be sensitive to both test repetition
which can reduce the sensitivity of the MWM tests, and to the evolution of the injury
across time (see section 4.1 for an elaborate discussion on this).

DJNKI-1 Protects Blood-Brain Barrier Integrity Acutely after
Brain Injury
Immunohistochemical staining for extravasated IgG was carried out to assess
BBB disruption at 3dpi as previously described (Pop et al., 2012). Representative
coronal slices with extravasated IgG (shown as intense green) at varying depths from
Bregma at 3dpi are shown for each group on Fig. 10A. Student’s t-test on IgG-stained
areas on these sections indicates that DJNKI-treated animals had significantly lower
IgG-stained surface area compared to controls (*p < 0.02) (Fig. 10B). This suggests that
DJNKI-1 administration helps ameliorate acute BBB disruption following jTBI.
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Discussion
This study was aimed at investigating the potential therapeutic impact of
competitive inhibition of JNK pathway in a juvenile TBI (jTBI) model. Hyperactivation of
the JNK pathway is a phenomenon that has been reported in various forms of brain
injuries (Borsello et al., 2003, Michel-Monigadon et al., 2010, Nijboer et al., 2010).
Experimental data from animal studies show that activation of JNK pathway peaks early
– in usually less than 12 hours – following brain injuries (Michel-Monigadon et al., 2010,
Nijboer et al., 2010). In broad agreement with these animal studies, Ortolano et al.
reported an increase in phospho-JNK (an index of JNK activation) from 1 to 48 hours
post-injury in brain tissue samples from 6 TBI patients, and confirmed this phospho-JNK
temporal profile experimentally in a CCI model in adult mice (Ortolano et al., 2009).
Other experimental data from murine ischemia-reperfusion model suggest that JNK
phosphorylation may initially drop, and then begin to rise from 1 hour until it peaks at 9
hours following stroke (Gao et al., 2005). Phosphorylation of c-Jun – a JNK substrate –
follows a similar pattern, peaking at 8 hours post-stroke, although it remains significantly
elevated at 24 hours (Gao et al., 2005). The choice of 3 hour post-injury DJNKI-1
administration time for this study therefore is appropriate, as it falls within a period of
active JNK hyperactivation, and is linked with positive outcomes in both permanent
ischemic brain injury model in 14d rat pups (Borsello et al., 2003) and in neonatal
hypoxic-ischemic brain injury model in 7d rat pups (Nijboer et al., 2010).
The drug of choice – DJNKI-1 – is a synthetic cell-penetrating peptide that is
protease-resistant and has been shown to be very promising in inhibiting JNK action
competitively at various levels of the pathway (Borsello et al., 2003, Borsello and Bonny,
2004). The drug was synthesized by linking HIV-TAT carrier peptide sequence to the 20amino acid JNK-binding motif of the scaffold protein JIP-1 (Borsello et al., 2003). DJNK-1 acts by competitively inhibiting the interaction of all JNK isoforms with JIP-1 and
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with their downstream substrates (Borsello et al., 2003, Borsello and Forloni, 2007). The
dosage used – 11mg/kg – was based on its previously reported efficacy in permanent
middle cerebral artery occlusion (MCAO) model in juvenile (P14) rats (Borsello et al.,
2003) and in other CNS injury models (Repici and Borsello, 2006, Repici et al., 2007)
where the drug was injected intraperitoneally (i.p.). Previous reports have indicated that
the drug is able to cross the BBB and penetrate the cerebral cortex within 1.5 hours after
i.p. injection in rodents, and could remain stable in brain parenchyma for at least 3
weeks (Repici et al., 2007, Ploia et al., 2011, Sclip et al., 2011).
The key finding of this study is that early administration of DJNKI-1 not only
improves histological, sensorimotor and cognitive outcomes at early time points but also
confers neuroimaging and functional improvements at later time points as observed at 4
to 8 weeks post-injury (Figs. 3D, 6B, 7A, 8E, etc.). This property is important for potential
clinical use and bodes well for long-term clinical efficacy of DJNKI-1 in juvenile TBI. In
the following sections, the main effects of early DJNK-1 intervention following jTBI in this
study are discussed, together with insights into potential mechanisms mediating these
effects.

DJNKI-1 and Improvement of Neurological and Cognitive
Functions
In this study, we found remarkable improvements in sensorimotor and cognitive
functions at both acute and later time points following DJNKI-1 treatment in our jTBI
model (Figs 7, 8, and 9). These findings are important with respect to scientific reports
that highlighted the persistence of neurological, cognitive, and behavioral sequelae
following moderate to severe TBI during childhood (Schwartz et al., 2003, Catroppa and
Anderson, 2009, Anderson et al., 2012), which have been confirmed in some animal
models of jTBI (Russell et al., 2011, Ajao et al., 2012).
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We found robust improvement in sensorimotor functions with the use of foot-fault
test (Fig. 7A, both short-term and long-term post-injury) and constant speed paradigm of
rotarod test (Figs. 7C and D, only at short-term), but not with either beam balance test
(Fig. 7B) or the constant acceleration paradigms of rotarod (Fig. 7E). Other labs that
used comparable acceleration paradigm have established that motor deficits on rotarod
are greatest and most evident at acute phases (1 – 7 days) following experimental TBI in
rodents, with recovery up to 88% of preinjury values by 14 days (Onyszchuk et al.,
2007). This is consistent with our results in constant speed paradigm (Figs. 7C, D), and
makes it improbable to see treatment effects on accelerating rotarod at later time points
(Fig. 7E). Lack of both pre-training and customized rotarod apparatus to accommodate
the smaller sizes of juvenile rats have been suggested to affect performance on
accelerating rotarod more adversely compared to constant speed rotarod following jTBI
(Russell et al., 2011). Rats have also been observed to use change in gait strategy and
motor skill learning to improve their performance on accelerating rotarod (Buitrago et al.,
2004, Barreto et al., 2010). These results suggest that DJNKI-1 improves neurological
function, although not all tests are sensitive enough to reveal the improvements in fine
motor skills (Russell et al., 2011). The motor deficits observed are warranted because
the injury encompasses parts of the motor cortex on the rat brains (Soblosky et al.,
1996, Ajao et al., 2012). On-going morphological and functional changes in white mater
tracts in this model (Ajao et al., 2012, Kamper et al., 2013) may also account for the
persistent motor dysfunction observed (Caeyenberghs et al., 2011b), and as such the
impact of DJNKI-1 treatment on the white matter should be further investigated. We
have reported long-term sensorimotor deficits up to 6 months in this jTBI model (Kamper
et al., 2013). Potential correction of these long-term deficits with DJNKI-1 should be
studied.
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With respect to emotional disorders, the decreased cumulative distance by
DJNKI animals in open field test (Fig. 8D) coupled with decrease in time spent in the
dark arm of zero maze at 60d by DJNKI animals (Fig. 8E) could indicate reduced
anxiety-like behavior compared to their saline counterparts (Kodama et al., 2008) as we
have previously reported (Ajao et al., 2012). Amelioration of anxiety-like behavior on
zero maze test (Fig. 8E) further substantiates DJNKI-1’s positive effects on functional
changes involving multiple brain networks. Anxiety-like symptoms and anxiety disorders
have been reported within 6 months in over 25% of clinical cases of juvenile TBI across
all severity levels according to one report (Max et al., 2011). Late onset of anxiety
disorders in adult patients has been previously reported (Whelan-Goodinson et al.,
2009). Younger children were found to be at an increased risk for developing anxiety
disorders following TBI (Vasa et al., 2002, Max et al., 2011). Damaged frontal lobe and
frontal white-matter systems are also associated with these anxiety-related disorders in
young TBI victims (Max et al., 2011). We have previously shown that the jTBI model
used in this study causes alterations in some white matter tracts both proximal to and
distal from the site of impact (Ajao et al., 2012). DJNKI-1 could hold some potential for
counteracting these post-injury symptoms.
Moreover, DJNKI-1 also confers some cognitive improvements at select time
points as seen in various MWM test formats (cued, spatial, and probe) (Fig. 9) which
assessed spatial learning and spatial memory functions. In a previous study (Ajao et al.,
2012) where the injury location was more anterior and less lateral to Bregma (1mm by
2mm) than in this current study (3mm by 4mm), we found no spatial learning or memory
differences at 30d and 60d between shams and injured rats in this jTBI model. However,
in a follow-up study, despite not showing overt spatial learning deficits, TBI animals in
this model use cruder MWM swim strategies which are more dependent on chance at
60d post-injury compared to sham animals which rely more on direct spatial learning
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strategy (Pop et al., 2012). DJNKI-1 treatment may be correcting for this subtle shortfall
in spatial learning strategy in treated animals (Fig. 9). Decrease in distance moved to
reach the platform by DJNKI-1 animals in the 60d cued MWM test (Fig. 9B), rather than
confounding the results of the spatial MWM, may be a further indication that DJNKI-1
improves motor coordination capabilities of the treated animals. While DJNKI-1 animals
displayed better spatial learning at 30d and 60d (Fig. 9C, D), all animals might have
become used to the repetitive nature of the test, thereby potentially limiting the test’s
sensitivity at later time points. Cognitive deficits, however, evolved over time following
injury (Kamper et al., 2013). While not explicit at 1 and 2 months post-injury (Ajao et al.,
2012), there are spatial memory differences at 3 and 5 months post-injury, and these
resolved at 6 months (Kamper et al., 2013). Therefore, differences in MWM test could
show up at much later time points with DJNKI-1 treatment, and this underscores the
potential of testing DJNKI-1 to arrest some long-term sequelae of juvenile TBI that have
been well-documented (Sbordone et al., 1995, Yeates et al., 2002, Schwartz et al.,
2003, Ajao et al., 2012).
The developmental time period is very important for formation of crucial
sensorimotor and cognitive abilities, and injury to the brain during this phase could elicit
unresolved imbalances in functional behavior (Giza, 2006, Giza et al., 2007, Ajao et al.,
2012). Scientific reports on genetic deletion (Wang et al., 2007, Yamasaki et al., 2011,
Yamasaki et al., 2012) and pharmacological inhibition (Borsello et al., 2003, Armstead et
al., 2011) of JNK or its upstream MAPK activators in developmental animal models have
highlighted the importance of JNK to normal brain development as well as its deleterious
role in developmental brain disorders. For example, deletion of JNK3 gene protects
neonatal mice against cerebral hypoxic-ischemic (HI) injury (Kuan et al., 2003, Pirianov
et al., 2007). BBB damage is strongly mediated by JNK hyperactivation in experimental
hypoxic-ischemic brain injury in P7 rat pups (Tu et al., 2011). These reports underscore
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the importance of JNK pathway in various forms of brain insults during development and
highlight the therapeutic importance of DJNKI-1.
Improvement in neurological and cognitive functions has been reported following
DJNKI treatment in CNS injury models such as: MCAO (Borsello et al., 2003, Esneault
et al., 2008), neonatal hypoxic-ischemia (Nijboer et al., 2010), intracerebral hemorrhage
(Michel-Monigadon et al., 2010), spinal cord injury (Repici et al., 2012), and controlled
cortical injury in adult mice (Ortolano et al., 2009). Tests utilized in these referenced
reports (rotarod, adhesive removal, beam walking, object recognition, cylinder rearing,
modified hole board, footprint, and forelimb placement tests) were customized and
standardized for assessing several neuromotor, proprioceptive, and cognitive abilities.
Chronic treatment with D-JNKI-1 has recently been shown to rescue memory
impairments and long term potentiation deficits in an Alzheimer disease mouse
(TgCRND8) model without any major side effects (Sclip et al., 2011). Our study provides
additional evidence that DJNKI-1 could ameliorate functional deficits following jTBI.
TBI in the pediatric brain exhibits both acute and chronic phases linked to the
disruption of learning and memory consolidation (Schwartz et al., 2003, Chapman, 2006,
Babikian and Asarnow, 2009). The pediatric population may be especially vulnerable to
this post-TBI cognitive deficits due to disruption of normal brain development and
emerging skills which often lead to neurocognitive stall (Chapman, 2006, Catroppa and
Anderson, 2009). JNK hyperactivation has been shown experimentally to specifically
mediate such stressful event in the hippocampus (Sherrin et al., 2010). The report
further shows that injection of DJNKI-1 reduced the activity of hippocampal JNK and
ameliorated the stress-induced functional deficit. It is plausible that in our study, DJNKI-1
treatment is mediating similar reduction of JNK activity in the hippocampus with resultant
improvements seen in learning and memory test (Fig. 9). We cannot however rule out
potential beneficial effects of JNK inhibition by DJNKI-1 in peripheral systems as inferred
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in models where DJNKI-1 was injected at a low dose that was not detected in the brain
(Benakis et al., 2010, Benakis et al., 2012). Peripheral actions of DJNKI-1 such as
reduction of peripheral inflammation may indirectly effect cognitive improvement (Wilson
et al., 2002, Benakis et al., 2010).
While it is not entirely clear how DJNKI-1 elicits these long-term improvements,
reduced neuronal apoptosis and resultant preservation of the brain’s sensorimotor
networks is a potential mechanism (Borsello et al., 2003). So also is preservation of BBB
integrity and prevention of edema formation. Neuromotor abilities have been shown to
correlate with brain edema and BBB integrity in experimental TBI (Li et al., 2012).
Very few pharmacological agents including several ones that failed clinical trials
(Doppenberg et al., 2004, Beauchamp et al., 2008, Janowitz and Menon, 2010) have
demonstrated such strong neurological and cognitive effects and for the length of time
comparable to those shown by DJNKI-1 in these results (Figs. 7 - 9). Some of the
problems that led to failure of several TBI-targeted clinical trials, such as insufficient
brain penetration and lack of long-term neurobehavioral testing (Doppenberg et al.,
2004) have been addressed with the use of D-JNKI-1 in this study. Its ability to
penetrate the brain (Repici et al., 2007) and its beneficial effect on both short-term and
long-term neurological and cognitive functions (Repici et al., 2012) (Figs. 7 - 9) increases
its profile as an ideal therapeutic candidate. It should also be noted that most of the
clinical trials in TBI have been carried out in severe TBI cases in adult patients
(Doppenberg et al., 2004). The potential suitability of D-JNKI-1 as a candidate drug for
moderate TBI in pediatric patients is another highlight of this study.
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DJNKI-1, Reduction of Lesion Volume and Amelioration of
Morphological Alterations
In our search for additional evidence of DJNKI-1’s effects following jTBI, we
found a consistent reduction in lesion volume over the experimental timeline in DJNKItreated rats (Fig. 3B, C, D). Similar reduction in lesion volume through inhibition of JNK
pathway – either with the use of DJNKI-1 or SP600125 (another small molecule JNKspecific inhibitor) – has been reported in various models of brain injuries, which include
transient and permanent middle cerebral artery occlusion (MCAO) (Borsello et al., 2003,
Hirt et al., 2004), focal ischemic brain injury (SP600125 was used here) (Gao et al.,
2005), intracerebral hemorrhage (ICH) (Michel-Monigadon et al., 2010), and neonatal
hypoxic-ischemic brain injury (Nijboer et al., 2010). Abnormal morphological alterations
that are coincident with massive brain contusion such as ventricular hypertrophy, cortical
thinning, hemorrhage/hematoma, herniation, cyst formation and disrupted corpus
callosum are also reduced in DJNKI-1 group (Table 1). This could be attributed to
reduced lesion volume in the brains of DJNKI-treated animals. In another study, we
reported long-term cortical thinning in jTBI animals at 3 and 6 months post-injury
(Kamper et al., 2013). DJNKI-1 may have the potential to correct this in the long-term.
The therapeutic effect of DJNKI-1 with respect to reduced lesion volume has previously
been attributed to: (1) inhibition of excitotoxicity and prevention of neuronal loss [as
shown in models of MCAO (Borsello et al., 2003, Hirt et al., 2004), and in TBI (Ortolano
et al., 2009)]; and (2) reduction in the loss of glial cells through reduction of glutamate
toxicity [for example in oligodendrocytes in the brain (Rosin et al., 2004)].
Another potential mechanism of action for DJNKI-1 is through salvaging of
oligodendrocytes, which could ameliorate the negative effects of jTBI on white matter
structure and function. We have previously reported a significant decrease in area
measurement of corpus callosum (through NF-200 and MBP staining, and through MRI

219

measurement) together with a concomitant increase in MBP immunoreactivity at early
(3d) and later (60d) time points following jTBI (Ajao et al., 2012). In another study, we
reported that the area of corpus callosum remains decreased in jTBI animals at 3 and 6
months post-injury (Kamper et al., 2013). Some studies have reported possible links
between JNK pathway inhibition, viability of oligodendrocytes, and resultant sparing of
white matter (Chew et al., 2010, Repici et al., 2012, Wang et al., 2012). Repici and
colleagues (Repici et al., 2012) in particular reported long-term (4 months) locomotor
recovery following administration of DJNKI-1 in a mouse model of spinal cord injury, and
positively correlated this functional recovery with white matter sparing. It is therefore
plausible that the short- and long-term functional recovery seen in this study is related to
DJNKI’s positive effects on the brain’s white matter structures and functions (Ajao et al.,
2012, Kamper et al., 2013).
To investigate possible effect of DJNKI-1 treatment on the white matter, we
measured the surface area of corpus callosum (CC) from T2-weighted images (T2WI) at
each of the time points. Increase in CC surface areas especially at 7d, 30d, and 60d
time points in the DJNKI-1 animals (Fig. 5) suggests that the drug is effecting structural
changes along the white matter that may be beneficial to recovery of function. We have
previously shown that this jTBI model decreases CC surface area in the injured animals
at 60d with respect to shams, and also decreases neurofilament-200 (NF200)
immunostaining along the CC at 7d, 30d, and 60d post-TBI (Ajao et al., 2012). This data
on CC area is consistent with the previous report. The CC contains commissural
pathways that enable interhemispheric communication which is essential for bimanual
motor function and other coordinated movements. The CC is highly vulnerable to TBI,
and damage to the CC in humans TBI patients has been linked with deficits in bimanual
motor functioning and coordinated movements (Caeyenberghs et al., 2011a). Decrease
in size and microstructural integrity of CC also underpin the poorer sensorimotor
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coordination on tasks requiring high degree of interhemispheric interactions seen in
older adults compared with their younger counterparts (Fling et al., 2011). Furthermore,
loss in the volume of deep white matter structures such as CC in children with TBI has
been strongly linked with poorer long-term social reintegration and neuropsychological
performance (Gale and Prigatano, 2010). DJNKI-1’s effect on the CC and possibly other
white matter structures may therefore have a potential for ameliorating not only
sensorimotor deficits but also behavioral deficits as well. Additional studies are being
carried out in Dr. Badaut’s lab to determine the cellular and downstream molecular
targets for DJNKI-1 supporting the neuroimaging and behavioral benefits.

DJNKI-1, Blood-Brain Barrier, and Edema Formation
We showed in this study that DJNKI-1 administration at 3 hours post-jTBI
significantly reduced IgG extravasation at 3d post-jTBI around the lesion and perilesion
ROIs (Fig. 10A, B). Water accumulation measured with T2 in these same 2 ROIs was
significantly reduced in DJNKI-treated compared to non-treated rats not just acutely but
also at later time points (Fig. 6A - C), suggesting that DJNKI prevents the edema
formation early one after jTBI by improving the BBB integrity. Meanwhile, ADC
measurements [which is used as an indicator of water mobility in the brain (Le Bihan,
2007, Obenaus and Ashwal, 2008)] showed no differences in the lesion and perilesion
ROIs (Figs. 6D - F) except for the increased ADC value found in DJNKI-1 group at 7d in
perilesion ROI (Fig. 6F). This may indicate a transient availability of larger intercellular
space in the perilesion of DJNKI-1-treated animals at this 7d time point only. While the
increased ADC value in the DJNKI-1 group could indicate some cell death, the reduced
ADC value in the saline group may also indicate an on-going neuronal and astrocytic
swelling (Badaut et al., 2011) which DJNKI-1 treatment counteracted.
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Edema formation is one of the secondary processes evident in TBI (Werner and
Engelhard, 2007, Shlosberg et al., 2010), and it is especially pronounced in juvenile TBI
(Giza et al., 2007, Fukuda et al., 2012, Fukuda et al., 2013). A mechanistic explanation
for the observation on edema above is a possible protective action of DJNKI-1 on BBB
and brain endothelial TJ, which prevents prolonged BBB opening and preserves
endothelial TJ integrity. In line with the proposed mechanism of action, attenuation of
BBB disruption, edema, and apoptosis by DJNKI-1 could result in salvaging more
neurons and glia that could have succumbed to premature cell death, and eventually
lead to the preservation of neuronal networks that are vital to various neurological and
cognitive functions. For example, in another study in this jTBI model in our lab that
looked at a different treatment strategy, edema formation was decreased acutely
alongside improved outcomes in BBB integrity and neurological functions, and reduction
in neuronal cell death and astrogliosis (Fukuda et al., 2013).
The action of JNK hyperactivation in disrupting inter-epithelial and interendothelial tight junctional proteins have been reported in the periphery, like in tricellular
tight junctions in human pancreatic duct epithelial cells, intestinal epithelial tight junctions
(Betanzos et al., 2004, Kojima et al., 2010, Samak et al., 2010) and in in vitro brain
endothelial cell cultures (Etienne et al., 1998, Adamson et al., 1999, Wolburg and
Lippoldt, 2002, Tai et al., 2010). Moreover, JNK hyperactivation appears to contribute
tremendously to TJ and BBB disruption in some brain disease models (Tai et al., 2010,
Kacimi et al., 2011, Tu et al., 2011). Conversely, inhibition of JNK reversed decrease in
TJ proteins including claudin-5 in the periphery (Carrozzino et al., 2009). JNK is actively
involved in ICAM-1-mediated lymphocyte transmigration across brain microvascular
endothelial cells in an in vitro model of neuroinflammation (Hudson, 2012). In human
brain endothelial cells exposed to inflammatory cytokines, JNK inhibition reduced the
cytokine-induced paracellular permeability (Lopez-Ramirez et al., 2012). Since capillary
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endothelial cells are one of the first points of contact in the brain for intraperitoneallyinjected, blood-borne DJNKI-1, the agent may conceivably be acting to reverse the
reduction in BBB TJ proteins (Berezowski et al., 2012). The reduction in IgG
extravasation at acute time-point provides an indirect, but fairly strong support for this
(Fig. 10A, B). Corroborating evidence for this comes from a recently reported study of
spinal cord injury (SCI) model performed in male Swiss mice where i.p. injection of the
same dose of DJNKI-1 that we used (11mg/kg) at 6 hour post-injury resulted in
significantly lower IgG extravasation volume and erythrocyte extravasation in DJNKI-1
group compared to saline controls (Repici et al., 2012). Further studies (such as staining
TJ proteins, etc. following DJNKI-1 treatment in jTBI) will however be needed to solidify
this hypothesis.
The main sites of action for DJNKI-1 in the brain endothelium that could result in
JNK inhibition are the JNK-binding motifs of the scaffolding protein, JIP-1 (Borsello et al.,
2003, Borsello and Forloni, 2007). All 3 isoforms of JNK are present in the brain
endothelium (Berezowski et al., 2012). DJNKI-1 competitively inhibits the interactions
between JNK isoforms and their upstream mediators and downstream substrates. More
than 50 substrates of JNK have been identified (Bogoyevitch and Kobe, 2006), and the
functions of some are yet to be determined.
Repair of disrupted BBB and preservation of brain endothelial junctional integrity
is a unique therapeutic avenue that has been proposed for traumatic brain injury
(Hawkins and Davis, 2005, Shlosberg et al., 2010). Disruption of BBB and brain
regulatory vascular mechanisms is of particular concern to the juvenile population due to
its susceptibility to brain injury-induced cerebral hemodynamic dysfunction (Armstead,
1999, 2005, Freeman et al., 2008, Udomphorn et al., 2008, Chaiwat et al., 2009,
Armstead et al., 2011), diffuse cerebral edema, and tight junction breakdown (Anthony et
al., 1997, Suh et al., 2001, Campbell et al., 2007, Giza et al., 2007, Freeman et al.,
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2008). Occurrence of impaired cerebral hemodynamic autoregulation has been
established in several clinical cases and experimental models of TBI (Armstead, 1999,
2000) and it appears to be more pronounced in pediatric/juvenile model of TBI versus
adult model (Armstead and Kurth, 1994, Armstead, 2000, 2004, 2005). Armstead and
colleagues have identified hyperactivation of JNK as a major mechanism for this
secondary consequence of jTBI (Armstead, 2003, Armstead et al., 2011). Using porcine
(piglet) model of lateral fluid percussion injury (FPI) which mimics many of the
pathophysiological features of jTBI including cerebral autoregulation impairment seen
clinically (Armstead and Kurth, 1994), they reported that JNK MAPK concentration was
increased in CSF by FPI, but blocked by JNK antagonists SP600125 and DJNKI-1
(Armstead et al., 2011). DJNKI administration following FPI blocked NMDA-induced
vasoconstriction and fully restored pial artery vasodilation (Armstead et al., 2011).
Although measurements of JNK was obtained from CSF in these studies, the increased
concentration of JNK in CSF reflects events in brain parenchyma (Armstead et al.,
2011). A major caveat is that the major cellular origin of this increased JNK is unknown,
with the possibility of neuronal, glial, smooth muscle, and endothelial origins, or a
combination of these sources. These reports nonetheless strengthen the theory that
DJNKI-1 may confer a protective effect on brain vascular system and BBB. More
investigation is needed, however, in this jTBI model to address the effect of DJNKI-1 on
neuroinflammation and on some other relevant pathways such as the JAK-STAT
pathway.

Conclusion
In this study, we provide evidence showing that administration of the competitive
JNK inhibitor – DJNKI-1 – at 3 hours post-jTBI is not only effective in reducing edema
formation and blood-brain barrier disruption at acute time points following juvenile TBI,
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but also confers reduction in lesion volume and recovery of neurological and cognitive
abilities that last into adulthood. Certain morphological alterations commonly seen in
brain-injured rodents are also less frequent following acute treatment with DJNKI-1.
These include reduction in the surface area of corpus callosum, ventricular hypertrophy,
cortical thinning, damaged hippocampus, herniation, and hematoma.
DJNKI-1 has the potential to mediate cellular processes in various types of brain
cells, including neurons, glial, smooth muscle, and endothelial, all of which could
experience JNK hyperactivation. Processes that DJNKI-1 could ameliorate in the brain
following jTBI may include: excitotoxicity (in neurons), apoptosis (in neurons and
endothelial cells), and vascular permeability and edema (in capillary endothelial cells).
Administration of DJNKI-1 through the intraperitoneal route, its facilitated passage
through the cell membrane (by virtue of its carrier peptide sequence, HIV-TAT), and its
lengthy half-life in brain tissue (up to 3 weeks) could ensure access of the drug to most
of these cell types, and potentially elicit additive or synergistic effects in the brain. These
beneficial effects appear to result in improved neurological and behavioral outcomes.
Major effects of DJNKI-1 in the periphery can however not be ruled out.
The prolonged efficacy of this agent makes it promising for potential clinical
applications. But further studies are needed to expound the mechanisms of action of
DJNKI at the BBB interface, in the gray and white matter, and in the periphery. The
molecular targets of DJNKI-1 that mediate reduced structural and histological damage
secondary to the primary insult, and engender beneficial functional outcomes need to be
further investigated. Such elucidation may help move DJNKI-1 into a clinical trial phase.
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CHAPTER 6
GENERAL CONCLUSIONS AND FUTURE DIRECTIONS

Model Development for Juvenile TBI
Clinical observations and research evidence have shown that TBI is complex and
heterogeneous in terms of its location, severity and pathophysiology (Saatman et al.,
2008). This heterogeneity is considered a major barrier in finding effective therapeutic
intervention (Saatman et al., 2008) and necessitated the development of various
experimental models of TBI (Dixon et al., 1987, Dixon et al., 1991, Cernak, 2005,
Morales et al., 2005, Morrison et al., 2011), each of which can model only parts of the
pathophysiological processes associated with brain injuries. Controlled cortical injury
(CCI) and fluid percussion injury (FPI) are the two most commonly used models of TBI
(Morales et al., 2005, Chodobski et al., 2011). Efforts have also been made to develop
suitable models of juvenile TBI (jTBI) mostly in piglets and rodents (Armstead and Kurth,
1994, Adelson et al., 1998, Prins and Hovda, 2003).
In this project, electromagnetically-actuated CCI on P17 rats was used to model TBI
in the developing brain (Brody et al., 2007). This model of choice has a number of
advantages. First is the ability to control the deformation parameters (velocity, impact
depth, time delay) of the model, which allows improved reproducibility of injury severity
in our lab and in other labs (Morales et al., 2005, Ajao et al., 2012). Secondly, this CCI
model is associated with key pathophysiological processes including acute hemorrhage
and hematoma, axonal injury, BBB dysfunction, and edema, all of which have been
observed clinically in young TBI patients (Duhaime et al., 1992, Giza et al., 2007,
Chodobski et al., 2011, Maxwell, 2012). Our findings confirmed that following jTBI, there
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were: acute increase in BBB permeability and edema, neuronal loss, white mater
changes, and brain deformities such as ventricular hypertrophy, herniation, and
hemorrhage (Ajao et al., 2012). These observations demonstrate the usefulness and
suitability of this model in investigating some important aspects of juvenile TBI.

Histological and Functional Effects of Juvenile TBI in Rodents
The traditional theory that prevailed for many decades is that brain injuries in young
humans would be far less damaging structurally and functionally due to putative high
plasticity and repair potential of the young brain (Kennard, 1936, Teuber and Rudel,
1962, Anderson et al., 2005, Dennis, 2010). Several findings in this project, however,
suggest otherwise. Some functional deficits associated with the initial injury, which are
sensorimotor, cognitive and behavioral in nature, remained unresolved up to 2 months
post-injury (Ajao et al., 2012, Pop et al., 2012). Electrophysiological measurement also
showed dysfunction in axonal conductance along a major white mater fiber at two
months post-injury (Ajao et al., 2012). This supports our hypothesis that TBI on P17 rats
will engender neurological dysfunction and deficits that will last for weeks after the initial
insult. Furthermore, data from similar animal cohorts have confirmed the persistence of
sensorimotor and cognitive deficits up to 6 months following jTBI (Kamper et al., 2013).
These observations are consistent with epidemiological data that showed prolonged
cognitive and behavioral deficits for years following TBI (Jonsson et al., 2013), and
suggest that injury at an early age could be detrimental to future brain development.
Such observations have triggered a rethink of how the developing brain responds to TBI
(Yeates et al., 2002, Anderson et al., 2005) with increasing number of investigators now
viewing the young brain as being more vulnerable than the adult brain for
pathophysiological signatures of TBI, such as subdural hematomas and diffuse cerebral
edema (Aldrich et al., 1992, Giza et al., 2007, Huh and Raghupathi, 2009).
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While there are literature evidence that the developing brain retains some ‘plasticity’
(defined as the ability to be remolded or reshaped after damage) (Anderson et al., 2012),
this plasticity does not fully compensate for deficits resulting from brain injuries
(McQuillen and Ferriero, 2004, Anderson et al., 2012, Levin, 2012). Several
developmental processes (e.g. white mater myelination and size) (see Chapter 5) and
overall maturation of the brain are disrupted by juvenile TBI (Ajao et al., 2012).
Furthermore, clinical reports of long-term deficits arise not just from moderate and
severe TBI (Yeates et al., 2002), but also in some forms of mild TBI (Rees, 2003, Carroll
et al., 2004, Stern et al., 2011). Recognition of the potentially life-long functional deficits
facing children who have experienced TBI, coupled with the significant socioeconomic
burden that is associated, should spur more research aimed at both prevention (Keenan
and Bratton, 2006) and mitigation of TBI effects (Kochanek et al., 2010).
Meanwhile, results from chapters 2 (Fig. 6: global increase of myelin basic
protein [MBP] in the corpus callosum observed at regions proximal and distal to lesion
cavity) and 5 (Fig. 4: ventricular hypertrophy of the contralateral hippocampus)
reinforced the idea that brain responses to focal brain injury is not just localized to the
immediate surroundings of the impact locus, but reaches distal brain regions (both grey
and white mater) as well (Ajao et al., 2012). Diffuse brain injuries have long been
associated with global (i.e. widely distributed) changes in the brain (Andriessen et al.,
2010), but focal TBI may also trigger non-localized responses (Dunn-Meynell et al.,
1994, Ding et al., 2011). The distal effects associated with focal TBI could be partly
attributed to the spreading out of the initial impact forces to vulnerable brain regions
(such as hippocampus, amygdala, and basal ganglia) (Wilde et al., 2007, McAllister,
2011) and to changes in the connection network of various brain parts (as seen with
herniation and injury to white matter tracts) (Huh and Raghupathi, 2009). For example, in
a follow-up study, we have reported reduced immunoreactivity for NF200 (a
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neurofilament that forms part of the neuronal cytoskeleton which supports and maintains
axonal/neuronal structure, and has also been implicated in intracellular transport to
axons and dendrites) in gray and white matter regions that are proximal and distal to the
point of initial brain impact following juvenile TBI in rats (Kamper et al., 2013).
Interestingly, these changes were measured at 6 months post-injury in adult rat brains.
The vulnerability of the central structures of the brain which support conveyance
of sensory and motor information to the cerebral cortex is partly responsible for
sensorimotor deficits seen after TBI (Wilde et al., 2007, Ajao et al., 2012) (chapter 5,
figure 5). Moreover, TBI in all its forms affect all major cell types in the neurovascular
unit – e.g. neurons, astrocytes, endothelial cells – as attested to in our findings (Ajao et
al., 2013; Submitted). Any form of therapeutic intervention would therefore be more
beneficial if it has the potential to target multiple protein molecule(s) and pathway(s) in
more than one cell type in the brain (Vink and Van Den Heuvel, 2004, Stoica et al.,
2009). Such multidimensional effects are afforded by the two pharmacological agents
used in this project – DJNKI-1 (for suppression of JNK hyperactivation following jTBI)
and cavtratin (for pharmacological mimicry of endogenous caveolin scaffolding domain).
See Figure 1 for a diagrammatical representation of the pathways affected by these two
pharmacological agents.

JNK Activation as a Therapeutic Target for Juvenile TBI
This project provides evidence in support of the theory that DJNKI-1 confers
protection against secondary processes of jTBI. This is through: prevention of excessive
brain tissue damage (e.g. reduction in lesion volume over a 60-day period with acute
DJNKI-1 treatment), reduction of injury-associated morphological alterations (e.g.
reduced frequency of ventricular hypertrophy and prevention of white mater size
reduction over time), reversal of BBB disruption and hyperpermeability, and consequent
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reduction in vasogenic edema (see chapter 5). In addition, acute administration of
DJNKI-1 promotes recovery of motor and cognitive functions both acutely and in the
long-term (see chapter 5, figs. 7 - 9). This ability to influence longitudinal recovery makes
DJNKI-1 particularly promising for ameliorating long-term dysfunction association with
juvenile TBI. However, the mechanism of action of DJNKI-1 has not been fully elucidated
in juvenile TBI.
One possible mechanism highlighted in this work (chapter 5) is the reduction in
vascular permeability and edema. We conclude from the observed reduction in IgG
extravasation in DJNKI1-treated rats (chapter 5, fig. 10), and in T2 values at the lesion
and perilesion brain ROIs in the same rats (chapter 5, fig. 6A - C), that DJNKI-1 protects
against vasogenic edema, while not ruling out protection against other forms of cerebral
edema (e.g. cytotoxic edema). We earlier hypothesized that DJNKI-1 treatment will
ameliorate BBB disruption and hyperpermeability in this model, and these findings
mostly support the hypothesis. Meanwhile, the action of DJNKI-1 may be conferring a
global neuroprotection following jTBI. The premise for this is that JNK isoforms (JNK-1, 2, and -3) are present not only in neurons but in other brain cell types such as
endothelial cells, astrocytes, etc. (Waetzig et al., 2006, Haeusgen et al., 2009, Tu et al.,
2011) whose actions are vital to neuronal survival and function. Hyperactivation of these
JNK isoforms has been shown extensively in neurons following various forms of brain
injuries or damage (Borsello et al., 2003, Ortolano et al., 2009). Activation in glia and
brain microvascular endothelial cells has also been highlighted (Xie et al., 2004, Wang et
al., 2012). In fact, Wang et al (2012) showed in a juvenile model of brain inflammation
that JNK hyperactivation is the common thread linking BBB disruption, oligodendroglial
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apoptosis in the white matter, and microglial activation with its consequent cytokine
production. The long-term difference in corpus callosal (CC) thickness observed
between DJNKI1-treated rats and control (with DJNKI-1 group showing increased CC
thickness especially at later time points, see chapter 5, fig. 5) is suggestive of a
protective role of JNK inhibition in the white mater structures of a developing brain. Since
DJNKI-1 is capable of inhibiting the hyperactivation of all 3 JNK isoforms in the varied
cell types in the brain, its actions may therefore constitute a form of global
neuroprotection following jTBI.
It is however important to further investigate the mechanisms of brain protection
that DJNKI-1 confers following post-TBI administration in the juvenile brain. It has been
suggested that DJNKI-1 may be playing a role in the periphery (e.g. in the liver, spleen,
etc.) that positively influences brain recovery following cerebral ischemia (Lehnert et al.,
2008, Touchard et al., 2010, Benakis et al., 2012). This route of action should be further
investigated in jTBI models.

Caveolins in Brain Homeostasis and in Recovery and Repair
after Juvenile TBI
Caveolins are believed to play important roles in brain homeostasis under normal
conditions and in response to brain pathology. In this project, we found increase in
caveolin-1 following jTBI at both acute and later time points (chapter 3, fig. 3). This longterm increase following jTBI suggests that caveolin-1 may be exerting some modulatory
effects long after the initial injury. We also found increase in caveolin-3 at acute time
points (chapter 3, fig. 5). These agree with literature evidence showing increase in
caveolins-1 and -3 in some forms of CNS injuries and disorders, including cold cortical
injury (Nag et al., 2007, Nag et al., 2009), spinal cord injury (Shin, 2007), and
experimental autoimmune encephalopathy (Shin et al., 2005). The increase in caveolins-
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1 and 3 coincided with the acute decrease in claudin-5 immunoreactivity and increased
in extravasated IgG, showing that caveolins may be associated with BBB disruption and
hyperpermeability. This is in broad agreement with our hypothesis that decreased tight
junction protein levels and BBB hyperpermeability will be associated with an increase in
expression of the caveolins, although we did not find a significant increase in the
expression of caveolin-2. Meanwhile, some reports have shown a lowering of caveolin-1
expression in some forms of brain injury such as ischemic-reperfusion injury (IR) (Shen
et al., 2006, Gu et al., 2011). This endogenous reduction in caveolin-1 in IR is
associated with increased nitric oxide production, increased activation of matrix
metalloproteinases (MMPs), BBB disruption, and overall poor histological and functional
outcomes (Gu et al., 2011, Gottschall and Barone, 2012).
We found a ubiquitous distribution of caveolin-1 in the brain following jTBI (in
neurons, astrocytes, etc., in addition to cerebral endothelium) (chapter 3, fig. 2), which
agrees with current literature reports (Cameron et al., 1997, Shin et al., 2005). Cav-1,
(as well as cav-2, and -3) have been reported to be present in non-caveolae regions in
neurons, and are associated with pro-growth and pro-survival signaling functions (Head
and Insel, 2007).
The role of prolonged increase in caveolin-1 expression should be a subject of
future research. It may be a compensatory mechanism to counteract long-term damage
in brain cells and improve function, or it could be detrimental to long-term functional
recovery (Patel et al., 2008, Gu et al., 2011, Stary et al., 2012) (Also see chapter 3).
We studied the effect of pharmacological mimicry of the caveolin scaffolding
domain (CSD) with the use of cavtratin. The CSD is not restricted to brain endothelial
cells (Song et al., 2007), but is also present in neurons (Head et al., 2008) and
astrocytes (Cameron et al., 1997). The ability of both of cavtratin to permeabilize the
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brain through its cell permeable adjunct (Antennapedia internalization sequence) and
influence multiple brain targets makes it a promising pharmacological tool.
Acute administration of cavtratin resulted in reduced lesion volume at 1d and 3d
post-injury (Chapter 4, Fig. 1). Cavtratin also reduced edema formation (as determined
by T2-weighted MRI) acutely in the lesion region of interest (ROI), but not in the
perilesion ROI (Chapter 4, Fig. 2). There was however no behavioral benefits (only
sensorimotor functions were tested) associated with cavtratin treatment at acute time
points (Chapter 4, Fig. 3). We therefore conclude that cavtratin could reduce edema
formation and ameliorate brain damage acutely. Future work should concentrate on
long-term study of the effect of cavtratin both on the pathophysiology of the brain and on
brain function as several secondary processes occurring acutely after jTBI could mask
some positive effects of the drug. Injection of cavtratin at multiple time points following
jTBI may also show if its effect could be optimized acutely and beneficial at long-term.
The effect of cavtratin on brain endothelial tight junction proteins (e.g. claudin-5,
occludin, etc.) as well as on IgG extravasation should be studied to further establish
examine the effect of the drug on the BBB integrity. The effect of cavtratin on eNOS, NO
production and MMP9 activation [which has been implicated in BBB disruption in
ischemic models (Gu et al., 2011)] should also be investigated to gain more insight into
the mechanism of action of the drug. In addition, the question of how caveolin-1 interacts
with JNKs in the brain should be studied through in vitro models. Combinatorial use of
both DJNKI-1 and cavtratin in jTBI should also be investigated for potential additive or
synergistic effects.
Overall, we have shown that acute administration of DJNKI-1 and cavtratin could
be beneficial in ameliorating some secondary processes associated with jTBI. In-depth
studies looking at the mechanisms of action of these drugs in juvenile TBI models should
be undertaken to further ascertain their clinical potential.
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